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ABSTRACT  
Secreted  Protein  Acidic  and  Rich  in  Cysteine  (SPARC)  is  a  matricellular  protein 
expressed during tissue repair and regulates cell proliferation and migration. It binds to, 
and interacts with collagen and regulates matrix metalloproteinase (MMP) expression. 
The  aim  was  to  determine  if  SPARC  modifies  intestinal  inflammation,  healing  and 
fibrogenesis.  
Intestinal disease was investigated using SPARC null (KO) and wild-type (WT) mice in 
which inflammation was induced by 3% dextran sodium sulphate (DSS) in the drinking 
water  for  7  days.  Inflammation  was  assessed  endoscopically,  clinically  and 
histologically on days 7, 14, 21 and 35 after initiation of DSS treatment. Systemic and 
colonic  cytokines  and  chemokines  were  quantitated  by  ELISA  and  CBA.  Colon, 
mesenteric  lymph  node  and  spleen  were  analysed  by  flow  cytometry  and 
immunofluorescence  for  inflammatory  cell  infiltrates.  To  determine  the  effect  of 
SPARC on the extracellular matrix (ECM) genes regulation, RNA from colonic tissue, 
and colonic myofibroblasts from WT and KO mice, were analysed by real time PCR for 
expression of ECM related genes.  
KO animals had significantly lower endoscopic scores of inflammation, suffered less 
weight loss, diarrhoea, faecal blood and had lower spleen/body weight ratios compared 
to WT animals consistent with less colonic and systemic inflammation. WT mice had 
higher levels of histological inflammation and damage when compared to KO animals 
and in the majority of KO animals the colonic mucosa had completely regenerated by 
day 35 in contrast to the WT mice. Compared to WT mice, in KO animal colons at day 
7 there was significantly less IL1β and MIG expression while TGFβ1 levels were higher. 
Flow  cytometric  analysis  identified  a  significantly  greater  percentage  of  FoxP3+ 
regulatory T cells in the spleen and draining lymph nodes of KO animals. KO mice also iii 
 
had fewer of cells, such as CD68+ macrophages and Ly6G+ neutrophils, of the innate 
immune e system infiltrating the inflamed colon. 
Collagen  (Col)  1α1,  Col3α1  MMP13  and  MMP3  expression  levels  were  reduced  in 
DSS-treated WT colons at day 7 and these were significantly lower than those observed 
in the KO colons. TIMP1 expression was significantly lower in KO mice at day 35 
when healing was complete in this group. TIMP2 and TGFβ1, TGFβ3 were not different 
between the groups at any time point.  The observation by others that collagen  fiber 
diameters  in  KO  colons  were  noted  to  be  significant  smaller  than  in  WT  animals 
suggesting that SPARC modifies the collagen bundling. Compared to unstimulated WT 
fibroblasts, KO cells had lower Col1α1 and Col3α1 expression. Stimulation with PMA 
reduced Col1α1 and Col3α1 and increased MMP13 and TIMP1 expression in all the 
isolated cells, but PMA had no effect on MMP3, TIMP2, TGFβ1 and TGFβ3 expression.  
DSS induced less colonic and systemic inflammation in KO compared to WT mice and 
the  inflammation  appeared  to  resolve  faster.  This  may  be  secondary  to  increased 
numbers of regulatory T cells and increased colonic TGF-β levels which may inhibit 
effector cell activity, including cytokine and chemokine expression and aid in the more 
rapid resolution of inflammation and restoration of the intestinal mucosa. SPARC is 
able to modify tissue healing potentially through the regulation of collagen expression, 
bundling and its degradation by MMPs, which impacts on tissue turnover rate and thus 
delays healing. Hence, SPARC might represent a promising therapeutic target in clinical 
management of inflammatory bowel diseases (IBD).  
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1.1 INFLAMMATORY BOWEL DISEASES    
The inflammatory bowel diseases (IBD), Crohn’s disease (CrD) and ulcerative colitis 
(UC),  are  life-long,  chronic,  inflammatory  disorders  of  complex,  and  aetiology  still 
largely unknown, that primarily present in the gastrointestinal tract of  young adults. 
Their development, however, is believed to result from defects in the interaction between 
the  host  and  their  intestinal  microflora,  in  combination  with  intestinal  epithelial  cell 
dysfunction resulting in an abnormal mucosal immune response (Kumar 2010; Podolsky 
2002a).  Morbidity  is  high  (costing  $2.7  billion  annually  in  Australia),  and  despite 
advances  in  both  the  understanding  of  the  genetic  aspects  behind  the  diseases  and 
improvements in the medical therapies available, both UC and CrD are increasing in 
incidence and prevalence worldwide and surgical intervention is still required in the 
majority of CrD patients (Harper et al. 1987; Podolsky 2002b). 
 
The IBD, especially CrD, have many characteristics of an autoimmune disease. CrD is 
characterised by a transmural granulomatous inflammation that may occur anywhere 
throughout the gastrointestinal tract (GIT), but it most frequently affects the terminal 
ileum and colon. UC, in contrast, is characterised by superficial inflammation resulting 
in epithelial cell destruction that only involves the colon and rectum (Fichtner-Feigl et 
al.  2005;  Podolsky  2002b;  Finkelstein  et  al.  2002;  Bouma  and  Strober  2003). 
Inflammatory  cells  within  these  regions  release  factors  that  are  chemotactic  for 
fibroblasts.  These  factors  can  stimulate  both  fibroblast  activation  and  proliferation 
leading  to  the  synthesis  and  deposition  of  extracellular  matrix  (ECM)  components 
(Kumagai et al. 2001). Intestinal fibrosis can then result from the excessive deposition 
of these fibrous ECM components and is a frequent occurrence as a consequence of the 
chronic inflammation that is the hallmark of IBD. In the intestine, the development of 3 
 
fibrosis may result in the serious complication of stenosis, or stricture, of the intestinal 
lumen, an adverse outcome particularly associated with CrD (Abreu et al. 2002; Harper 
et al. 1987). To date, there is a marked lack of understanding of the process of intestinal 
fibrosis and in the availability of effective therapies for the treatment or prevention of 
this  complication.  The  data  on  current  therapies  such  as,  corticosteroids,  immune 
modulators, antibiotics and surgery, primarily focus on the short term control of clinical 
disease activity, but these therapies may not alter the natural history of the diseases or 
the long term development of intestinal fibrosis in CrD (Harrison and Hanauer 2002; 
Rutgeerts et al. 2005). These anti-inflammatory treatments target specific components 
of the immune response and while colectomy (partial or total surgical removal of the 
large bowel) is occasionally necessary, it is not a cure for CrD. Hence, there is still a 
great need for alternative and more specific therapeutic strategies for IBD.   
 
To understand the pathogenesis behind IBD, one first needs to understand the normal 
function of the GIT mucosal immune system. The upper and lower respiratory tract, 
urogenital tract and the GIT have a combined surface of greater than 400 m
2 that is 
primarily covered by a single layer of epithelial cells. This single cell layer has many 
important  physiological  functions,  including  as  a  barrier  in  face  of  an  external 
environment rich in pathogens. The gut is exposed to an estimated 10-15 kg of food 
protein  per  year  and  is  colonised  by  at  least  1000  different  species  of  commensal 
microorganisms (Murphy 2008; Savage 1977). As a defense against the multitude of 
microorganisms, the mucosal tissue is populated with many immune cells. The normal 
healthy  intestinal  mucosa  is  thus  often  described  as  experiencing  a  “physiological 
inflammation”,  as  it  contains  large  numbers  of  effector  lymphocytes  and  other 
leucocytes that are normally associated with chronic inflammation, and are generally 4 
 
not present in other organs in the absence of tissue injury or disease. In order to monitor, 
and control, the “physiological  inflammation”, a tight regulatory system  is required. 
(Neurath et al. 2002; Neutra et al. 1996; Murphy 2008).  
 
The  immune  response  seen  in  the  intestine  is  also  different  from  the  systemic 
inflammation that is controlled by the spleen and other peripheral immune organs. This 
difference  is  mainly  due  to  the  antigenic  environment  of  the  intestine  (intestinal 
microflora and dietary antigen) which is in contrast to the generally sterile environment 
that surrounds systemic  immune  system  (Mayer 2005). The  fact that the  mesenteric 
lymph  node  (MLN)  are  the  first,  and  largest,  lymph  nodes  to  be  formed  during 
embryogenesis  further  highlights  the  importance  of  intestinal  immune  system 
(Newberry and Lorenz 2005).  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
1.1.1 Intestinal immune system in colon   
In order for the intestinal immune system to function optimally it requires a mechanism 
that is finely balanced between mounting an effective immune response to pathogenic 
antigens while suppressing any potentially destructive responses against the commensal 
microflora or food antigens. The intestinal immune system thus has certain distinctive 
features that allow  it to maintain this balance, such as the presence of an  intestinal 
barrier, gut-associated lymphoid tissue (GALT) as well as both the innate and adaptive 
immune systems that are phenotypically and  functionally specifically adapted to the 
intestinal microenvironment.  
The intestinal epithelium is composed primarily of intestinal epithelial cells and is the 
first  line  of  defense.  Under  normal  conditions,  the  intestinal  epithelium,  with  the 5 
 
overlaying mucus layer, serves as a barrier between the luminal contents and the GI 
mucosa. A defect in this barrier, however, is frequently observed in both CrD and UC 
and is central to the development of the colitis in animal models of these diseases (Su et 
al. 2009). The layer of epithelial cells, however, not only forms a barrier between the 
body and the luminal contents but is also responsible for importing nutrients into the 
body,  the  release  of  antibodies  into  the  lumen  and  the  production  of  antimicrobial 
peptides as well as pro-inflammatory cytokines in response to activation of the immune 
defense system (Artis 2008). The epithelial layer also contains other specialised cell 
populations that confer further protection to the host. These include the goblet cells that 
secrete a protective mucus layer that covers the epithelium and paneth cells that secrete 
antimicrobial peptides such as the defensins and lysozymes which help to prevent direct 
access of microorganism to the intestinal mucosa (Cash et al. 2006; Schenk and Mueller 
2007).  
 
The intestine is associated with several types of lymphoid organs collectively known as 
GALT.  As  the  intestine  is  a  primary  site  for  encounters  with  foreign  antigens,  the 
presence of GALT, not only provides a rapid immunological response, but also provides 
an immune response that is specific to the gut. GALT includes the Peyer’s Patches (PP) 
found  within  the  small  intestine  and  isolated  lymphoid  follicles  (ILF),  which  are 
distributed throughout the large intestine and are sites where the immune response is 
frequently initiated. PP and ILF are connected by a lymphatic network to the draining 
MLNs that play a crucial role in initiating and shaping the immune responses to the 
intestinal foreign antigens. (Lorenz et al. 2003; Murphy 2008). The PP and ILF have a 
similar structure with each containing specialised M cells, antigen presenting dendritic 6 
 
cells (DC)s, and T and B lymphocytes which play important roles in generating the 
mucosal immune response.  
 
The innate immune responses occur rapidly in order to provide immediate protection to 
the host. Overlapping with this system, there is the adaptive immune system that takes a 
longer time to respond (>96 hours), but is more efficient in the elimination of specific 
pathogens (Murphy 2008). The innate immune system eliminates harmful pathogens by 
phagocytic mechanisms and production of cytokines, it also promotes the release of co-
stimulatory signals that can then activate an adaptive immune response. 
 
Immune responses in the colon take place in three distinct locations: the lamina propria 
(LP), the ILF scattered throughout the colon, and the MLN as shown in Figure 1.1. DCs 
are present in large numbers within the LP and ILF, where they are able to capture and 
sample bacterial antigen from the gut lumen by penetrating their finger-liked processes 
across the epithelium without disrupting its integrity (A and B in Figure 1.1). Antigens 
from pathogens that penetrate the mucosal barrier are taken up by local DCs and carried 
via the lymphatics to the draining MLN. DC can also signal to the innate and adaptive 
immune cells that are present within the LP to eliminate the harmful pathogens (C in 
Figure  1.1).    In  addition,  DCs  situated  in  GALT  such  as  ILF  can  sample  luminal 
antigens via specialised epithelial cells (M cells). The M cells continually monitor the 
luminal contents, transport molecules and particles into the mucosa via phagocytosis 
and endocytosis from the gut lumen and releasing them into the extracellular space by 
transcytosis. The transported antigen is then taken up and sampled by the underlying 
antigen  presenting  DCs.  Antigen  containing  DCs  then  meet  and  activate  the  naï ve, 
antigen–specific  T  lymphocytes  located  within  in  the  ILF  in  order  to  generate  an 7 
 
immune response (D in Figure 1.1). These DCs also migrate to the draining MLN in 
order to present the antigen to other naï ve lymphocytes (E in Figure 1.1) (Murphy 2008; 
Izcue et al. 2006, 2009; Banchereau et al. 2000). Following antigen stimulation, the 
activated lymphocytes migrate into the draining MLNs where further maturation occurs. 
Following this, the mature cells migrate through the lymphatic circulation, though the 
thoraric duct and via the bloodstream in order to return to the LP layer of the colon as 
mature lymphocytes (or effector cells) (F in Figure 1.1). This occurs with the help from 
the gut-specific homing integrins and chemokines, mucosal vasacular addressin cellular 
adhesion molecules (MAdCAM)-1 and CCL28 (mucosal epithelial chemokine) (Izcue 
et al. 2009; Iwata et al. 2004). Once the mature lymphocytes have returned to the gut, 
they are able to clear the intestinal mucosa of the foreign antigens (Eksteen et al. 2006; 
Kato  et  al.  2000)  and  once these  foreign  antigens  are  cleared,  most of  the  effector 
lymphocytes will die by apoptosis, leaving a small population of memory cells with a 
longer  lifespan  that  can  rapidly  mount  another  immune  response  for  any  future 
encounter with the same antigen (Eksteen et al. 2005; Murphy 2008).  
 
A second immune response that can also be generated through the activation of cells 
located in the GALT is driven through B lymphocytes that produce antigen specific 
immunoglobulins (Ig). These Igs within the mucosal tissues or MLN can promote the 
differentiation of the B cells into plasma cells that are able to secrete higher amounts of 
IgA and other Ig isoforms into the LP. Secreted IgA is then able to inhibit mucosal 
adherence by the bacteria, neutralise viruses and enhance clearance of the pathogenic 
microorganism (Murphy 2008; Neurath et al. 2002).   
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Image adapted and modified from (Izcue et al. 2006) 
Figure  1.1  The  intestinal  immune  responses  occur  within  the  epithelium,  LP,  and 
GALT and MLN. A, B) DCs can sample bacterial antigen by penetrating the epithelium 
with their dendrites or by capturing antigen carried across the epithelium. C) DCs can 
then signal to effector T cells, Tregs and also other components of the innate immune 
system. D) M cells that are present in the ILF can transport antigen from the lumen and 
are  then  taken  up  by  local  DCs  in  the  ILF,  antigen  containing  DCs  then  meet  and 
activate the naï ve, antigen–specific T lymphocytes located within the ILF in order to 
generate an  immune response.  E) In addition to their  local role, intestinal DCs also 
migrate into the draining MLN where they present foreign antigen to T cells. F) Naï ve T 
cells  activated this way return to the blood and preferentially  migrate back  into the 
colon,  where  they  will  again  encounter their  cognate  antigen.  G)  T  cells,  including 
effector T cells, also migrate to the spleen;  in many disease  models,  local  intestinal 
inflammation induces the accumulation of activated T and innate immune cells in the 
spleen. 
D 
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1.1.2 Innate immunity in the colon  
The  innate  immune  response  is  composed  of  mechanical,  chemical  and  cellular 
elements. The intestinal epithelial cells form the cellular barrier between the host and 
the environment as well as providing a mucus secretion that covers and protects the 
monolayer  of  cells.  This  constitutes  the  mechanical  aspect.  The  chemical  elements 
include  the  involvement  of  pattern  recognition  receptors  (PRR)  like  the  Toll-like 
receptors (TLR) and nucleotide oligomerisation domain (NOD) receptors that are able 
to recognise and bind “highly conserved pathogen-associated molecular patterns” that 
are located on the cell surface of most of the noneukaryotic organisms. These PRR are 
subsequently able to activate the nuclear factor (NF)-κB signaling pathway that controls 
expression  of  many  inflammatory  cytokines  and  chemokines.  The  release  of  these 
factors then can promote the attraction of effector immune cells to the site of the insult. 
Each class of the innate immune cells (e.g. DC, eosinophil, neutrophils, mast cells etc) 
then secrete a characteristic profile of cytokines and pro-inflammatory mediators that 
have overlapping functions in order to progress the immune response (Kumar 2010; 
Takeda and Akira 2005). This cellular innate immune response also protects the tissue 
through the processes of phagocytosis by macrophages and the killing of the invading 
microbial agent by natural killer cells (Biron et al. 1999; Arseneau et al. 2007).  
 
1.1.2.1 Macrophages 
Intestinal  macrophages  (especially  in  the  colon)  represent  the  largest  population  of 
mononuclear  phagocytes  in  the  body  (Lee  et  al.  1985),  and  are  capable  of 
phagocytosing (engulfing and killing) pathogens as a non-specific defense against any 
invading antigen to maintain tissue homoestasis. It has been shown that depletion of 
macrophages  results  in  more  severe  intestinal  inflammation  in  the  dextran  sodium 10 
 
sulphate (DSS)-induced colitis model in the mouse (Qualls et al. 2006). Macrophage 
depletion, however, has also been shown to reduce the development of the spontaneous 
colitis  observed  in  interleukin  (IL)-10  deficient  mice  (Wirtz  and  Neurath  2007) 
suggesting that the intestinal macrophages could have a dual function within the gut.     
 
Blood monocytes originate in the bone morrow from a common myeloid progenitor and 
are the progenitors for all resident macrophages subsets, e.g. Kupffer cells in the liver, 
osteoclasts in the bone and intestinal macrophages in the gut. From the circulation, the 
blood  monocytes  migrate  into the tissue  where  they  mature  into  fully  differentiated 
resident  macrophages.  The  intestinal  resident  macrophage,  unlike  other  resident 
macrophages subsets (e.g. Kupffer cells), has not been shown to proliferate suggesting 
that continuous replenishing of the  intestinal population of  macrophages  must occur 
solely by the migration of blood monocytes to the intestine in response to the potent 
chemokine  activity  of  transforming  growth  factor  (TGF)-β  and  IL-8  that  are 
constitutively produced by mucosal epithelial cells and mast cells under homeostasic 
conditions (Smythies et al. 2006; Smith et al. 2010). When this homeostasis is disturbed, 
such as in the presence of inflammation, there will be an increase in recruitment of 
blood-borne  monocyte  precursors  to  boost  the  mononuclear  phagocyte  numbers  in 
inflamed  tissue.  This  macrophage  type  is  considered  to  be  the  inflammatory 
macrophage (Schenk and Mueller 2007; Heinsbroek and Gordon 2009). Depending on 
the  extracellular  microenvironment,  murine  studies  suggest  that  these  inflammatory 
macrophages  may  further  polarise  into  macrophages  with  either  M1  and/or  M2 
characteristics (Smith et al. 2010).  
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Intestinal resident macrophages are phenotypically and functionally different from the 
inflammatory macrophages and their precursor blood monocytes as shown in Table 1.1. 
The  intestinal  macrophages  do  not  express  the  lipopolysaccharide  (LPS)  receptor 
(CD14) and several innate response receptors (e.g. TLR4), make it unresponsive to LPS 
and other microbe associated molecular patterns that present abundantly in the intestinal 
microflora. Intestinal macrophages also lack the Fc receptors for Igs (CD16, CD32 and 
CD640), the complement receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18), and 
the integrin α2β1. These Fc and complement receptors on phagocytes usually mediate 
cellular  activation,  secretion  of  pro-inflammatory  cytokines  and  induction  of  potent 
adaptive immune responses. Low, or absent, cell surface expression of CD40, CD80 
and CD86 give intestinal macrophages a reduced ability to respond to certain immune 
stimuli and also make then unable to activate a T cell-mediated immune response, hence 
they do not act as antigen presenting cells (APCs). The intestinal macrophages, however, 
retain and even have enhanced phagocytic and bactericidal capabilities. In combination 
this allows them to maintain the homeostasis in the gut without an over-response to the 
‘healthy microflora’ found within the intestinal lumen (Smythies et al. 2005; Smith et al. 
2001; Heinsbroek and Gordon 2009; Sartor 2003; Smith et al. 2010). 
 
By contrast, the inflammatory macrophages recruited to the mucosa during intestinal 
inflammation produce pro-inflammatory cytokines (Burgio et al. 1995; Rugtveit et al. 
1994)  that  result  in  epithelial  cell  apoptosis,  epithelial  barrier  dysfunction,  tissue 
necrosis,  development of  granulomas  and  the  formation  of  fibrosis  (Heinsbroek  and 
Gordon  2009).  The  LP  macrophages  isolated  from  the  inflamed  intestine  of  IBD 
patients  also  demonstrate  high  expression  of  CD14,  CD80,  CD86  and  increased 
activation of NF-κB (Rugtveit et al. 1997; Schenk et al. 2007; Neurath et al. 1998). In 12 
 
patients  with  CrD,  the  number  of  CD14  expressing  macrophages  was  significantly 
increased  in  the  intestine  compared  with  normal  control  subjects,  these  cells  also 
produce higher levels of interferon (IFN)-γ, tumour necrosis factor (TNF)-α and IL-23 
(Kamada et al. 2008; Reimund et al. 1996). In addition, and in marked contrast to the 
resident intestinal macrophage, the inflammatory macrophage also expresses Triggering 
Receptor Expressed on Myeloid cells-1 (TREM-1) which is an efficient amplifier of 
both  the  acute  and  chronic  inflammatory  reaction  and  is  generally  expressed  on 
peripheral  blood neutrophils and the monocytes and  macrophages  located within the 
secondary  lymphoid  organs.  Engagement  of  TREM-1  to  its  receptor  on  TREM-1-
positve myeloid cells results in enhanced secretion of the pro-inflammatory cytokines 
(e.g. TNF, IL-1β, -6, -8, MCP-1) (Bouchon et al. 2000; Schenk et al. 2007).   
 
To date, there is still a lack of a definite, unique marker that can fully distinguish the 
resident intestinal macrophage from the recruited inflammatory macrophages. This is 
particularly  true  in  the  murine  immune  system.  The  human  intestinal  macrophages 
generally  express  the  myeloid  markers  CD13,  CD33,  CD68  and  HLA-DR  (major 
histocompatibility complex (MHC) class II  molecule) at  levels  comparable to blood 
monocytes and most resident macrophages in other organs (Smith et al. 2001) and in an 
elegant study by Schenk et al., CD68 (a cytoplasmic marker) was used as a marker to 
identified  intestinal  macrophage  from  both human and  murine  model  (Schenk et al. 
2007).  CD11b  was  used  in  this  study  to  identify  the  infiltrating  inflammatory 
macrophages  as  there  is  a  lack  of  CD11b  expression  by  the  intestinal  resident 
macrophages. There was high expression of CD11b on colonic macrophages isolated 
from IBD patients (Rogler et al. 1997) and inflammatory peritoneal macrophages in 13 
 
mice (Rosas et al. 2010). This suggests that CD68 and CD11b can be used to identify 
the resident intestinal macrophages and inflammatory macrophages respectively.  
 
Table  1.1  Phenotypic  and  functional  differences  between  monocytes,  infiltrated  and 
intestinal  macrophages.  (Adapted  from  (Heinsbroek  and  Gordon  2009;  Smith  et  al. 
2010))  
Phenotype  Monocytes  Inflammatory 
macrophage 
Intestinal 
macrophage 
Toll-like receptors-  TLR-2  +  +  - 
                                 TLR-4  +  +  + 
CD4  +  +  Low 
CD11a/LFA-1  +  +  - 
CD11b/MAC-1  +  +  - 
CD11c/integrin α  +  +  - 
CD14  +  Low  - 
Fc receptors (CD16, CD32, CD64)  +  +  - 
Complement receptors (CR3, CR4)    +  - 
Chemotaxis (CCR5, CXCR4)  +  +  - 
Costimulatory molecules- CD40, CD86  +  +  - 
                                           CD80  -  +  - 
MHC molecules HLA-DR  +  +  + 
       
Function       
Phagocytosis   +  +  + 
Killing   +  +  + 
Chemotaxis   +  +/-  - 
Antigen presentation  +  +  ? 
Cytokines production (TNF-α, IL-1,-6,-8)  +  +  - 
Activation inflammatory responses (TREM-1)  +  +  - 
 
1.1.2.2 Dendritic Cells 
Dendritic Cells (DC) are professional APCs that are involved in most of the antigen 
presentation to T cells located within mucosal tissue and the draining MLN. As the DC 
are part of both the innate and adaptive immune system, they enable immune system to 
determine whether there should be a response, or not, to a potential invading antigen. 
The  DCs  are  central  to  determining  whether  a  regulatory  or  effector  cell  response 
predominates, and whether tissue specific homing of antigen specific effector cells takes 
place.  The  microbial  products  play  a  central  role  in  modulating  DC  function  and 
influencing these different immune outcomes (Zhang et al. 2006). The LP and MLN 14 
 
contain  unusual  subsets  of  DCs,  which  have  unique  functional  properties  that  are 
different from those DCs found in the spleen. For example CD103
+CD11c
+CD11b
+ DCs 
promote T cell expression of the gut homing receptors, CCR9 and α4β7, by producing 
retinoic acid while another subset of DCs (CX3CR1
+CD11c
lowCD11b
+) were shown to 
promote the generation of regulatory T (Treg) cells through the production of retinoic 
acid  and  TGF-β  in  the  colon  (Kelsall  and  Strober  1997;  Williamson  et  al.  2002; 
Svensson et al. 2008). Besides the antigen presenting functions and the maintenance of 
the local Treg cell pool, LP DCs also are able to promote colonic Th17 cell generation 
following activation by commensal microorganisms (Atarashi et al. 2008), can mediate 
IL-23-dependent granuloma  formation as well as the chronic  intestinal  inflammation 
observed in CrD patients (Mizoguchi et al. 2007; Krajina et al. 2003; Mowat 2003). 
 
1.1.3 Adaptive Immunity in the Colon  
Adaptive  immunity  is  the  immune  response  of  antigen–specific  lymphocytes  to  an 
antigen  and  the  development of  an  immunological  memory,  which  can  increase  the 
immune  response  with  a  subsequent  exposure  to  the  same  pathogen  and  act  as  the 
second wave of mucosal immunity. Lymphocytes are the primary cell involved in the 
adaptive immune response and can be subcategorised into T lymphocytes (T-cells) and 
B lymphocytes (B cells). In the intestine, T lymphocytes are located within the LP and 
the epithelial monolayer. T lymphocytes consist of two major subclass based on their 
expression of the CD markers. The CD4 cells are commonly known as T helper (Th) 
cells owing to the “help” they provide for B cells to trigger antibody production. The 
CD8 cells are known as cytotoxic T cells due to the high expression of macrophages–
activating IFN-γ and granzymes. Both groups of cells are only able to recognise antigen 
bound to self- MHC proteins. The CD4 cells recognise peptides bound on to MHC class 15 
 
II molecules and the CD8 cytotoxic T cells recognise peptides bound to the MHC class I 
molecules (Murphy 2008).  
 
1.1.3.1 CD4 T cells Subclasses 
The  development  and  differentiation  of  naï ve  CD4  T  cells  or Th  cells  is  under  the 
control of transcription factors such as T box that is expressed in T cells (T-bet) and the 
signal transducer and activators of transcription (STAT)-4, -6, GATA-binding protein-3 
and  retinoic-acid-receptor-related  orphan  receptor  (ROR)-γt  as  well  as  a  range  of 
cytokines.  The  pattern  of  cytokines  that  are  secreted  have  been  used  to  define  the 
different types of CD4+ Th cells found both in the mouse and human  (Brand 2009; 
Mosmann  et  al.  1986;  Rotteveel  et  al.  1988)  (Figure  1.2).  Depending  on  which 
cytokines are produced, different immune responses can be generated (Agnello et al. 
2003; Brand 2009). 
 
IL-12  activates  the  STAT4  signaling  pathway,  which  is  necessary  for  optimal 
differentiation of naï ve T cells into IFN-γ producing Th1 cells. IFN-γ then activates the 
STAT1  pathway  and  subsequently  T-bet  expression  (Kaplan  et  al.  1996). Th1  cells 
cannot be generated in vitro or in vivo without expression of T-bet, and over expression 
of T-bet is able to override and suppress Th2 signal and drive T cells to become Th1 
cells (Szabo et al. 2002). T-bet activation is also required for optimal IL-12 receptor 
expression and IL-12 responsiveness in Th1 cells (Lugo-Villarino et al. 2003). Th1 cells 
primarily produce IFN-γ, which is important for macrophages activation, and IL-12 that 
is crucial in directing the cytotoxic CD8 T cells responses. In combined these provide 
protection  against  the  presence  of  intracellular  pathogens  such  as  viruses  and 16 
 
intracellular bacteria. Aberrant Th1 cell responses, however, are thought to be involved 
in autoimmune diseases and chronic inflammation as in IBD.  
 
IL-4 stimulation leads to activation of the STAT-6 pathways that are required for the 
expression of the Th2 regulator transcription factor, GATA-3. GATA-3, together with 
other proteins, drives T cells towards a Th-2 phenotype. GATA-3 further drives the 
expression of IL-4, creating a positive feedback loop and inducing expression of further 
cytokines  such  as  IL-4,  IL-5  and  IL-13.  These  cytokines  are  primarily  involved  in 
allergic type reactions and the elimination of extracellular pathogens (Zhu et al. 2002; 
Shimoda et al. 1996; Heller et al. 2005). IL-13 produced by T cells, and natural killer 
cells, increases gut epithelial cell turnover during infection in order to enhance repair of 
any damage (Murphy 2008).  
 
It has been postulated that the inflammation that occurs in CrD is primarily mediated 
through Th1 cells, while the inflammation of UC is driven by Th2 cells. In support of 
this paradigm, active intestinal inflammation in CrD is associated with high levels of the 
Th1-polarising cytokine IL-12 when compared to the healthy controls and patients with 
UC (Monteleone et al. 1997).  This concept, however, has been challenged. Both human 
and animals studies show that both the Th1 and Th2 adaptive immune responses are 
involved in CrD pathogenesis, and at distinct stages of the disease. The initiation of the 
CrD-like intestinal inflammation in the SMAP1/YitFc mouse model of colitis is indeed 
Th1 mediated and requires the expression of IFN-γ and TNF-α. The chronic stage of the 
inflammation in these mice, however, is driven by IL-5 and IL-13, the Th2-polarising 
cytokines (Bamias et al. 2005). In addition, in children with CrD, intestinal mucosal T 
cells  initially  demonstrate  a  strong  Th1  response  in  the  acute  stages of  the  disease, 17 
 
which is characterized by the high levels of IFN-γ. This response, however, is noted to 
diminish over time with more prolonged inflammation (Kugathasan et al. 2007). The 
expression  of  IL-4  and  IL-5  has  also  been  shown  to  be  involved  in  human  CrD 
pathogenesis (Desreumaux et al. 1997) and this is further complicated by the recent 
discovery of the Th17 cell that appears to play a major role in both autoimmunity and 
the pathogenesis of inflammation in CrD. Collectively, the strict Th1/Th2 paradigm no 
longer appears to adequately explain the IBD pathogenesis.  
 
Development  of  the  Th17  cell  can  be  divided  into  three  stages,  differentiation, 
amplification and stabilisation. Naï ve T cells can differentiate  into Th17 cells in the 
presence of TGF-β, which is able to drive the Smad signaling pathway, and IL-6 that 
activates  the  STAT3  pathway.  STAT3  transcription  factor  is  then  involved  in  the 
expression of the ROR-γt and ROR-α, which induce IL-17A expression in T cells. IL-21 
is essential for the amplification of Th17 cell numbers. IL-21, which is induced by IL-6 
through STAT3 activation independently of ROR-γt, leads to activation of ROR-γt that 
induces further expression of IL-17A (Nurieva et al. 2007).  
 
The naive T cell is not responsive to IL-23 demonstrating that IL-23 is not required for 
the differentiation of naï ve T cells into Th17 cells. IL-23 is, however, important for the 
expansion of these cells (Veldhoen et al. 2008). TGF-β upregulates IL-23R expression 
and promotes T cell responsiveness to IL-23 (Zhou et al. 2008; Mangan et al. 2006). 
Th17 T cells are then able to produce IL-17A, IL-17F, IL-21, and IL-22, which enhance 
neutrophil  trafficking  to  the  site  of  infection  and  expression  of  colony  stimulating 
factors that link the innate with the adaptive immunity (Stockinger and Veldhoen 2007). 
Th17 cells are associated with the inflammation in IBD where the Th17 cytokines listed 18 
 
above are upregulated in IBD patients and are present at higher levels in the inflamed 
colon tissue and serum when compared to healthy controls (Fujino et al. 2003; Nielsen 
et  al.  2003;  Seiderer  et  al.  2008).  IL-17  also  stimulates  IL-6,  IL-8  and  monocyte 
chemotactic protein-1 (MCP-1) secretion via NF-κB and MAP kinase activation in the 
intestinal subepithelial myofibroblasts where these cytokines are shown to contribute to 
intestinal inflammation (Hata et al. 2002).  
 
 
 
 
 
 
 
Image adapted from (Brand 2009) 
Figure 1.2 Development of Th1, Th2, Th17 and iTreg cells from naï ve CD4+ T cells. 
An APC (e.g. DC) provides factors derived from the innate immune response to naive T 
cells together with antigenic peptides in the context of MHC class II molecules to the 
TCR, which is associated with the CD3 protein and the costimulatory signals (CD28 
and ICOS), that ultimately lead to polarized T cells responses. (Cytokines inducing the 
development  of  Th1,  Th2,  Th17  and  iTreg  cells  are  marked  in  red.  Main  effector 
cytokines  of  these  four  cell  lines  are  marked  in  blue.  Cytokines  which  inhibit  the 
development of Th17 cells are marked in black.) 
 
1.1.3.2 Regulatory T cells 
Regulatory  T  (Treg)  cells  are  vital  for  normal  mucosal  immune  homeostasis.  The 
gastrointestinal tract is frequently the first organ to suffer inflammation when the Treg 19 
 
cells are dysregulated, or deficient, due to the constant antigenic stimulation that bathes 
the intestinal mucosa (Wan and Flavell 2008). They also appear to play a role in the 
inflammatory processes involved in IBD as reduced numbers of Treg cells have been 
observed in the blood and sera in IBD patients when compared to controls (Boden and 
Snapper 2008).  
 
Treg cells are able to be defined by to the presence of a marker for the transcription 
factor forkhead box P3 (FoxP3). These cells also express other markers that include IL-
2 receptor α chain (CD25) and cytotoxic T lymphocytes associated protein 4 (CTLA-4), 
which have been used in the past to identify the Treg cells. These markers, however, are 
not exclusive to the Treg cell. The differentiation of naï ve T cells into Treg cells and the 
triggering of FoxP3 expression appears to be dependent on the TGF-β-Smad3 signaling 
pathway that is enhanced by the vitamin A metabolite retinoic acid (Mucida et al. 2007; 
Coombes et al. 2007). Treg cells secrete the two anti-inflammatory cytokines, IL-10 and 
TGF-β, which are important in both the control, and downregulation, of the effector T 
cells and innate immune cellular responses. IL-10 not only acts on innate immune cells 
in the intestine and also reduces Th cell proliferation. TGF-β has a similar effect on the 
differentiation  of  Th  cells,  but  also  inhibits  the  differentiation  of  naï ve  T  cells  into 
effector  Th  cells  (Zheng  et  al.  2007;  Zenewicz  et  al.  2009;  Wan  and  Flavell  2008; 
Maloy et al. 2003).  
 
Tregs also promote the differentiation of naï ve T cells into the Th17 phenotype in a 
TGF-β-dependent manner. Naï ve T cells can express both FoxP3 and ROR-γt when 
stimulated with TGF-β and depending on what other signals are received these cells can 
become either Treg or Th17 cells. High  levels  of TGF-β promote the expression of 20 
 
FoxP3 and permit the generation of Treg cells, while low levels of TGF-β, or TGF-β in 
the presence of IL-6, induces IL-23R expression and mediates Th17 cell differentiation. 
Retinoic acid, which enhances Treg cell differentiation, however, can also inhibit the 
development of the Th17 cell (Mucida et al. 2007; Veldhoen et al. 2006; Zhou et al. 
2008).  IL-2,  which  promotes  the  development  of  Treg  cells,  can  also  inhibit  the 
generation of Th17 cells, further supporting the reciprocal relationship between Treg 
and Th17 cells (Laurence et al. 2007).  
 
1.1.4 Summary 
In  summary,  if  potential  harmful  pathogens  breach  the  epithelial  barrier  of  the  gut, 
APCs such as DC, macrophages, and potentially fibroblasts  (Parsonage et al. 2005), 
phagocytose  or  process  the  pathogens  before  presenting  the  antigen  components  to 
naï ve CD4 T cells. The activated T cells then undergo differentiation into either effector 
(Th1, Th2 or Th17) or regulatory cells. The effector T cells can then mount a specific 
immune  response  through  the  expression  of  unique  cytokines  and  aid  in  B  cell 
activation. Once the pathogen has been cleared, the Treg cells help in the suppression of 
inflammation in order to restore the homeostasis of the GIT. Together, both innate and 
adaptive  immune  systems  work  synergetically  to  maintain  homeostasis  within  the 
vulnerable gut microenvironment.   
 
1.2 WOUND HEALING AND TISSUE FIBROSIS  
As  mentioned earlier,  fibrosis resulting  in  stricture formation that leads to intestinal 
obstruction and surgery  is  not an uncommon occurrence  in IBD, especially  in CrD. 
Fibrosis is the undesired end result of the wound repair process resulting from chronic 21 
 
injury. When tissue injury occurs a signal from the damaged tissue i.e. epithelial cells, 
triggers the release of inflammatory mediators that initiate haemostasis (Figure 1.3). 
Thereafter,  epithelial  cells  secrete  growth  factors  and  chemokines  that  stimulate  the 
proliferation  and  recruitment  of  leukocytes  that  produce  pro-fibrotic  cytokines  and 
include TGF-β, IL-13 and TNF-α (Wynn 2004; Theiss et al. 2005; Fiocchi et al. 2006; 
Fichtner-Feigl  et  al.  2006).  Matrix  metalloproteinases  (MMPs)  are  produced  by 
stimulated myofibroblasts, and epithelial cells, and are able to disrupt the ECM to allow 
efficient cellular recruitment to the site of injury. Neutrophils and macrophages remove 
the  tissue  debris  and  dead  cells,  and  secrete  the  chemical  signals  that  promote  the 
recruitment  and  activation  of  T  cells.  The  T  cells  have  an  important  role  in  the 
production of IL-13, which is involved in the formation of granulation tissue (Seno et al. 
2009).  
 
Fibroblasts and subepithelial  myofibroblasts are subsequently recruited and activated 
within the granulation tissue and these cells are the primary source of collagen synthesis 
and  deposition.  In  the  normal  intestine,  both  fibroblasts  and  subepithelial 
myofibroblasts  in  the  submucosa,  intermuscle  connective  tissue  of  the  muscularis 
propria, and serosa are the primary sources of collagen mRNA and protein expression 
(Pucilowska, McNaughton, et al. 2000). Subepithelial myofibroblasts are later involved 
in wound contraction that aids in the closure of the wound site following angiogenesis. 
Lastly,  the  epithelial  cells  divide  and  migrate  over  the  basal  membrane  in  order  to 
regenerate the epithelium to complete the wound repair process without the formation of 
scar tissue.  
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When injury continues, however, as in the case of the chronic inflammation associated 
with CrD, fibrosis can develop. Fibrosis is characterised by excessive ECM deposition 
without complete regeneration of the injured tissue and results in the formation of a 
permanent  fibrotic  scar  with  disruption  to  the  normal  tissue  architecture  (Lund  and 
Rigby 2008; Wynn 2004; Diegelmann and Evans 2004). 
 
Image adapted from (Wynn 2004) 
Figure1.3 The pathogenesis of fibrotic disease 
 
Inflammation  normally  occurs  prior  to  fibrosis  formation,  but  several  experimental 
models have demonstrated that the level of fibrosis is not necessary linked with the 
severity of inflammation. This suggests that the mechanisms of fibrogenesis may be 
different  from  those  that  regulate  inflammation.  The  schistosomiasis–induced  liver 23 
 
fibrosis model has demonstrated that fibrosis can occur in the liver prior to the induction 
of  chronic  inflammation  (Wynn  et  al.  1995)  and  mediated  by  a  Th2  response  that 
involves the secretion of  IL-3, IL-4 and IL-13 (Kaviratne et al. 2004). This showed that 
CD4 T cells and the developing Th cellular responses are involved and play important 
roles  in  both  the  development  of  inflammation  and  fibrosis  (Wynn  et  al.  1995; 
Hoffmann et al. 2000; Fichtner-Feigl et al. 2005).    
 
1.3 SECRETED PROTEIN ACIDIC AND RICH IN CYSTIENE  
Secreted Protein Acidic and Rich  in Cystiene (SPARC),  is also known as basement 
membrane 40 and osteonectin, and was first described as a major component in human 
and bovine bones. It is, however, expressed by a wide variety of cell types in adult 
vertebrates and is located primarily within the tissues that undergo consistent cellular 
turnover i.e. the bone and gut. It is also strongly expressed in fibroblasts, endothelial 
cells, epithelial cells and macrophages located within sites of injury (Reed et al. 1993; 
Puolakkainen et al. 1999;  Latvala et al. 1996). SPARC  has demonstrated numerous 
functions in the modulation of cell-matrix interactions and cell function without actually 
participating in the structural scaffold of ECM (Brekken and Sage 2000; Tai and Tang 
2008). Due to many of its novel roles, SPARC has been directly, and indirectly, showed 
to  be  involved  in  the  processes  of  both  inflammation  and  fibrosis  in  many  organs 
including the lung, liver, pancreas heart and adipose tissue. Its function within the colon 
is less well understood and is the focus of this thesis (Wang et al. 2010; Klopcic et al. 
2008; Chang et al. 2010; Kos et al. 2009; Pershouse et al. 2009; Reding et al. 2009; 
Savani et al. 2000).  
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1.3.1 Structure and general functions 
SPARC is a 32 kD protein after the cleavage of the signal sequence, and is secreted in a 
form that migrates at a molecular weight of 43 kD on a SDS-PAGE gel. The sequence 
of the SPARC gene, and the protein it encodes, are highly conserved among species 
(Yan and Sage 1999) with the structure of the human protein consisting of 286 residues 
organized in three domains (Figure 1.4). In vitro studies have shown that SPARC can 
be proteolytically cleaved into peptides with functions that are different from the native 
protein (Phan et al. 2007; Tai and Tang 2008; Kos and Wilding 2010; Bradshaw and 
Sage 2001; Brekken and Sage 2000). The NH2 terminal domain is an acidic region that 
contains the major immunological epitopes of the protein. Peptide 1.1, a sequence of 
this  domain,  has  been  shown  to  promote  cellular  rounding,  induces  de-adhesion  in 
endothelial cells and fibroblasts, a process that involves loosening of the structural links 
between the cytoskeleton and the ECM, and can inhibit the migration of cells (Lane and 
Sage 1990; Hasselaar and Sage 1992).  
 
The second domain is a Cys-rich, follistain-like domain which binds activin, inhibin and 
proteoglycans. It contains a sequence named peptide 2.1 located at the NH2- terminal 
end of the domain that is involved in, de-adhesion and inhibition of endothelial cell 
proliferation (Murphy-Ullrich et al. 1995; Funk and Sage 1993, 1991). It also contains 
two  copper  binding  sites  one  of  which,  with  the  sequence  KGHK,  stimulates  cell 
proliferation  of  endothelial  cells  and  fibroblasts,  and  angiogenesis  (Funk  and  Sage 
1993).  
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The third domain, the C-terminal extracellular domain, contains two EF-hand motifs 
that bind calcium with high affinity. It contains a sequence known as peptide 4.2 that 
interacts with endothelial cells and binds fibril-forming collagens (Tremble et al. 1993; 
Sasaki et al. 1998; Lane and Sage 1990).  
 
 
 
 
 
 
 
Image adapted and modified from (Bradshaw and Sage 2001; Kos et al. 2009) .  
Figure  1.4  Structure  of  the  SPARC  protein.  A  ribbon  diagram  derived  from 
crystallographic  data  shows  the  three  modular  domains  of  SPARC.  Representative 
activities attributed to each domain are shown beneath the designated amino acids. (The 
follistatin-like  domain  contains  the  peptide  2.1  shown  in  green;  The  (K)GHK 
angiogenic peptide (amino acids 114–130) shown in black; The E-C domain contains 
the amino acids 255–274 (peptide 4.2) shown in yellow.) 
 
From its structure, SPARC appears to be an inhibitor of the cell cycle and is an anti-
adhesion  molecule,  which  causes  cellular  rounding.  In  vitro  studies  have  also 
demonstrated that SPARC is able to regulate cellular differentiation, inactivate cellular 
response to certain growth factors and is also able to modulate cellular proliferation and 
migration. SPARC interacts with the ECM components and to induce MMP expression 
and  has  a  crucial  role  in  cell-matrix/cell-cell  involved  events  like  tissue  renewal, 
remodeling,  and  embryonic  development.  Owing  to  these  properties,  SPARC  is 26 
 
considered  a  regulatory  protein  of  ECM  reorganisation,  wound  healing-fibrosis, 
angiogenesis, inflammation and even tumorigenesis (Raines et al. 1992; Bassuk et al. 
1999; Hasselaar et al. 1991; Kupprion et al. 1998; Tai and Tang 2008; Brekken and 
Sage 2000; Bradshaw and Sage 2001).   
 
1.3.2 SPARC and ECM  
The ECM not only provides a structural framework for the support of cells, but also acts 
as a reservoir for embedded cytokines and growth factors. The ECM harbours cryptic 
information  within  the  molecules  that  make  up  the  ECM  network.  The  ECM  is 
composed  of  a  complex  mixture  of  insoluble  structural  macromolecules,  including 
collagen,  laminin,  fibronectin,  and  proteoglycans  that  are  produced  locally  by 
fibroblasts, epithelial, smooth muscle and endothelial cells. Besides that, matricellular 
proteins that consist of thrombospondin 1, 2, tenascin and SPARC, are also transiently 
secreted into the ECM but do not become part of the ECM mesh.  They are not detected 
within  the  established  normal  ECM  but  are  abundantly  expressed  at  sites  of  ECM 
turnover and can act to modulate cell-cell/cell-matrix interactions (Podhajcer et al. 2008; 
Simon-Assmann et al. 1995; Aumailley and Gayraud 1998; Phan et al. 2007). SPARC 
knockout  (KO)  mice  are  characterised  with  decreased  bone  turnover,  early  cataract 
development, altered collagen content in the lens and collagen fibril diameter in the 
dermis and greater size of subcutaneous adipose tissue pads when compared to control 
animals. This highlights the essential interaction of SPARC with the ECM in multiple 
tissues (Kos and Wilding 2010; Chlenski and Cohn 2010). 
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ECM components such as the fibril-forming collagen I, III, V, and basement membrane 
collagen IV, vitronectin, laminin are able to bind to SPARC (Brekken and Sage 2000). 
Collagen may serve as a storage site for SPARC in the ECM or may directly modulate 
the de-adhesive and anti-proliferative activity of SPARC (Sasaki et al. 1998). SPARC 
has been shown to increase MMP production and activity (Tremble et al. 1993), which 
play important roles in healing and fibrosis and will be discussed further. The affinity of 
collagen  binding  to SPARC  is  increased  when  a  single  peptide  bond  located  in  the 
SPARC,  within  the  third  C-terminus  extracellular  domain,  is  cleaved  by  several 
different  MMPs  including  MMP-2,  -3,  -7,  and  -13.  Collectively,  these  observations 
suggest that SPARC acts in both an autocrine, or paracrine, positive feedback loop such 
that SPARC stimulates the expression of MMP-2, which is then able to proteolytically 
cleave SPARC, that in turn increases the affinity of SPARC for collagen (Brekken and 
Sage 2000). This interaction between collagen and SPARC may also result in further 
remodeling of the ECM. This was  further demonstrated in the  Mov-13  mice, which 
carry a mutation in the collagen 1α1 gene, and do not express collagen I in most tissues. 
These  mice  have  impaired  deposition  of  SPARC  within  the  ECM  and  die  in  utero 
(Raines et al. 1992).  
 
Besides collagen, vitronectin in the ECM interacts and binds to SPARC in vivo, which 
is also demonstrated by the colocalisation of both proteins in blood vessel walls of a 
variety  of  tissues.  This  binding,  however,  can  be  inhibited  by  type-1  plasminogen 
activator inhibitor (PAI-1), inhibitor of both urokinase type plasminogen activator (uPA) 
and tissue type plasminogen activator (tPA). Plasma vitronectin normally will not bind 
to SPARC, but it can be converted to a multimeric SPARC  binding  form by PAI-1 
(Rosenblatt  et  al.  1997).  Thus,  PAI-1  can  affect  and  interfere  with  the  binding  of 28 
 
vitronectin to SPARC, due to the SPARC stimulated production of PAI-1 by endothelial 
cells.  This  can  act  as  another  potential  feedback  loop  for the  regulation  of  SPARC 
function and its association with the ECM (Lane and Sage 1994).  
 
Finally, SPARC has been shown to enhance fibronectin–induced assembly of ECM via 
the  intergrin-linked  kinase  (Barker  et  al.  2005).  All  these  interactions  suggest  that 
SPARC  participates
  in  the  regulation  of  tissue  remodeling  and  repair  where  it  is 
necessary to facilitate production of an ECM permissive for cell migration, proliferation, 
and differentiation (Bradshaw and Sage 2001).  
 
1.3.3 SPARC and other proteins  
Binding  and  interacting  with  other  proteins  and  cytokines  is  the  other  major 
characteristic of SPARC. SPARC was shown to bind the platelet derived growth factor 
(PDGF) dimers AB and BB and vascular endothelial growth factor (VEGF), which has 
20% homology to PDGF. Both PDGF and VEGF lose their mitogenic potency after 
binding  to  SPARC  as  SPARC  prevents  the  binding  of  PDGF  to  its  receptors  on 
fibroblasts thus affecting the biological activity of PDGF. SPARC also decreases the 
binding of VEGF to the endothelial cells and reduces the association of VEGF with its 
cell surface receptor Flt-1, which in turn inhibits endothelial cell proliferation induced 
by  VEGF.  In  addition,  SPARC  has  been  shown  to  interact  with  and  inhibit  the 
proliferative effect of basic fibroblast growth factor on smooth muscle cells (Bradshaw 
and Sage 2001; Yan and Sage 1999).  
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1.3.3.1 SPARC and TGF-β 
TGF-β  is  a  homodimeric  25kDa  protein.  It  is  secreted  and  maintained  in  a  latent 
complex where the cytokine non-covalently interacts with a latency-associated peptide 
(LAP).  The  latent  TGF-β  complex  is  sequestered  within  the  ECM  by  a  covalent 
attachment between LAP and a latent TGF-β binding protein (LTBP). Both the LAP 
and LTBP need to be proteolytically removed before the mature TGF-β protein can 
function. Latent TGF-β can be activated by a number of physical processes including 
heat,  acid,  reactive  oxygen  species,  and  biological  processes  such  as  proteolysis  or 
integrin  mediated  activation.  A  number  of  proteases  including  plasmin,  thrombin, 
MMP-2 and MMP-9 have been shown to be capable of directly activating latent TGF-β 
in vitro (Annes et al. 2003; Border and Noble 1994; Jenkins 2008).  
 
SPARC can induce MMP-2 and MMP-9 (Tremble et al. 1993; Kato et al. 2001), which 
can  cleave  the  LAP  releasing  active  TGF-β  (Ge  and  Greenspan  2006;  Yu  and 
Stamenkovic 2000). Both SPARC and TGF-β increases the production of PAI-1, which 
inhibits the formation of plasmin that is also known to be an activator of latent TGF-β1. 
Recently, SPARC has been showed to regulate the basal expression of PAI-1 in lung 
fibroblasts through the β catenin pathway (Chang et al. 2010). Reduction of plasmin not 
only down regulates the expression of TGF-β and also reduces the protease activity 
against SPARC, thus prolonging its activity in tissue (Hasselaar et al. 1991). SPARC 
has  been  shown  to  inhibit  the  production  of  thrombospondin-1  which  is  a  major 
activator of TGF-β1 in the endothelial cells (Murphy-Ullrich and Poczatek 2000; Lane 
et al. 1992). SPARC is also able to interact with TGF-β through the TGF-β/TGF-βRII 
complex and increase the downstream signaling of the SMAD-2 pathway. Incubation of 30 
 
epithelial  and  endothelial  cells  with  SPARC  induces  SMAD-2  phosphorylation  and 
increased expression of the TGF-β resposive genes (Francki et al. 2004).  
 
SPARC has the ability to modulate the activity of TGF-β and vice versa with TGF-β1 
reported to regulate the  expression  of  SPARC  in  fibroblasts  (Lane  and  Sage  1994). 
Mesangial cells isolated from SPARC null mice demonstrate a diminished expression of 
TGF-β1 that can be restored to WT levels  by the exogenous application of  SPARC 
(Francki et al. 1999). From the above, SPARC appears to have a positive correlation 
with TGF-β but the exact mechanism underlies the interaction of SPARC and TGF-β 
remain unknown to date, but modulation of SPARC/TGF-β pathway might represent a 
potential target to restore the mucosal immunity as TGF-β is a potent anti-inflammatory 
cytokine. 
 
1.3.4 SPARC in wound healing and fibrosis  
Wound repair is a complex, dynamic process in which various cell populations interact 
in  different  ways.  Immunohistochemical  and  in  situ  hybridization  techniques  have 
demonstrated  that  SPARC  is  expressed  spatially  and  temporally  in  injured  tissue, 
implying that SPARC is involved in repairing dermal wounds (Reed et al. 1993), the 
healing  of  intestinal  anastomosis  and  in  short  bowel  syndrome  (Puolakkainen  et  al. 
1999), wounded cornea (Seet et al. 2010; Latvala et al. 1996) and ischemic myocardium 
(Porter et al. 1995). Fibroblasts and macrophages start expressing SPARC in the healing 
wounds where it is also released by platelet degranulation (Reed et al. 1993). SPARC in 
turn induces MMP-1, MMP-3, MMP-9 expression by fibroblasts which are required in 
the wound healing processes (Tremble et al. 1993).  31 
 
Besides the capacity of SPARC to interact with the ECM, and various growth factors 
(e.g. PDGF, TGF-β and etc), SPARC also plays a vital role  in  angiogenesis that is 
important  in  wound  healing  process.  SPARC  is  expressed  in  the  newly  synthesised 
blood vessels from a variety of tissues (Reed et al. 1993). SPARC is also able to interact 
with vascular ECM and modulate the proliferation and migration of the endothelial cells. 
In vitro, intact SPARC protein has an anti-angiogenic activity and inhibits endothelial 
cell proliferation, however, the KGHK motif on the second domain is a strong inducer 
of angiogenesis and stimulates endothelial cell proliferation both in vitro and in vivo 
(Lane et al. 1994).  
 
SPARC KO mice have an enhanced rate in wound closure and this might be linked with 
the withdrawal of the inhibitory effect of SPARC on cellular proliferation or with the 
increase  in  subdermal  fat  in  the  KO  animals.  As  many  cells  that  infiltrate  into  the 
wound bed to repair the injured tissue have been shown to originate from the subdermal 
fat and muscle layer (Kurman and Argyris 1975), it been speculated that if there is an 
increase in fat there may also be an increase in the availability of cells that contributed 
to wound closure thus accelerating wound healing (Bradshaw and Sage 2001). 
 
There is a strong association between SPARC and tissue scarring and fibrosis. There are, 
however,  contradictory  reports  on  its  role  in  the  development  of  fibrosis  as 
demonstrated  in  two  bleomycin-induced  pulmonary  fibrosis  murine  models.  In  one 
SPARC null mice were seen to develop a more prominent fibrotic response than the 
wild type controls with enhanced collagen deposition and greater alveolar architectural 
destruction (Savani et al. 2000). This suggested that SPARC was anti-fibrogenic. In the 
second  “bleomycin-induced  pulmonary  fibrosis”  model,  Strandjord  et  al.  however, 32 
 
showed that SPARC KO mice’s lung had decreased collagen accumulation (Strandjord 
et al. 1999) and this finding was supported by recent work that demonstrated that the 
inhibition  of  SPARC  with  siRNA  decreased  the  expression  of  type  I  collagen  and 
attenuated the pro-fibrotic effect of TGF-β1 in cultured normal human fibroblasts (Zhou 
et al. 2005) and murine skin fibroblasts (Wang et al. 2010).  
 
It is thus unclear whether SPARC plays an anti- or pro-fibrogenic role in intestinal 
inflammation. As mentioned previously, SPARC can down-regulate the expression of 
ECM components such as fibronectin and laminin (Raines et al. 1992; Lane and Sage 
1994) and increases ECM degradation by MMPs. It has been showed that SPARC can 
induce  cyclooxygenase  (COX)-2  mediated  prostaglandin  (PG)-E2  synthesis,  which 
then  increases  MMP-1  and  -9  expression  by  macrophages  and  fibroblasts 
(Shankavaram et al. 1997; Tremble et al. 1993). On the other hand, SPARC also can 
reduce PGE2 levels which are linked with the development of intestinal fibrosis in the 
rat (Elson et al. 1995; Shankavaram et al. 1997). Furthermore, SPARC interacts with 
other growth factors in ECM which may enhance its anti-fibrogenic role as PDGF-BB 
and AB bind to SPARC and are prevented from binding to their fibroblast receptors 
when they bind to SPARC (Brekken and Sage 2000), thereby potentially inhibiting the 
induction  of  interstitial  collagen  secretion  and  the  mitogenic  effect  of  fibroblasts, 
smooth  muscle  cells,  and  myofibroblasts  resulting  in  diminished  ECM  deposition 
(Bradshaw and Sage 2001).  
 
The complex interaction of SPARC with the pro-fibrogenic TGF-β further complicates 
our understanding of SPARC’s role in fibrosis. As TGF-β is a pleiotropic cytokine that 
is ubiquitously expressed by all cells and tissues within the body and besides its crucial 33 
 
role in maintaining homeostasis in the gut as mentioned earlier, it is also implicated in 
the  pathogenesis  of  fibrosis  (Border  et  al.  1992;  Sato  et  al.  2003).  Alveolar 
macrophages in the bleomycin model of pulmonary fibrosis are thought to produce the 
active TGF-β that is involved in the pathological matrix remodelling process (Khalil et 
al. 1996). TGF-β is also able to pair with IL-13 to causes fibrosis, IL-13 can activate 
TGF-β by upregulating the expression of MMPs that can cleave the active TGF-β from 
its inactive, latent form and stimulate macrophages production of TGF-β1 that in turn 
activates the fibroblasts and enhances collagen deposition (Lee et al. 2001). Hence, the 
roles  that  SPARC  plays  in  intestinal  wound  healing  and  fibrosis  require  further 
investigation.  
 
1.3.5 SPARC in inflammation 
As in fibrosis, SPARC’s role in inflammation and the recruitment of inflammatory cells 
can  vary  in  different  organs.  In  the  bleomycin-induced  pulmonary  fibrosis  model, 
SPARC  KO  mice  exhibited  increased  leucocytes  infiltration  and  a  greater  fibrotic 
response (Savani et al. 2000), by contrast, decreased recruitment of inflammatory cells 
and reduced liver fibrosis was observed in the thioacetamide-liver fibrosis model with 
enforced down regulation of SPARC (Camino et al. 2008). It has been suggested that 
SPARC KO animals have an impaired immune response with decreased numbers of 
neutrophils and B cells but increased numbers of T cells, and are unable to mount an 
innate immune response to the bacterial product LPS in the mouse footpad swelling 
model (Rempel et al. 2007). These differences in the recruitment of inflammatory cells 
may also be a result of anomalies in the collagen content and the collagen bundle size in 
SPARC KO mice that make the ECM more “permeable” than their WT counterparts. 
This may allow the infiltrating inflammatory cells to migrate more freely (Llera et al. 34 
 
2010), an explanation that has been shown to be valid in the contact hypersensitivity 
model  in  the  SPARC  KO  mice  where  DC  migration  was  increased  in  vivo.  This 
accelerated the onset of T cell priming with greater numbers of epidermal Langerhans 
cells migrating to draining lymph nodes (Sangaletti et al. 2005). SPARC was shown to 
be pro-inflammatory in the kidney as significantly less recruitment of macrophages in 
response to angiotensin II was found in the tubulointestinal space of SPARC KO mice 
when compared to the WT  (Socha  et  al. 2007). SPARC, therefore,  is possibly pro-
inflammatory in the GIT as increased SPARC expression levels were found in inflamed, 
non fibrosed colonic surgical UC specimens (Lawrance, Fiocchi, et al. 2001).  
 
The pro-inflammatory cytokines TNF-α, IL-1β and IL-6, are crucial in the amplification 
of the mucosal inflammation observed in IBD. TNF-α and IL-1β are primarily secreted 
by monocytes, macrophages, activated intestinal macrophages, neutrophils, fibroblasts, 
and SMC, inducing the production of prostaglandins, proteases and other mediators of 
inflammation and tissue injury (Bosani et al. 2009). The mRNA expression of these 
cytokines  is  increased  in  the  inflamed  intestinal  mucosa  of  IBD  patients,  with  IL-6 
noted  to  be  particularly  high  (Raddatz  et  al.  2005).  SPARC  has  demonstrated  an 
inhibitory  effect  on  lysophosphatidic  acid-induced  proliferation  and  survival  in 
mesothelial-ovarian  cancer  cells  by  the  downregulation  of  IL-6  production  (Said, 
Najwer, et al. 2007). SPARC might play a regulatory role on the expression of these 
pro-inflammatory cytokines due to its capacity to modulate the activities of the cells that 
produce the cytokines.  
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1.3.6 SPARC in tumorigenesis 
There is clear evidence that chronic inflammation is linked the development of cancer 
as  it  has  been  observed  that  the  inflammatory  cells  recruited  to  an  area  of  tissue 
remodeling  will  secrete  proteases  and  angiogenic  mediators  that  favour  tumour 
development (Coussens and Werb 1996). Inflammatory cells, however, can also attack 
tumour cells (Podhajcer et al. 2008). Reduced tumour growth has  been observed  in 
SPARC KO mice that have been injected with mammary tumour cells compared to the 
wild type controls, where there were also greater numbers of infiltrating inflammatory 
cells  which were primarily polymorphonuclear  leucocytes (PMN)s and  macrophages 
(Sangaletti et al. 2003). Melanoma cells lacking SPARC expression can also induce 
PMN recruitment and tumour cell rejection via a mechanism that involves the increased 
release of chemotactic factors for inflammatory cells such as IL-8 (Alvarez et al. 2005). 
In a recent murine model of pancreatic carcinoma, however, macrophage recruitment 
and polarisation to the M2 phenotype was  increased and this resulted  in accelerated 
tumour progression and enhanced  metastasis  in the SPARC KO  mice  (Arnold et al. 
2010).  
 
Genome  expression  analysis  of  human  colorectal  cancer  cell  lines  resistant  to 
chemotherapeutic  agent  showed  deceased  levels  of  SPARC  (Tai  et  al.  2005).  The 
frequent inactivation of SPARC expression by promoter hypermethylation is related to 
rapid  progression  of  colon  cancers,  immunohistochemicaal  analysis  of  292  primary  
colorectal cancers showed that SPARC expression in neoplastic cells improves 5 year 
survival  rate  (Yang  et  al.  2007).  These  studies  suggested  that  SPARC  has  anti-
tumorigenic role in colon cancer. So, a better understanding on the role of SPARC in 
intestinal inflammation could be helpful in our understanding of colon carcinogenesis.  36 
 
1.4 ANIMAL MODELS OF INTESTINAL INFLAMMATION 
Animal  models  of  intestinal  inflammation  have  been  proven  to  be  extremely  useful 
tools  in  the  study  of  the  mechanisms  involved  in  IBD  and  can  be  divided  into  3 
categories depending on the cellular defect involved. 1) Models that depend on a defect 
in the epithelial barrier function (e.g. DSS, TNBS/oxazalone induced colitis); 2) Models 
with a defect in the innate immune system (e.g. mice with STAT3 deficiency in myeloid 
cells); and 3) Models with a defect in the adaptive immune system (e.g.  CD45RB
Hi 
transfer model) where mutant mice which lack certain genes, are required (Heinsbroek 
and Gordon 2009; Wirtz and Neurath 2007). The disadvantage of using animal models 
is  that  none  of  the  models  are  able  to  represent  all  aspect  of  the  human  disease. 
Choosing an appropriate animal model, however, can still be of use in the investigation 
of  specific  pathophysiological  mechanisms  and  the  testing  of  new  or  emerging 
therapeutic agents. Of the models, the barrier disruption colitis models with chemical 
such as DSS and trinitrobenzenesulfonic acid (TNBS) are the most widely used due to 
the low cost and ease to perform. They also exhibited many of the immunological and 
histopathological features seen in human IBD (Wirtz et al. 2007).  
 
Feeding mice for several days with DSS polymers in the drinking water induces a very 
reproducible acute colitis characterised by bloody diarrhea, ulcerations and infiltrations 
with granulocytes (Wirtz et al. 2007). Most in vivo and in vitro studies on the DSS-
induced colitis model suggest that DSS interferes directly with the intestinal epithelial 
cell barrier as the primary event that then leads to a mucosal inflammation (Wirtz and 
Neurath  2007;  Yan  et  al.  2009).  The  acute  DSS  colitis  model  is  very  useful  in  the 
investigation  of  the  contribution  of  the  innate  immune  mechanisms  of  colitis.  The 37 
 
adaptive  immune  system  does  not  appear  to  be  involved  in  the  acute  phase  of  the 
inflammation in this model as both T and B cell deficient mice are also able to develop 
severe colitis (Dieleman et al. 1998). Feeding susceptible mouse strains (e.g. C57BL/6 
and Swiss Webster mice) with several cycles of DSS, however, can result in chronic 
inflammation that is characterised by marked infiltration of mononuclear cells (Melgar 
et al. 2005; Mahler et al. 1998; Wirtz and Neurath 2007). In both the acute and chronic 
DSS-induced colitis models, DSS is able to induce the secretion of large amount of pro-
inflammatory cytokines like IL-6 and TNF-α which caused tissue damage (Strober et al. 
2002). The DSS-induced  model of colitis was used  in our studies to investigate the 
effect that SPARC can play on both the innate and adaptive immunity associated with 
intestinal inflammation.  
 38 
 
1.5 AIMS AND OBJECTIVES OF THE PROJECT 
The  IBD  are  chronic  incurable  conditions  and  not  all  patients  respond  to  current 
therapies. The development of alternate therapeutic strategies is thus a priority. SPARC 
is involved in many of the cellular processes associated with inflammation, healing and 
fibrosis and may be a possible therapeutic target in the management of IBD. A greater 
understanding of the mechanisms through which SPARC is involved in inflammation is 
required. 
  
SPARC is expressed at a low level in uninflamed adult colon, but it is expressed at the 
mesenchymal-epithelial border and in the smooth muscle layer in normal foetal intestine 
and also at the sites of inflammation and fibrosis in the adult GIT. SPARC can influence 
the infiltration of innate immune cells such as neutrophils and macrophages, into sites 
of inflammation but its overall role is unclear. SPARC might also be able to affect the 
adaptive immunity by influencing the production of various cytokines that promote the 
differentiation of T cells either into effector T cells such as Th17 T cells, or into Treg 
cells  that  suppress  the  immunological  responses.  Both  SPARC  and  TGF-β  have 
regulatory roles on cell proliferation, differentiation, inflammation and wound healing 
and they also modulate the activities of each other. Lastly, the capacity of SPARC to 
modify the activities of fibroblasts/myofibroblasts in ECM turnover also makes SPARC 
a potential target to improve healing and in the management of fibrotic diseases. Both 
human and animal studies, however, suggest that the roles of SPARC in inflammation, 
fibrosis as well as on tumorigenesis, appear to depend on diverse functions that may be 
specific to a given microenvironment. The studies described in this thesis, therefore, 
were undertaken to investigate possible effects of SPARC on the in vivo and in vitro 
development of intestinal inflammation, healing and fibrosis.  39 
 
The specific hypothesis: 
SPARC induces intestinal inflammation due to its regulatory role on the immune 
system  and  ECM  modulation  with  consequences  on  both  tissue  damage  and 
healing. 
 
General aim: 
To analyse the role of SPARC on intestinal inflammation in the murine model of 
DSS-induced colitis. 
 
The specific research aims: 
1)  To  characterise  and  compare  the  effect  of  SPARC  on  intestinal 
inflammation in the murine model of DDS-induced colitis. 
a.  To characterise the inflammatory symptoms and involvement of SPARC 
in DSS induced colitis.  
2)  To determine differences in the immune cellular infiltrates during intestinal 
inflammation in the presence and absence of SPARC.   
a.  To  establish  which  innate  immune  cells  infiltrate  to  colon  during 
intestinal inflammation.  
b.  To establish which adaptive T cells infiltrate to colon during intestinal 
inflammation. 
3)  To determine the roles of SPARC in ECM expression in vivo and in vitro 
a.  To determine the collagen content in vivo in the DSS induced colitis. 
b.  To investigate which the expression ECM genes are modulated by the 
presence or absence of SPARC in vitro.  40 
 
 
 
 
 
 
Chapter 2 
 
Materials and Methods 
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2.1 MATERIALS 
All chemical reagents used in the experiments outlined in this thesis were of analytical or 
biochemical  grade,  unless  otherwise  indicated  and  were  purchased  from  the  following 
manufacturers: 
2.1.1 General reagents and biochemicals 
Ammonium chloride (NH4Cl)  BDH Biochemicals (UK) 
Anaesthetics (Ketamine; Xylazine)  Troy Laboratories (AUS) 
Agarose  Sigma Aldrich (USA) 
Bovine serum albumin (BSA)   Sigma Aldrich (USA) 
Dextran sodium sulphate (DSS)  MP Biomedicals (AUS) 
DePeX mounting medium, Gurr®  Merck Pty Ltd (AUS) 
Dimethyl sulphoxide (DMSO)   Sigma Aldrich (USA) 
Dithiothreitol (DTT)   Sigma Aldrich (USA) 
EDTA  Merck Pty Ltd (AUS) 
Ethanol (100%)  Sigma Aldrich (USA) 
Ethiduim bromide  Merck Pty Ltd (AUS) 
Goat serum  DAKO (Denmark) 
Hydrogen chloride (HCl)  Sigma Aldrich (USA) 
Hydrogen peroxidase 30%  BDH Biochemicals (UK) 
Ionomycin calcium salt  Sigma Aldrich (USA) 
Isopropanol  Sigma Aldrich (USA) 
Magnesium chloride (MgCl)  Merck Pty Ltd (AUS) 
PBS tablet  Amersham Biosci (UK) 
Percoll ™  GE Healthcares  (USA) 
Phorbol 12-myristate 13-acetate (PMA)  Sigma Aldrich (USA) 
Picric acid   Sigma Aldrich (USA) 
Potassium chloride (KCl)  Merck Pty Ltd (AUS) 
Potassium hydrogen carbonate (KHCO3)  BDH Biochemicals (UK) 
Sirius red  Merck Pty Ltd (AUS) 
Sodium azide (NaN3)  Sigma Aldrich (USA) 
Sodium carbonate (Na2CO3)  Merck Pty Ltd (AUS) 42 
 
Sodium chloride (NaCl)  Merck Pty Ltd (AUS) 
Sodium hydroxide (NaOH)   Sigma Aldrich (USA) 
Tris (Hydroxymethyl Methane)  BDH Biochemicals (UK) 
Trypan blue  Sigma Aldrich (USA) 
Tween-20  Sigma Aldrich (USA) 
Water,”Ultrapure”, DNase/RNase-free  Gibco
® Invitrogen (USA) 
Xylene   Sigma Aldrich (USA) 
   
 
2.1.2 Tissue culture reagents and cell line 
Dulbecco's modified eagle medium (DMEM)  Gibco
® Invitrogen Co. (USA) 
Foetal bovine serum (FBS)  Gibco
® Invitrogen Co. (USA) 
L-Glutamine  Gibco
® Invitrogen Co. (USA) 
Hank's balanced salt solution (HBSS)  Gibco
® Invitrogen Co. (USA) 
HEPES   Gibco
® Invitrogen Co. (USA) 
Penicillin /Streptomycin/Fungizone (PSF)  Gibco
® Invitrogen Co. (USA) 
RPMI 1640 Medium  Gibco
® Invitrogen Co. (USA) 
TrypLE Express™.  Gibco
® Invitrogen  Co.(USA) 
A549 human epithelial cells   Gift from A/P. J.Allan, UWA, AUS 
 
 
2.1.3 Enzymes 
Collagenase IV  Worthington Biochemical (USA) 
Dispase II   Roche  diagnostics (Germany)  
DNase I  Invitrogen Co. (USA) 
Trypsin 250  Difco™, BD Biosciences (USA) 
 
 
 43 
 
2.1.4 RNA studies and reverse transcription reagents 
Bromochloropropane (BCP)  Sigma Aldrich (USA) 
dNTP  Invitrogen Co. (USA) 
GlycoBlue™ Co-precipitant  Ambion (USA) 
OligodT15   Promega (USA) 
PCR reaction buffer, 10x  Invitrogen Co. (USA) 
Magnesium chloride, 25mM  Invitrogen Co. (USA) 
RNAsin ®  Promega (USA) 
SuperScript™III  First-stand  synthesis SuperMix 
for qRT-PCR, 50 reactions 
Invitrogen Co. (USA) 
SYBR green I  Molecular Probes, Invitrogen Co. (USA) 
Platinum Taq DNA polymerase  Invitrogen Co. (USA) 
TRI Reagent®  Ambion (USA) 
 
2.1.5 Antibodies 
Immunofluorescence   
Rat anti mouse CD11b   BD Pharmingen (USA) 
Rat anti mouse CD68   abcam® (USA) 
Rat anti mouse F4/80   AbD serotec (UK) 
Rat anti mouse Ly6G   Biolegend® (USA) 
Goat anti rat Alexa Fluor® 594 IgG  Molecular Probes, Invitrogen  (USA) 
   
Flow cytometry   
Hamster anti mouse FITC CD3e   BD Pharmingen (USA) 
Rat anti mouse FITC CD4   eBioscience (USA) 
Rat anti mouse PERcp-Cy5.5CD4   BD Pharmingen (USA) 
Rat anti mouse Allophycocyanin CD25   eBioscience (USA) 
Rat anti mouse PE IFN γ  BD Pharmingen (USA) 
Rat anti mouse Alexa Fluor® 488 IL-4  Biolegend® (USA) 
Rat anti mouse Alexa Fluor® 647 IL-17A  Biolegend® (USA) 
Rat anti mouse PE FoxP3  eBioscience (USA) 44 
 
   
Immunohistochemistry   
Monoclonal mouse anti human -SMA  Chemicon, Millipore Corp (USA) 
Monoclonal mouse anti desmin  Novacastra, Leica (Germany) 
Polyclonal goat anti-human vimentin  Chemicon, Millipore Corp (USA) 
Polyclonal rabbit anti-cow  keratin  Dako (Germany)  
 
2.1.6 Commercial kits  
BD™ CBA Mouse Flex set (100 tests): 
IL-1β 
IL-4 
IL-5 
IL-6 
IL-10 
IL-13 
IL-17A 
IFN-γ 
TNF-α 
MCP-1 
MIG 
MIP-1α 
MIP-1β 
RANTES 
Mouse/Rat soluble protein master buffer kit 
 (500 tests) 
BD Biosciences (USA) 
Biotin blocking system   DAKO (Denmark) 
Cytofix/cytoperm™ fixation/permeabilisation  
kit with Golgistop™ (monensin)  
BD Biosciences (USA) 
DNase removal kit  Ambion (USA) 
Liquid DAB substrate chromogen system  DAKO (Denmark) 
LSAB® Streptavidin HRP  DAKO (Denmark) 
Mouse regulatory T cell staining kit   eBioscience (USA) 
ProLong® Gold antifade reagent with DAPI  Invitrogen Co. (USA) 
Quantikine® mouse/rat/porcine/canine 
immunoassy for mouse TGF-β  kit 
R&D System (Aus) 
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2.1.7 Laboratory instruments, equipment and software 
25 cm
2 vented tissue culture flasks  BD Biosciences (USA) 
175 cm
2 vented tissue culture flasks  BD Biosciences (USA) 
6 cm culture dishes  BD Biosciences (USA) 
24 well microtitre plates  BD Biosciences (USA) 
96 well microtitre plates  BD Biosciences (USA) 
0.6, 1.5 & 2 ml MAXYMum recovery™ microfuge tubes  Axygen Scientific (USA) 
15 & 50 ml Falcon tubes  BD Biosciences (USA) 
19 G needles  Terumo Medical Corp (USA) 
23 G needle  Terumo Medical Corp (USA) 
10, 20, 50ml syringes  BD Biosciences (USA) 
Aperio Scanscope Digital Slide Scanner  Aperio (USA) 
Aperio's ImageScope Viewer-Spectrum positive pixel 
count algorithm software 
Aperio (USA) 
BD CBA array software  BD Biosciences (USA) 
Benchtop centrifuge 5414 D (refrigerated)  Eppendorf  (Germany) 
Bio-Rad power packs  Bio-Rad Laboratories (USA 
Cell scraper  Sarstedt AG & Co (Germany) 
Cell strainer (40, 70, 100μm nylon)  BD Biosciences (USA) 
CO2 incubator  Forma Scientific Inc (USA) 
Disposable 0.2 μM bottle top filter  Nalgene Nunc International (USA) 
Double deionised water system  Millipore Pty, Ltd (AUS) 
DU 640 Spectrophotometer  Beckman Coulter (USA) 
FACSCanto™ Flow Cytometer  BD Biosciences (USA) 
FACSDIVA™ software  BD Biosciences (USA) 
FlowJO 7.6 software  Treestar Inc (USA) 
Fluostar Optima microtitre plate reader  BMG Laboratories (Aus-Pacific) 
Freezing microtome cryostat: Leica Cryocut 1800  Leica Microsystems (Germany) 
GraphPad Prism 5.0  GraphPad Software (USA) 
J2-MI Centrifuge  Beckman Coulter (USA) 
Megafuge 1.0R centrifuge  Heraeus Sepatech (Germany) 
McIlwain tissue chopper  Mickle Laboratory Engineering (UK) 
Microtome: Microm HM 325   GMI Inc (USA) 46 
 
Millipore filter 0.22 μM  Millipore Corp (USA) 
MultiScreenHTS vacuum manifold  Millipore Corp (USA) 
MultiScreenHTS 96-well filter plates  Millipore Corp (USA) 
Nanodrop 1000 spectrophotometer   Thermo Fisher Scientific (USA) 
Nikon TE2000-E Microscope/camera  Coherent Life Science (AUS) 
Rotor-Gene 3000 System  Corbett Research (USA) 
Olympus IX-81 inverted fluorescence microscope  Olympus (Japan) 
PTC-100 thermocycler  MJ research Inc (USA)  
Rotor-Gene 6 software  Corbett Research (USA) 
Sakura Tissue Tek VIP-E150 tissue processor   GMI Inc (USA) 
Shandon Linistain™ GLX Linear Stainer   Thermo Scientific (AUS) 
Superfrost ®plus slides  Menzel-Glä ser (Germany) 
VersaDOC 3000 Imaging System  Bio-Rad Laboratories (USA 
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2.1.8 Common solution and buffers 
ACK lysis buffer  8.9g NH4Cl, 1g KHCO3, 37.2mg EDTA in 1lt of 
double deionised water , and stored at 4° C. 
Acetone/methanol fixative  Acetone-methanol mixture 1:1(v/v), and stored at 
-20C. 
BSA/PBS:  1mg/ml stock solution prepared in 1 x PBS, and 
stored at -20C. 
Digestion solution  Dissolve 0.05 g of collagenase IV, 0.05 g of 
DNase I and 0.3 g of dispase II in 100 ml of 1 ×  
PBS. 
FBS  Heat-inactivated by heating for 30 minutes  at 
56° C. 
Flow buffer  PBS supplemented with 5% FBS, 0.01% NaN3, 
filtered sterilised and stored at 4C. 
High serum Dulbecco’s Modified 
Eagle Medium (H-DMEM): 
10% foetal bovine serum (FBS), 0.025M HEPES 
buffer. 1X PSF, 2% L-glutamine in DMEM. 
Low serum Dulbecco’s Modified 
Eagle Medium (L-DMEM): 
2% FBS, 0.025M HEPES buffer. 1X PSF, 2% L-
glutamine in DMEM
. 
Percoll solution  9 parts percoll mixed with 1 part 10x PBS, sterile 
solution and stored at 4C. 
Phosphate buffered saline (PBS)  50mM KPO4, 150mM NaCl, in deionised water, 
pH 7.2 (without adjustment). 
Alternatively, 1 PBS tablet (Amersham Biosci ) to 
100ml of deionised water (1x).  
PMA  1mg/ml stock solution prepared in DMSO, and 
stored at -20C. 
Predigestion solution  1 ×  HBSS containing 5 mM EDTA and 1 mM 
DTT. 
10% SDS:  10% (w/v) in double deionised water, stored at 
RT. 
Tris-buffered saline (TBS):    10mM Tris, 150mM NaCl in double deionised 
water. pH adjusted to 7.5 with 1M HCl 
TBS-Tween (0.2%) (TBST):  0.2% Tween-20 detergent in TBS 
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2.2 METHODS 
2.2.1. Animal care and housing 
129/SvJ  ×   C57/BL6 wild-type  (WT)  and  SPARC  null  (KO)  mice  were  originally 
obtained from Dr E. Helene. Sage, Hope Heart Institute, Washington State, USA on a 
mixed  background  (Norose  et  al.  1998).  Animals  were  maintained  under  specific 
pathogen free (except for norovirus) conditions at Fremantle Hospital. The use of mice, 
the colitis model and interventional procedures were approved by the Animal Ethics 
Committee (AEC) of the University of Western Australia (UWA). Unless specifically 
stated, female mice aged 10-12 weeks were used in all experiments and only animals 
weighing >19g at time of commencing the experiments were used. Mice were allowed 
food and water al libitum. Wet food was provided to particular mice, if required, during 
the experiments. Confirmation of complete ablation of SPARC
 gene was demonstrated 
in all SPARC null mice by genotyping using PCR (by Mrs. Frances Lloyd). 
 
2.2.2 Induction of colitis by Dextran Sodium Sulphate (DSS) 
Colitis was induced by the addition of DSS [3% (wt/vol) (MP Biomedicals LLC, Aus)] 
to the drinking tap water for 7 days. Control mice received plain tap water without DSS. 
DSS at a concentration of 3% has been shown previously in our lab to induce colitis 
with low animal mortality. As the efficacy of DSS varies between batches, the majority 
of the experiments were undertaken using the same batch number. Each new DSS batch 
was tested for efficacy. 
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Mice were given 7 days of DSS (induction), followed by a recovery period of 1-7 weeks 
without DSS (Figure 2.1). The mean daily DSS-water consumption was recorded for 
each group. Body weights were assessed and stool samples were examined for blood 
daily during the treatment period and weekly during the recovery period. 
Figure  2.1:  Overview  of  the  experimental  design  to  investigate  acute,  recovery  and 
chronic phases. Mice receiving DSS for 7 days were used to examine the acute inflammatory 
response. Mice that received 3% DSS for 7 days followed by plain tap water for 1, 2 and 4 
weeks (D14, D21 and D35 respectively) were used to investigate the progression to chronic 
inflammation or recovery. Age matched control groups (non DSS treated) were present for each 
time point. (↑ and ↑ represents points of analysis) 
 
 
2.2.3 Endoscopic monitoring of colitis  
A high
 resolution mouse video endoscopic system was used to monitor the colitis and 
the mice were routinely scoped 1 day prior to sacrifice. Mice
 were anaesthetised using 
an  intraperitoneal  ketamine/xylazil  injection  of  a  0.01ml/g  body  weight.  The 
experimental
 endoscopy  setup,  denoted  "Coloview  system",  consisted  of  a  miniature
 
endoscope (scope 1.9 mm outer diameter), a xenon light source,
 a triple chip camera, 
and an air pump (Karl Storz, Germany) to achieve regulated inflation of the  mouse
 
colon. The endoscopic procedure was viewed on a colour monitor
 and digitally recorded.
 
All endoscopic procedures were viewed by Dr. Borut Klopcic.
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Colitis  was  staged  using  the  modified  murine  endoscopic  score  of  colitis  severity 
(MEICS, Table 2.1)(Becker et al. 2005). The MEICS system consists of 5 parameters: 
Thickening of the colon wall, changes of the normal vascular pattern, presence of fibrin, 
mucosal granularity and stool consistency. Endoscopic grading was performed for each 
parameter (scored between 0 and 3) leading to a cumulative score of between 0 (no 
signs of inflammation) and 15 (endoscopic signs of very severe inflammation). Healthy 
mice usually have a score of 0-3.  
Table 2.1 The MEICS system.  
          Total 
Colonic 
Thickening 
0 
Transparent 
1 
Moderate 
2 
Marked 
3 
Non- transparent 
0-3 
Vascular 
Pattern 
0 
Normal 
1 
Moderate 
2 
Marked 
3 
Bleeding 
0-3 
Visible  
Fibrin 
0 
None 
1 
Little 
2 
Marked 
3 
Extreme 
0-3 
Mucosal 
Granularity  
0 
None 
1 
Moderate 
2 
Marked 
3 
Extreme 
0-3 
Stool 
Consistency 
0 
Normal+solid 
1 
Still shaped 
2 
Unshaped 
3 
Spread 
0-3 
        Overall  0-15 
 
 
2.2.4 Tissue dissection 
2.2.4.1 Colon 
All mice were scarified by lethal injection followed by cervical dislocation unless stated 
elsewhere.  The  colon  was  removed  from  each  animal  and  the  colon  length  was 
measured from the end of anus to caecum (Figure 2.2  #). Approximately 1mm from 
the anus was discarded to remove the rectum as it has a different tissue fibro-structure to 
the colon. Tissue was then harvested for the different analyses as shown in figure 2.2: i) 
cryosection,  ii)  paraffin  section,  iii)  tissue  explant  for  cytokine  analysis,  iv)  flow 
cytometric analysis v) RNA expression if not performing flow cytometry.   51 
 
  
 
 
 
 
 
Figure 2.2: Picture of the colon showing regions of tissue collected for different 
experimental  purposes:  i)  cryosection,  ii)  paraffin  section,  iii)  tissue  explant  for 
cytokine analysis,  iv) flow cytometric analysis v) RNA expression if not performing 
flow cytometry.   
 
2.2.4.2 Lymphoid organs-spleen and mesenteric lymph nodes  
The spleen and mesenteric lymph nodes were removed from each WT and SPARC KO 
mouse and collected into H-DMEM (Gibco
® Invitrogen Co., Aus) and kept on ice until 
use.  
2.2.4.3 Plasma and explant cultured supernatant 
Blood  was  drawn  by  cardiac  puncture  immediately  prior  to  sacrifice.  Blood  was 
collected in microtubes containing heparin and spun at 8400 g for 20 minutes at 4° C. 
The plasma was transferred to fresh tubes and snap frozen and kept at -80° C. 
The  colonic  tissues  for  cytokine  detection  were  washed  in  RPMI-1640  (Gibco
® 
Invitrogen Co., Aus) supplemented with antibiotics. The tissues were then placed in a 
96 well tray that contained serum free RPMI-1640 supplemented with antibiotics for 
~22-24 hour. The culture supernatants were collected and spun at 12000 g at 4° C to 
remove any tissue debris then snap frozen and stored at -80° C until use. 
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2.2.5 Preparation of paraffin sections 
Colonic tissue was cleaned and then fixed by immersion in neutral-buffered formalin 
and processed in the Sakura Tissue Tek VIP-E150 tissue processor (GMI Inc, USA) at 
the Pathwest Histopathology Department at Fremantle Hospital. It was then embedded 
in paraffin wax and stored at RT. Sections, 4.5μm thick, were cut using a Microm HM 
325  Microtome  (GMI  Inc,  USA),  floated  on  water  of  a  45° C  water  bath  prior  to 
mounting on Superfrost™ slides. Paraffin sections were dried at 55°C overnight and 
stored at RT until H&E stained. 
2.2.6 Haemotoxylin and eosin (H&E) staining 
Paraffin sections were stained with H&E using the Shandon Linistain™ GLX Linear 
Stainer (Thermo Scientific, AUS). 
All  H&E  stained  paraffin  sections  were  assessed  blindly  by  Dr  Cynthia  Forrest 
(specialist  gastroenterological  histopathologist)  according  to  the  scoring  system  by 
Dieleman  (Dieleman  et  al.  1998).  In  this  scoring  system,  4  features  are  graded  as 
outlined in Table 2.2: The severity of inflammation (acute and chronic) and depth of 
inflammation were scored from 0-3, while the level of crypt damage and regeneration 
were scored between 0 and 4. These changes were also quantified as to the percentage 
of the total colonic circumference that was involvement by the disease process: i) 1-
25%; ii) 26-50%; iii) 51-75%; iv) 76-100%. Total inflammatory score (a score of 0-56) 
then was given to each sample based on multiplying the score of each feature by the 
percentage  of  the  tissue  involved  and  adding  the  totals  together.  The  regeneration 
feature was not graded in the day 7 sections, the peak of acute inflammation.  
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Table 2.2 Histological grading of colitis. 
 
2.2.7 Preparation of cryosections  
Colon and spleen were embedded in Tissue-Tek® O.C.T (optimum cutting temperature) 
freezing medium (ProSciTech, Aus), snap frozen in liquid nitrogen and stored at -80° C. 
Briefly, cryoembedded tissues were cut by Miss Kristine Fu into 7μm thick sections on 
a  freezing  microtome cryostat chamber at a temperature of between -15 and -20° C. 
Sections were mounted onto Superfrost™ slides, dried at RT for approximately 1 hour 
and then stored at -80° C.  
 
Feature  Grade  Description 
Inflammation   0  None 
  1  Slight 
  2  Moderate 
  3  Severe 
     
Depth   0  None 
  1  Mucosa 
  2  Mucosa and submucosa 
  3  Transmural 
     
Crypt damage  0  None 
  1  Basal 1/3 damaged 
  2  Basal 2/3 damaged 
  3  Only surface epithelium intact 
  4  Entire crypt and epithelium lost 
     
Regeneration  4  No tissue repair 
  3  Surface epithelium not intact 
  2  Regeneration with crypt depletion 
  1  Almost complete regeneration 
  0  Complete regeneration or normal tissue 
     
Precent involvement  1  1-25% 
  2  26-50% 
  3  51-75% 
  4  76-100% 
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2.2.8 Immunofluorescent staining of cryosections 
Slides were fixed in ice cold acetone for 2 minutes and then rehydrated in PBS for 10-
15  minutes  and  blocked  with  5%  goat  serum  for  30  minutes.  The  sections  were 
incubated  in  the  optimal  concentration  (Table  2.3) of  primary  antibody  prepared  in 
commercial  antibody  diluent  (DAKO,  Denmark)  overnight  at  4° C  in  a  humidified 
chamber  and  then  washed  3  times  for  10  minutes  in  PBS.  The  sections  were  then 
incubated in goat anti-rat IgG secondary antibody conjugated to AF 594 (Invitrogen Co., 
USA) for 1 hour at RT in a dark, humidified chamber. After washing a further 3 times 
in  PBS,  slides  were  mounted  with  Prolong  Gold  Antifade  reagent  with  DAPI 
(Invitrogen  Co.,  Aus).  Slides  were  viewed  and  photographed  with  Olympus  IX-81 
inverted fluorescence microscope. The DAPI stained nuclei blue when viewed under the 
ultra violet (UV) filter while the proteins of interest stained red when view with green 
filter. Each section was viewed at x200 magnification and photographed. The numbers 
of positive cells were counted in 5-15 fields.   
 
 
Table  2.3  Rat  monoclonal  antibodies  directed  against  cell  surface  markers  used  in 
fluorescence staining.  
 
 
 
 
 
 
 
 
 
Antibody clone  Dilution  Source  Isotype 
CD11b (M1/70)  1:400  Pharmingen  IgG2b,κ 
CD68 (Kp1)  1:400  abcam  IgG1, κ 
F4/80 (CI:A3-1)  1:200  AbD serotec  IgG2b 
Ly6G (1A8)  1:400  Biolegend  IgG2a,κ 55 
 
2.2.9 Sirius red staining and analysis. 
Sirius red staining, described previously in the literature (Lopez-De Leon and Rojkind 
1985), was used in order to quantify the collagen content in the colon. Briefly, colonic 
paraffin sections were dewaxed by immersion for 2 minutes each in 3 changes of xylene, 
followed by ethanol with of 2 changes of 100% and 1 change of 70% ethanol. The 
dewaxed tissue sections were then rehydrated in tap water followed by double deionised 
water.  Sections  were  stained  by  immersion  in  a saturated  solution  of  picric  acid  in 
double deionised water that contained 0.1% Sirius red (Merck Pty Ltd, AUS) for 30 
minutes at RT. Thereafter, excess Sirius red stain was washed off by briefly immersing 
the sections in 3 changes of double deionised water. Slides were then blotted dry and 
transferred to xylene before mounting with DePeX.  
Stained  slides  were  scanned  and  digitally  captured  by  an  Aperio  Scanscope  Digital 
Slide Scanner. The images were analysed with Aperio's ImageScope Viewer-Spectrum 
positive  pixel  count  algorithm  software,  which  converts  the  images  according  to 
investigator defined parameters (based on a series of positive and negative control of 
collagens and picric acid) into markup images and quantifies the area and intensities of 
the positive and negative stains. The software quantified the pixels and colour-coded 
them to strong, medium, and weak positive and negative staining as shown below. Only 
tissue sections of the full colon quantified and ignored those with artifact area caused by 
tissue overlapping. Below shown a markup image generated by the software (Figure 
2.3).  56 
 
 
 
 
 
 
 
Figure 2.3 Original and markup images generated by Aperio's ImageScope Viewer 
software.  A)  Collagen  stained  red  while  picric  acid  stained  non-collagenous 
components to pale  yellow. B) The software quantified the pixels and colour-coded 
them to strong, medium, and weak positive and negative staining. Areas with tissue 
overlapping were not included.   
 
 
2.2.10 Detection of cytokines 
2.2.10.1 Cytokine bead assay  
Beads with different fluorescent intensities were coated with analyte-specific capture 
antibodies. This enabled the simultaneous detection of multiple analytes from a single 
sample. The capture beads were incubated with recombinant standard or test samples 
and  phycoerythrin  (PE)-conjugated  detection  antibodies  that  were  added  to  form 
sandwich complexes.  
 
A customized 15plex BD™ Cytometric bead array (CBA) Flex set was used to detect 
the  following  cytokines  and  chemokines  simultaneously  in  the  tissue  explants  and 
serum samples from individual mice: IL-1β, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17A, IL-
Original   Markup  
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12/IL23p40, TNF-α, IFN-γ; RANTES, MCP-1, MIP-1α, MIP-1β, MIG. Serum samples 
were  diluted  1:4  in  assay  diluent  and  supernatants  from  tissue  explants  were  used 
undiluted (except 1:60 for IL-6 analysis). The assay was set up in multiscreen HTS filter 
plates (Milipore) and performed according to the manufacturer’s instructions. A typical 
standard obtained by serial dilution of recombinant protein. The detection limit for most 
cytokines was ≤ 2pg/ml (Table 2.4). Samples were analysed on a BD FACSCanto™ 
instrument  using  BD  FACSDIVA™  software  and  BD  FCAP  Array™  software.  All 
cytokines  were  measured  at  the  protein  level  without  ex  vivo  stimulation  of  the 
cells/tissues (serum free) as this may reflect the in vivo conditions better (Melgar et al. 
2005).  
Table 2.4 Detection limit of cytokines according to the manufacturer (BD, USA). 
 
 
 
 
 
 
 
 
 
 
 
Cytokine 
Detection 
limit (pg/ml) 
Proinflammatory :    
Mouse IL-6  (Bead B4)  1.4 
Mouse TNF-α (Bead C8)  2.8 
Mouse IL-1ß   (Bead E5)   1.9 
    
Th 1 involved    
Mouse IFN-γ (Bead A4)  0.5 
    
Th 2 involved    
Mouse IL-5  (Bead A6)   0.9 
Mouse IL-4 (Bead A7)   0.3 
Mouse IL-13 (Bead B8)   2.4 
    
Th 17 involved    
Mouse IL-17A flex set (Bead C5)  0.95 
   
Chemokines/Chronic inflammation involved   
Mouse MCP (Bead  B7)  2.7 
Mouse MIP-Iα  (Bead  C7)  2.3 
Mouse MIP-Iβ (Bead  C9)  0.6 
Mouse RANTES (Bead D8)  3.3 
Mouse MIG (Bead D9)  3 
    
Anti inflammatory   
Mouse IL-10 Flex Set (Bead C4)   9.6 58 
 
2.2.10.2 Enzyme-linked immunosorbent assay (ELISA) 
To  measure  TGF-β  protein  levels  the  Quantikine®  mouse/rat/porcine/canine 
immunoassy  for  mouse  TGF-β  (R&D  Systems,  Aus)  was  used  according  to  the 
manufacturer’s instructions modified to include neutralisation of the sample with 2.4 N 
NaOH  instead  of  1.2N  NaOH  following  activation  with  acid.  The  explant  culture 
supernatants and serum samples were diluted 1.3 and 60- fold respectively following 
sample activation. Recombinant protein from 31.2 to 2000 pg/ml served as a standard 
curve.  
2.2.11 Preparation of single cell suspensions for flow cytometry 
Single cell suspensions from the spleen and mesenteric lymph nodes were obtained by 
gentle dispersion using frosted glass slides. For flow cytometry, the cells were filtered 
through a 40μm wire mesh and the red blood cells were lysed with ACK lysis buffer. 
The samples were kept on ice until stained.  
 
To obtain sufficient cells for flow cytometry, cells from 4 murine colons were pooled. 
Single cell suspensions from the colon were prepared as described (Weigmann et al. 
2007) with slight modifications. Briefly, the colons were washed in PBS and incubated 
with  predigestion  solution  for  20  minutes  at  37° C  to  release  the  intraepithelial 
lymphocytes (IEL). The colons were then denuded of the epithelial layer and washed 
twice with PBS to remove the EDTA and DTT from the predigestion solution as these 
affect  the  collagenase  activity.  They  were  then  finely  cut  with  a  McIlwain  tissue 
chopper  followed  by  2  washes  in  PBS.  The  minced  tissue  was  then  digested  with 
Digestion solution in order to obtain the LP mononuclear cells (LPMC). The cells were 
washed twice with H-DMEM and purified with percoll (GE Healthcare, Aus).  The 59 
 
leucocytes from the IEL and LPMC fractions were then recovered from the interphase 
of a 70/40% percoll gradient for 20 minutes at 1000g at RT. 
 
2.2.12 Flow cytometry 
2.2.12.1 Surface and Intracellular Staining  
The single leucocyte cell suspensions were seeded into U bottom plates, washed with 
flow  buffer  and  then  analysed  by  FACS.  The  cells  were  then  incubated  in  50μl 
stimulation solution (DMEM that contained 750ng/ml of ionomycin (Sigma), 50ng/ml 
PMA, 10ug/ml monensin (BD)) for 12 hours at 37° C to enhance cytokine production 
and prevent secretion out of the cell. The cells were then washed twice with flow buffer, 
and  stained  with  flurochrome  conjugated  antibodies  solution  (50μl  per  well,  in 
optimised dilution, Table 2.5) at 4° C in the dark for 30 minutes. Cells were then washed 
twice  with  flow  buffer,  fixed  and  permeabelised  with  the  BD  Cytofix/Cytoperm  kit 
according to the manufacturer’s instructions.  
 
The intracellular stain (50μl per well, in optimised dilution, Table 2.5) was applied and 
incubated for 30 minutes in the dark at 4° C. Cells were then washed twice with Perm 
buffer and resuspended in flow buffer and analysed with BD FACSCanto™ instrument 
using BD FACSDIVA™ software.  
 
All staining for Treg cells was performed using the mouse regulatory T cell staining kit 
(eBioscience, USA) according to the manufacturer’s instructions. The single cells were 
suspended in the H-DMEM and keep at 4° C until ready for staining. 60 
 
Table  2.5  Primary  antibodies  directed  against  cell  surface  markers  and  intracellular 
secretory molecules in flow cytometry. 
 
 
2.2.12.2 Analysis by flow cytometry 
All data were collected with BD FACSCanto™ instrument using BD FACSDIVA™ 
software  with  analysis  by  FlowJo  software  (version  7.6,  Tree  Star  Inc,  USA).  The 
lymphocyte population was identified on the basis of size (forward scatter [FSC]) and 
granularity (side scatter [SSC]). The lymphocytes were further characterized by their 
cell surface  markers. All gating was set based on the appropriate isotype control as 
shown in Figure 3.1.  
 
In order to quantify the regulatory T cells, the  CD4+ CD25+ population within the 
lymphocyte population was selected and the Treg marker, FoxP3+ cells analysed. For 
each sample 100 000 gated lymphocyte events were recorded. The results represent the 
pooled data of mean percentage of cells of interest out of the total gated cells from 1-3 
independent experiments.  
Host species  Antibody  clone  Dilution  Conjugate  Isotype 
Surface         
Hamster  CD3e (145-2C11)  1:250  FITC  IgG1,κ 
Rat  CD4 (RM4-5)  1:250  FITC  IgG2a 
    1:250  PerCP-Cy™5.5   IgG2a,κ  
Rat  CD25 (PC61.5)  1:250  Allophycocyanin
    
IgG1 
         
Intracellular         
Rat   IFN γ  1:250  PE   
Rat  IL-4(11B11)  1:250  AF488  IgG2b,κ  
Rat  IL-17A  1:250  AF647  IgG1,  κ 
Rat  FoxP3(FJK-16s)  1:100  PE  IgG2a 61 
 
Isotype Control 
Th cells 
 
 
 
 
 
 
 
 
 
Figure  2.4:  The  lymphocyte  population  was  gated  on  the  basis  of  the  forward 
scatter  (FSC)  and  side  scatter  (SSC).  T  helper  cells  (CD3+  CD4+)  were  further 
analysed based on intracellular marker (e.g. IFN-γ). All gating was determined by the 
appropriate isotype control.  62 
 
2.2.13 RNA Analysis  
All buffers, distilled water, microfuge tubes, micropipette tips, and any implements that 
were used in RNA work were RNase free. 
2.2.13.1 Tissue homogenisation for RNA isolation from colon tissue 
Colonic tissue was harvested and snapped frozen in liquid nitrogen and kept at -80° C. 
The  colonic  pieces  were  transferred  to  a  pre-chilled  2ml  microtube  that  contained 
stainless steel beads. Sufficient amount of TRI Reagent® (~1ml; Ambion Inc., USA) 
was added to each tube and homogenised with a tissue lyser (QIAGEN Pty Ltd, USA) 
at 30Hz, 10 minutes RT. 
  
2.2.13.2 Cell lysis for RNA isolation from fibroblasts cells 
Fibroblasts were lysed directly in the culture wells with 1ml TRI Reagent® (Ambion 
Inc.,  USA)  per  10cm
2 of  culture  dish  area.  Fibroblasts  were  incubated  at  RT  for  5 
minutes then passed through a pipette several times to ensure complete lysis. The cell 
lysate  was  transferred  to  a  labelled  1.5ml  MAXYMum  Recovery™  microfuge  tube 
(Axygen Scientific) and stored at 20° C prior to RNA extraction. 
 
2.2.13.3 RNA Extraction  
Briefly, cell lysates in TRI Reagent
® were thawed at RT, and 100µl of BCP (Ambion 
Inc., USA) per 1ml of Tri Reagent
® added prior to vigorous vortexing for 10 seconds. 
The tubes were then incubated for 10 minutes at RT and centrifuged at 12000 g for 15 
minutes at 4° C. The upper, aqueous phase, containing RNA was transferred to fresh 
1.5ml microfuge tubes, then 500µl of isopropanol per 1ml of Tri Reagent
® and 4µl of 63 
 
GlycoBlue  CoPrecipitant  (diluted  1:20  in  RNA  storage  buffer)  (Ambion  Inc.,  USA) 
were added. Tubes were vortexed and incubated for 15 minutes at RT to allow for RNA 
precipitation. RNA was pelleted by centrifugation at 12000g for 10 minutes at 4° C, and 
the supernatants removed. RNA pellets were washed with 1ml of 75% ethanol per 1ml 
of Tri Reagent
® then re-centrifuged at 12000g for 5 minutes at RT. The supernatants 
were decanted and excess ethanol removed using a pipette. RNA pellets were air dried 
for 5-10 minutes then dissolved  in  15l of Ultrapure DNAse RNAse distilled water 
(Gibco®, Invitrogen Co., USA). RNA was allowed to fully dissolve by incubating at 
4C overnight prior to DNase treatment and assessment of the yield and quality.  
 
2.2.13.4 DNase treatment 
Genomic  DNA  was  removed  using  a  DNase  removal  kit  (Ambion  Inc.,  USA). The 
RNA was incubated with DNase I (2 Unit/µl) for 30 minutes at 37° C and subsequent 
steps were carried out according to manufacturer’s instructions.  
 
2.2.13.5 Quantification of RNA 
The  concentration  and  purity  of  RNA  was  determined  using  a  Beckman  DU640 
spectrophotometer. RNA was diluted at 1:50 in RNAase free distilled water and the 
OD260 and OD280 measured against a RNase free distilled water blank. To determine the 
RNA concentration  in µg/ml, the A260 was multiplied by the dilution  factor and the 
extinction  coefficient  (1  A260  =  40µg  RNA/ml).  Alternatively,  RNA  samples  were 
measured  undiluted  using  a  Nanodrop  1000  spectrophotometer  (Thermo  Fisher 
Scientific.  The  A260/A280  ratio  of  the  RNA  is  an  indication  of  its  purity.  The  RNA 
isolated with this protocol typically exhibited an A260/A280 ratio of 1.8–2.1. 64 
 
2.2.13.6 Reverse transcription of RNA 
Reverse transcription of RNA to cDNA was performed using SuperScript III Reverse 
Transcriptase (Invitrogen Co., USA) according to manufacturer’s protocol with a slight 
modification to use half reaction volume. Briefly, 0.75L of oligo dT15 (Promega, USA) 
and 0.5µl of 10mM of dNTPs were added to 1g of RNA, and made up to 6.75L with 
RNAase  free  distilled  water  in  RNAase  free  PCR  tubes.  The  RNA  mixture  was 
incubated for 5 minutes at 65° C to disrupt the secondary structures, then rapidly chilled 
to 4
oC for at least 1 minute. To each tube, a master mix that consisted of 2µl of 5x first 
strand  buffer,  0.5µl  of  0.1M  of  DTT,  0.25µl  of  recombinant  RNasin®  ribonuclease 
inhibitor  (2500  Units)  (Promega,  USA)  and  0.5µl  of  SuperScript  III  reverse 
transcriptase  (200  Units)  (Invitrogen  Co.,  USA)  was  added  to  yield  final  reaction 
volume of 11.25l. Samples were mixed and centrifuged before being incubated for 1 
hour at 50
oC for DNA extension. Finally, tubes were heated to 70C for 10 minutes to 
inactivate the reverse transcriptase. All cDNA samples were stored at 4C, and analysed 
within 3 days, otherwise stored at -20C.  
 
2.2.13.7 Real-time Quantitative Polymerase Chain Reaction 
Real-time  quantitative  PCR  was  performed  using  continuous  monitoring  of  the 
amplification process with SYBR green, a high-affinity double-stranded DNA-binding 
fluorescent  dye.  Each  PCR  reaction  consisted  of  1μg  cDNA,  75  pmoles  MgCl2, 
20mmoles  each  dNTP,  10µmol  each  forward  and  reverse  primer,  0.5  Units  of  Taq 
polymerase  (Invitrogen  Co.,  USA),  and  1×   PCR  buffer  (Invitrogen  Co.,  USA),  4x 
SYBR to give a final  volume of 20μl. Samples were run alongside a set of serially 65 
 
diluted plasmid DNA standards (10
2 - 10
8 copies) specific for each gene examined in 
order to allow copy number quantitation, as well as a no template negative control.  
 
PCR was performed using a Rotor Gene 3000
TM Real Time thermal cycle and analysed 
using the commercial software (Corbett Life Science). During the amplification process, 
SYBR green dye intercalates with double stranded cDNA, and is excited at 470nm to 
emit  a  fluorescence  signal  detected  by  the  Rotor  Gene  at  510nm.  The  level  of 
fluorescence  was  measured  after  the  72° C  elongation  step  of  each  cycle.  The 
fluorescence  increased  proportionally  to  the  amount  of  DNA  present,  theoretically 
doubling every cycle (which gives an efficiency of 1 on the standard curve).  
 
The PCR cycling profiles comprised an initial enzyme activation step of 95C for 5 
minutes, then 35-45 cycles consisting of denaturation at 95C for 15 seconds, a variable 
annealing temperature for 20 seconds (Table 2.6) and primer extension of 72C for 20 
seconds.  Data were acquired after each cycle, after the 35-40 cycles, the reaction was 
held for 15 seconds at 72C followed by a melting curve program (72–99° C with a 
rising heating rate by 1C on each step and a continuous fluorescence measurement)
 and 
finally a cooling step to 40° C for 3 minutes. At the completion of the PCR, the melt 
curve was generated. PCR products were analysed and quantified using the Rotor Gene 
6 software (Corbett Life Science).  
First, all genes were normalised to a housekeeping gene (β-actin or HPRT) and then 
expressed as a relative ratio with its non-treated control. 66 
 
Table 2.6: The sequences and PCR conditions of different primers.    
Gene of interest  Primer sequences (5’-3’)  Annealing temp (° C)  Cycles 
β-actin  Fwd: CTGGCACCACACCTTCTA  
Rev: GGTGGTGAAGCTGTAGCC  
68  35 
HPRT  Fwd:  GTAATGATCAGTCAACGGGGGAC 
Rev:  CCAGCAAGCTTGCAACCTTAACCA 
60  40 
TGF-β1  Fwd:  GCCCTGGACACCAACTATTGC  
Rev:  AGCTGCACTTGCAGGAGCGCAC  
58  40 
TGF-β3  Fwd: GCTCTTCCAGATACTTCGAC 
Rev: AGCAGTTCTCCTCCAGGTTG 
60  40 
Collagen Iα1  Fwd: GGCGGCCAGGGCTCCGACCC 
Rev: AATTCCTGGTCTGGGGCACC 
66  35 
Collagen IIIα1  Fwd: CCCAGAACATYACATAYCAC 
Rev: GATTARAACAAGAKGAACACA 
56  40 
MMP-13  Fwd: TGAACATCCATCCCGTGACC 
Rev: GGCATGACTCTCACAATGCG 
58  45 
MMP-3  Fwd: GTGGTTGTGTGCTCATCCTACC 
Rev: TAGTGTTGGAGTCCAGCTTC 
60  45 
TIMP-1  Fwd:ARTCAACSAGACCACCTTATACCA 
Rev: ASCTGRTCCGTCCACAARCA 
54  40 
TIMP-2  Fwd: CTGGACGTTGGAGGAAAGAA 
Rev: GTCRAGAAACTCYTGCTTGG 
55  40 
SPARC  Fwd: ACTGAGAAGCAGAAGCTGCG 
Rev: CAGGCGGAACAGCCAACCAT 
58  40 
COX-2  Fwd: AAAACCGTGGGGAATGTATGAGCAC 
Rev: AAACTTCGCAGGAGGGGGATGTTG 
62  40 67 
 
 2.2.14 Primary colonic fibroblasts cultures 
All cell culture media and reagents were obtained from Gibco
® Invitrogen Co., AUS 
unless otherwise stated.  
 
2.2.14.1 Tissue Collection and Fibroblast Isolation 
 
The  procedure  used  to  culture  primary  mouse  colon  fibroblasts  was  modified  from  the 
original method (Strong et al. 1998; Freshney 2005) where the colon was enzymatically 
disaggregated. First, the colon was opened up longitudinally and cut horizontal into 2-3mm 
strips. These strips were then washed in warm Ca
2+ Mg
2+ free HBSS
® solution buffered 
with 20mM HEPES, 2mM L-glutamine, 100 IU/ml penicillin/streptomycin/fungizone, and 
10% FBS for 15 minutes, subsequently washed in RMPI solution as supplemented as above 
for  15  minutes.  Thereafter,  the  strips  were  washed  with  PBS  twice  and  minced  with  a 
McIlwain  tissue  chopper.  The  minced  tissue  was  incubated  with  Difco  trypsin  1:250 
(2.5mg/ml)/collagenase IV (400U/ml)/DNase I (350U/ml) enzyme cocktail at 37° C. The 
cells were collected every 30 minutes until complete disaggregation. Trypsin was removed 
by centrifugation and neutralized by with H-DMEM to stop the trypsin reaction. The pellets 
were resuspended in H-DMEM and plated in culture flasks. The non-attached cells were 
carefully removed wash with PBS 24 hours later.  
 
2.2.14.2 Maintenance and subculturing of cell cultures 
Culture media were replaced every 3 to 4 days with pre-warmed H-DMEM. Cells were 
passaged upon reaching 80-95% confluency. To passage cells,  media  were aspirated 
from the flask and cells rinsed with PBS. An appropriate volume of prewarmed TrypLE 
Express™, diluted 1:5 in PBS, was added and the flask rocked to coat the cell sheet. 68 
 
Flasks were then incubated at 37º C for approximately 5 minutes, or until cells were 
completely dislodged. Flasks were checked at regular intervals using a light microscope 
to  ensure  the  cells  were  completely  detached  from  the  surface  of  the  flask  and,  if 
necessary, gently tapped to dislodge the remaining cells. Once the cells were completely 
detached from the surface of the flask, an equal volume of H-DMEM was added to 
inactivate the TrypLE Express™. Equal volumes of the cell suspension were seeded 
into 2 or more new flasks and topped up with an appropriate volume of H-DMEM. 
 
2.2.14.3 Immunohistochemistry 
The  established  fibroblast  cultures  were  stained  for  α-smooth  muscle  actin  (SMA), 
desmin,  vimentin  and  keratin  to  confirm  that  the  cells  were  mesenchymal 
fibroblasts/myofibroblasts and not epithelial cells. Cells were grown as monolayers on 
glass coverslips, or directly in 24 wells tissue culture plates. The cells were washed 
twice with 1x PBS, fixed with ice cold methanol and acetone in a 1:1 ratio for 3 minutes, 
air dried and washed twice with 1x PBS at RT. Subsequently, cells were stained with 
the avidin-biotin-peroxidase complex system (streptABcomplex /HRP; Dako, Denmark) 
as described by the suppliers. Briefly, the cells were incubated in TBST for 5 minutes 
and  in  ARK  diluent  containing  1%  BSA  for  3  minutes  to  permeablise  the  cells. 
Following permeablisation, cells were incubated in DAKO
TM peroxidase block solution 
for 5 minutes to block endogenous peroxidase activity and rinsed with double deionised 
water. The cells were then incubated with DAKO
TM serum free protein biotin blocking 
solution to block non-specific staining and washed 3x with TBS. Primary antibodies, at 
various dilutions (Table 2.7), were applied to the cells and incubated in a humidified 
environment overnight at 4° C. A no-primary control was undertaken in each run. 
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Table 2.7: Primary antibodies and their corresponding dilutions and diluent used for 
immunohistochemistry.  
 
 
 
Following incubation and extensive washing (3x in TBS, 3x in double deionised water 
after  2  minutes  of  TBS  bath),  the  cells  were  incubated  with  biotinylated  primary 
antibody  (mouse  monoclonal  α-SMA  and  desmin)  and  treated  with  DAKO  LSAB
+ 
yellow linking solution diluted 1:2 in TBS. Those cells incubated in non mouse origin 
antibody were further incubated with IgG (with respective origin) for 20 minutes at RT 
and washed 3x in a TBS bath. All cells were then incubated with DAKO LSAB
+ red 
label streptavidin-HRP for 30 minutes at RT. Cells were washed as above with TBS and 
double deionised water 3 times. The cells were then stained with DAB staining reagent 
for 5 minutes and washed with double deionised water. 
 
2.2.14.3.1 Visualisation of cells after staining 
The cells were visualised using the Nikon TE2000-E microscope at the magnification of 
200-300x. The actin filaments on nucleus in α-SMA positive cells shown brown, while 
Primary Antibody    Dilution  Diluent 
Monoclonal mouse anti human -
SMA (Chemicon Inc)  
1:500  ARK  diluent  prepared  by  1%  of  BSA  in  TBS 
supplemented with biotinylatation and blocking reagent 
from DAKO
TM 
 
Monoclonal mouse anti desmin 
(Novacastra) 
1:50  ARK  diluent  prepared  by  1%  of  BSA  in  TBS 
supplemented with biotinylatation and blocking reagent 
from DAKO
TM 
 
Polyclonal Goat anti-human 
vimentin (Chemicon Inc) 
1:20  TBS 
 
 
Polyclonal rabbit anti-cow  
keratin (DAKO) 
1:200  TBS 70 
 
desmin and vimentin had brown cytoplasmic stain with DAB. Fibroblasts cells stained 
negative with keratin, which is an epithelial cell marker.  
 
2.2.14.4 Stimulation of fibroblasts cell cultures 
Cells were seeded in T-25 culture flasks, and grown to 80-90% confluence to avoid 
contact inhibition. Upon reaching the desired confluency, fibroblast growth was arrested 
by  replacing  the  H-DMEM
 with  L-DMEM  (DMEM  with  2%  FCS,  0.025M  HEPES 
buffer. 1X PSF, 2% L-glutamine), for 24 hours prior to stimulation. 
 
All fibroblasts were stimulated with PMA (Sigma Aldrich, USA), which mimics the 
state of active inflammation that occurs during tissue injury (Lyass et al. 1988; Sturges 
2004). The PMA was prepared by diluting a stock solution to the working concentration 
of  10ng/ml  in  L-DMEM. 
  Fibroblast-like  cells  seeded  in  T25  culture  flasks  were 
incubated with PMA treated L-DMEM
 for 24 hours. Following the 24 hours stimulation, 
cells were harvested for RNA analysis.  
 
2.2.15 Statistical Analysis 
Statistical significance was calculated using GraphPad Prism (Version 5.0) (GraphPad 
software, Inc, USA). All graphs and comparison of differences between groups were 
assessed using Student’s unpaired t-test.  
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 Chapter 3 
 
Contribution of SPARC 
to the inflammatory 
response in DSS colitis 
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3.1. INTRODUCTION 
IBD are chronic inflammatory disorders which affect the human gastrointestinal tract. 
CrD and UC are categorised as typical IBD. There are numerous murine models that 
have  been  developed  to  investigate  the  pathology  that  lies  behind  IBD.  The  DSS-
induced model of colitis is one of the most commonly used. DSS is directly toxic to the 
gut epithelial cells located within the basal crypts. It reduces the integrity of the mucosal 
barrier  allowing  the  translocation  of  proteins  across  the  epithelial  surface  that  then 
promote acute inflammation with recruitment and activation of immune cells (Okayasu 
et al. 1990; Wirtz et al. 2007). The destructive effects of DSS are generally reversible 
with the regeneration of colon mucosal tissue upon withdrawal of the DSS (Da Silva et 
al. 2006). Administration of DSS to mice over a long period of time however has been 
shown  to  induce  chronic  intestinal  inflammation  with  symptoms  and  histological 
features similar to those observed in human IBD (Mahler et al. 1998; Melgar et al. 2005; 
Okayasu et al. 1990).  
 
SPARC is a matricellular glycoprotein that is involved in diverse biological processes, 
including  tissue  remodeling,  wound  repair,  morphogenesis,  cell  differentiation, 
adhesion,  proliferation,  migration,  and  angiogenesis  (Brekken  and  Sage  2000; 
Jendraschak and Sage 1996;  Norose et al. 2000). A deficiency  in SPARC has  been 
reported  to  reduce  both  renal  inflammation  and  fibrosis  (Socha  et  al.  2007).  These 
effects, however, may not be universal across different tissues as the bleomycin-induced 
lung injury in SPARC KO mice resulted in increased recruitment of neutrophils to the 
site of acute inflammation (Savani et al. 2000) and enhanced inflammation, though not 
always with evidence of fibrosis.  
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Pro-inflammatory cytokines such as IL-1β, IL-6 and TNF-α, enhance the inflammatory 
process, which is crucial to the recruitment of leucocytes and their subsequent activation 
to secrete various growth factors including PDGF and TGF-β. TNF-α is a chemotactic 
agent for both macrophages and neutrophils, and it also modulates the MMPs and tissue 
inhibitors  of  metalloproteinase  (TIMP)s  levels  within  the  ECM  (Dayer  et  al.  1985; 
Gharaee-Kermani and Phan 2001; Lee et al. 1995). It is not surprising, therefore, that 
high levels of the pro-inflammatory protein TNF-α are present within the serum and 
mucosal samples taken from patients with IBD (Murch et al. 1991; Braegger et al. 1992; 
Reimund et al. 1996) . IL-1β is also an important mediator of inflammation in multiple 
models  of  autoimmunity,  including  collagen-induced  arthritis,  experimental 
autoimmune encephalomyelitis, as well as IBD. Serum levels of IL-6 are increased in 
patients  with  active  IBD  and  have  been  shown  to  decrease  following  successful 
treatment of the inflammation (Suzuki et al. 2001; Mahida et al. 1991). SPARC has 
been  suggested  to  modulate  inflammation  through  affecting  the  bioavailability  of 
cytokines and chemokines via MMPs (Soehnlein and Lindbom 2010), e.g. MMP-2, and  
MMP-3  which  can  cleave  pro-IL1β  to  form  IL-1β  (Schonbeck  et  al.  1998).  Thus, 
SPARC  might  represent  a  potential  therapeutic  target  that  worked  as  Infliximab,  a 
monoclonal antibody against TNF-α, which is widely used to treat CrD.  
 
The contribution of SPARC on the inflammation in the intestine will be investigated in 
this chapter through examination of several aspects of the disease including endoscopic, 
clinical, histological, and assessment of the pro-inflammatory cytokines levels within 
tissues. This investigation will be performed on SPARC KO mice with DSS-induced 
colitis. Tissues will be analysed at early and late time points to elucidate any potential 74 
 
role  for  SPARC  in  the  development  of  acute  inflammation,  recovery,  or  in  the 
development of chronic inflammation.  
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3.2 RESULTS 
3.2.1  Clinical  symptoms  and  histopathological  changes  during  the   
periods of acute inflammation and recovery 
3.2.1.1 Weight loss 
Clinical symptoms appeared in both the WT and SPARC KO mice between 2-7 days 
after DSS exposure included loss of body weight, diarrhoea and faecal blood, which 
providing a gross clinical indication of disease. Loss of body weight was observed from 
day 2 in all DSS-treated mice (Figure 3.1). The WT mice generally underwent a greater 
weight loss than the SPARC KO mice when treated with DSS although that was not 
statistically significant. Both groups of mice, however, regained the weight once DSS 
treatment was stopped. Both WT and SPARC KO mice had bloody liquid stools during 
the DSS treated period.   
 
Figure 3.1: Changes in the body weight of WT and SPARC KO treated with DSS 
and water control. The loss of body weight was calculated by dividing the difference 
in weight on the specified day by the body weight of day 0 and expressed as percentage. 
Values are mean ±  SEM n=15)    WT untreated;    SPARC KO untreated;    WT 
DSS-treated;    SPARC KO DSS-treated. 
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3.2.1.2 Colon length 
The  colon  length  is  often  used  as  morphological  parameter  for  the  degree  of 
inflammation in DSS colitis. During the peak of inflammation, it was observed that the 
colon shortened. At day 7, both DSS-treated WT and SPARC KO mouse colons had an 
average colon length of 6.5cm while those of the control mice averaged 8.6cm although 
this was not statistically significant. During the recovery stage (Day 14, 21 and 35), the 
length of the colon from both groups of mice, treated with DSS, gradually returned to 
normal  length consistent with  resolution of the  inflammation (Figure  3.2). The WT 
mice, however, had a shorter average colon length than the SPARC KO mice consistent 
with continuing inflammation and a slower healing rate.  
 
 
 
 
 
Figure  3.2:  A)  Colon  length  in  WT  and  SPARC  KO  mice  during  acute, 
chronic/recovery phases of colitis. B) Representative image of colon immediately after 
removal from the mice at day 7. (n=4)   WT untreated;    SPARC KO untreated;    
WT DSS-treated;    SPARC KO DSS-treated. 
 
 
During acute inflammation, all the WT mice treated with DSS had an increase in spleen 
weight  (Chapter  4)  and  enlargement  of  the  MLNs  (data  not  shown),  where  such 
enlargement were observed less frequently in the SPARC KO mice treated with DSS. 
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3.2.1.3 Endoscopic Scoring 
Endoscopically, the inflammation was primarily located in the distal colon (2-3cm from 
the anus) in both WT and SPARC KO animals. At day 6, both WT and SPARC KO 
showed  marked  signs  of  mucosal  inflammation  as  described  in  Table  2.1:  soft  and  
bloody stool, thickening of the mucosa, , bleeding, loss of visible blood vessel structures 
and the presence of fibrin (Figure 3.4 a). After DSS removal, the stool almost back to 
normal solid shaped and translucency and vascular pattern gradually restored as seen in 
day 13 (Figure 3.4 b), 20 (Figure 3.4 c) and 34(Figure 3.4 d). Granular mucosa surface 
formed on the colon tissue closest to rectum.  
 
WT mice had significantly higher MEICS scores than SPARC KO especially at day 6 
(p=0.039),  20  (p=0.019)  and  34  (p<0.0001)  (Figure  3.3  A).  This  suggests  that 
inflammation is worse and that the speed of recovery from the inflammation is slower in 
the presence of SPARC. 
 
 
 
 
 
Figure  3.3:  MEICS  of  WT  and  SPARC  KO  mice.  A)  Line  graph  (*p<0.05, 
***p<0.001) comparing SPARC KO-DSS to WT-DSS mice at difference time points. B) 
Scatter  plot  to  show  the  variation  in  each  group  and  compared  with  day  6:  WT 
**p<0.01;*** p<0.001; SPARC  KO- ## p<0.01. Values are  mean ±  SEM based on 
records of 8-15  mice per time point  from  3 different experiments. Statistical  values 
using Student’s unpaired t-test. The untreated controls (WT, KO) are not shown as they 
had a score of “0” for MEICS.   WT DSS-treated;    SPARC KO DSS-treated.     
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Figure  3.4  a:  Representative  endoscopic  images  at  day  6  showing  the  colon  of 
healthy control (A, B, C, D), DSS-treated WT (E, F,G, H) and DSS-treated SPARC 
KO  (I,  J, K,  L)  mice. When treated with DSS for 7 days, both WT and KO mice 
showed signs of inflammation: loose and bloody stool (     E, I), thickening of colonic 
wall with reduction in translucency (F, J), altered vascular pattern (       F, J) and present 
of fibrin (       G, K). The lowest panel (D, H, L) showed the colon closest to rectum, 
which has a different fibrosturcture to the distal and proximal colon.  
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Figure 3.4 b: Representative endoscopic images at day 13 showing the colons of 
mice recovering from DSS treatment. The stool is an almost normal solid shape but 
thickening of the colonic wall and altered vascular patterns are still present in both WT 
and SPARC KO mice (A, C). The lowest panel (B, D) shows the colonic closest to 
rectum where there was the presence of granular mucosa. 
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Figure 3.4 c: Representative endoscopic images showing the colon of DSS-treated 
WT and SPARC KO mice at day 20. The translucency has returned to the SPARC 
KO colons (C) while some WT mice still demonstrate mucosal thickening. The mucosal 
surface was still “granulated” and this persisted until day 34 (B and D).  
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Figure 3.4 d: Representative endoscopic images showing the colon of DSS-treated 
WT  and  SPARC  KO  mice  at  day  34.  The translucency  and  vascular  pattern  had 
returned  to  normal  in  majority  of  the  animals,  but  some  of  the  WT  mice  still 
demonstrate thickening of the mucosa and the mucosal closet to the rectum was still 
“granulated” (B).  
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3.2.1.4 Histological score 
Histopathological  analysis  was  undertaken  following  H&E  staining.  SPARC  KO 
animals  that  received  DSS  treatment  appear  to  have  a  trend  towards  a  lower  total 
inflammatory score (Figure 3.5 A) and in all the histological features (Figure 3.5 B) 
although not statistically significant. Tissues at day 7 demonstrated moderate to severe 
inflammation in both WT and SPARC KO mice, with transmural inflammation detected 
in some animals, particularly the WT animals. The crypts were lost from the colon with 
a reduction in the goblet cell number, focal ulceration, infiltration of inflammatory cells, 
including neutrophils, into the mucosa and oedema of the submucosa (Figure 3.6 A). 
Regeneration,  indicated  by  reepithelisation  and  proliferation  of  new  crypts,  began 
following the removal of the DSS as seen at days 14 to 35. Overall, the WT DSS-treated 
mice still demonstrated crypt damage and ulceration at day 21 in contrast to the SPARC 
KO mice (Figure 3.6 C). At day 35, majority of SPARC KO DSS-treated mice had 
completely regenerated the colonic mucosa (Figure 3.6 D), while the WT DSS-treated 
animals had still not fully resolved the inflammation. A small number of treated WT 
mice also still demonstrated moderate inflammation, crypt damage with ulceration.  
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Figure  3.5:  A)  Total  inflammatory  score.  Extent  of  inflammation  quantified  and 
expressed as an inflammation score as shown in table 2.3. B) The score for 4 different 
features of histology. The untreated controls are not shown as they had a score of “0” 
to  all  assessed  features.  Each  time  point  consisted  of  10-15  mice  from  3  different 
experiments. Value is mean ﾱ SEM. Statistical values using Student’s unpaired t-test 
comparing mice at difference time points with mice at peak of inflammation (day 7): 
*p<0.05; **p<0.01; ***p<0.0001.    WT DSS-treated;     SPARC KO DSS-treated. 
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Figure 3.6 A: Representative photographs of H&E-stained sections of the distal colon 
at day 7  demonstrating ulceration, mononuclear cell infiltrate involving part to all of 
the colonic wall with disruption of the normal crypt architecture and loss of goblet cells 
(↑) and submucoa oedema (#). Left panel-40x, Bar: 500µm; Right panel-100x, Bar: 100 
µm) 
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Figure 3.6 B: Representative photographs of H&E-stained sections of the distal colon at 
day 14. Ulceration (↑); Regeneration of crypts ( ) and reepithelisation that occurred 
from  the  edge  of  the  ulcerations  was  seen  in  both  WT  and  KO-treated  mice.  Inset 
showing mitotic figures (↑) 400x. Left panel-40x, Bar: 500µm; Right panel-100x, Bar: 
100 µm. 
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Figure 3.6 C: Representative photographs of H&E-stained sections of the distal colon 
at days 21. Both WT and SPARC KO mice colons continued to heal. Left panel-40x, 
Bar: 500µm; Right panel-100x, Bar:100 µm 
 
 
 
 
 
 
 
 
Figure 3.6 D: Representative photographs of H&E-stained sections of the distal colon 
of SPARC KO at day 35 where complete regeneration occurred Left panel-40x, Bar: 
500µm; Right panel-100x, Bar:100 µm 
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3.2.2 Cytokine production by DSS treated mice during the periods of 
acute inflammation and recovery 
To further investigate the impact of SPARC on the infiltration of inflammatory cells 
during  the  development  of  colitis,  the  production  of  selected  cytokines  within  the 
colonic tissue was determined. IL-1β, IL-6 and TNF-α are pro-inflammatory cytokines 
that are not only present during the early stage of inflammation but are also implicated 
in pathogenesis of IBD. The DSS-treated animals demonstrated significantly elevated 
levels of all 3 of these cytokines at day 7 when compared to the untreated animals. The 
production of IL-1β was also noted to be significantly higher (p=0.025) in the WT DSS-
treated animals when compared to the DSS-treated SPARC KO mice at day 7 (Figure 
3.7 C). The levels of all 3 cytokines fell rapidly following withdrawal of the DSS in 
both the WT and SPARC KO animals. WT DSS-treated animals, however, maintained a 
slightly higher mean concentration of these cytokines when compared to the SPARC 
KO mice. This trend is consistent with the MEICS (Figure 3.3) and histological scores 
(Figure 3.5) detailed above. 
 
In an attempt to maintain homeostasis, regulatory or anti-inflammatory cytokines, such 
as IL-10 and TGF-β, are produced by the body to counteract the inflammatory reaction 
triggered by pro-inflammatory cytokines. The change in production of IL-10 in DSS-
treated  colons  was  similar  to  that  observed  for  the  pro-inflammatory  cytokines  and 
peaked at day 7 with a rapid decrease following withdrawal of the DSS. DSS-treated 
WT  animals  also  demonstrated  significantly  higher  (p=0.034)  levels  of  IL-10 
production than the untreated WT animals (Figure 3.10 A). No statistically significant 
trend was found between the DSS-treated WT and SPARC KO mice (Figure 3.10  C). 
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Despite the variation between animals, TGF-β1 was produced at significantly higher 
concentrations (p=0.017) by the DSS-treated SPARC KO animals when compared to 
the DSS-treated WT mice (Figure 3.11 C). This is in contrast to the trend observed for 
the other cytokines as detailed above.  
 
The levels of IL-1β, IL-6 and TNF-α in the plasma of the DSS-treated mice were low 
(<10 pg/ml; data not shown), suggesting that DSS-induced colitis is a more localized 
inflammation (colonic) rather than a systemic inflammation. In contrast, the level of 
TGF-β1, and to lesser extend of IL-10, were abundantly present in the plasma, but no 
statistically  significant  differences  were  detected  between  the  DSS-treated  WT  and 
SPARC KO animals. 
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Figure 3.7: IL-1β production in the colon of WT and SPARC KO mice measured 
with CBA. (A) WT VS WT-DSS (B) SPARC KO VS SPARC KO-DSS (C) WT-DSS 
VS SPARC KO-DSS. IL-1β production in the acute, chronic/recovery phases. Mean ±  
SEM (n =10-20 mice per group from 3 different experiments per time point) (*p=0.05). 
 WT  untreated;   SPARC  KO  untreated;   WT  DSS-treated;   SPARC  KO 
DSS-treated 
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Figure 3.8: IL-6 production in the colon of WT and SPARC KO mice measured 
with CBA. (A) WT VS WT-DSS (B) SPARC KO VS SPARC KO-DSS (C) WT-DSS 
VS SPARC KO-DSS. IL-6 production in the acute, chronic/recovery phases. Mean ±  
SEM (n =10-20 mice per group from 3 different experiments per time point) (*p=0.05). 
 WT  untreated;   SPARC  KO  untreated;   WT  DSS-treated;   SPARC  KO 
DSS-treated 
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Figure 3.9: TNF-α production in the colon of WT and SPARC KO mice measured 
with CBA. (A) WT VS WT-DSS (B) SPARC KO VS SPARC KO-DSS (C) WT-DSS 
VS SPARC KO-DSS. TNF-α production in the acute, chronic/recovery phases. Mean ±  
SEM (n =10-20 mice per group from 3 different experiments per time point) (*p=0.05). 
 WT  untreated;   SPARC  KO  untreated;   WT  DSS-treated;   SPARC  KO 
DSS-treated 
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Figure 3.10: IL-10 production in the colon of WT and SPARC KO mice measured 
with CBA. (A) WT VS WT-DSS (B) SPARC KO VS SPARC KO-DSS (C) WT-DSS 
VS SPARC KO-DSS. IL-10 production in the acute, chronic/recovery phases. Mean ±  
SEM (n =10-20 mice per group from 3 different experiments per time point) (* p=0.05).  
 WT  untreated;   SPARC  KO  untreated;   WT  DSS-treated;   SPARC  KO 
DSS-treated 
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Figure  3.11:  TGF-β1production  in  the  colon  of  WT  and  SPARC  KO  mice 
measured with ELISA. (A) WT VS WT-DSS (B) SPARC KO VS SPARC KO-DSS 
(C) WT-DSS VS SPARC KO-DSS. TGF-β1 production in the acute, chronic/recovery 
phases. Mean ±  SEM (n =10-20 mice per group from 3 different experiments per time 
point) (* p=0.05).   WT untreated;   SPARC KO untreated;   WT DSS-treated; 
 SPARC KO DSS-treated 
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3.3 DISCUSSION 
SPARC has been shown to play an active role in cell migration, ECM regulation and 
wound healing (Bradshaw and Sage 2001; Brekken and Sage 2000; Lane and Sage 1994; 
Latvala  et  al.  1996).  A  role  for  SPARC  in  colonic  inflammation  and  pathologies, 
however,  has  not  been  studied  extensively.  There  are  conflicting  conclusions  in  the 
literature regarding the role of SPARC  in  inflammation, suggesting that its function 
could be organ and model specific (Savani et al. 2000; Rempel et al. 2007; Socha et al. 
2007). The widely used DSS-induced colitis model not only exhibits inflammatory and 
histopathological features that are similar to the human colitis, but it also can be used to 
analyse the patency and repair of the epithelial barrier, leucocytes behavior, lymphocyte 
responses and the production of both pro and anti-inflammatory cytokines as described 
in chapter 1(Dieleman et al. 1998; Dieleman et al. 1994; Hall et al. 2011; Wirtz et al. 
2007).  Thus,  this  model  was  chosen  to  investigate  the  role  of  SPARC  in  intestinal 
inflammation.  
 
Ingestion of 3-10% DSS for 7-10 days has been shown to induce acute inflammation 
that depends on the susceptibility of the mice strain and the molecular weight of DSS 
(Okayasu et al. 1990; Melgar et al. 2005; Mahler et al. 1998; Wirtz and Neurath 2007). 
Chronic inflammation can also be achieved by the administered of 3-5 cycles of DSS in 
the drinking water with a period of 2 weeks without DSS between each DSS cycle 
(Okayasu et al. 1990). A single DSS cycle, however, is sufficient to induce chronicity in 
the C57BL/6 mice strain (Melgar et al. 2005) and the WT mice used in this study. The 
data presented in this chapter demonstrated that there is a potential pro-inflammatory 
role of SPARC in the colon in the DSS-induced model of acute colitis in mice. The 
clinical parameters of weight loss, colonic shortening and splenic enlargement were less 95 
 
in the SPARC KO mice when compared to the WT mice and this was accompanied with 
significantly lower micro-endoscopic score (p<0.001). Several WT mice also developed 
a chronic, slow healing inflammation while majority of SPARC KO mice resolved the 
intestinal inflammation by day 35 as determined by endoscopy and lesser extend on 
histology.  In  a  pilot  study  using  a  small  number of  mice  (n=4)  which  received  2-3 
cycles of DSS in order to induce chronic inflammation, SPARC KO mice also had less 
inflammation and lower MEICS than the WT mice (9 vs 5.5; p=0.029, data not shown).   
 
In  humans,  endoscopy  of  the  colon  is  an  important  diagnostic  method  for  the 
investigation  of  colonic  diseases.  The  use  of  the  mouse  micro-endoscopic  system 
provides  valuable  and  accurate  information  in  the  assessment  and  monitoring  of 
intestinal inflammation and its resolution (Becker et al. 2005). The micro-endoscopic 
assessment  of  SPARC  KO  mice  clearly  demonstrated  that  they  develop  less 
inflammation when treated with DSS than the WT controls. The endoscopic scoring was 
more sensitive at detecting differences between the animals and was a better way to 
evaluate  inflammation  levels  than  the  histology  or  the  use  of  surrogate  markers  to 
evaluation disease activity such as weight loss and stool consistency.  
 
Histopathologically, DSS-treated SPARC KO mice had lower histological score (total 
inflammatory score) and less crypt damage than WT mice. At day 7, both, WT and 
SPARC KO treated animals, showed similar levels of inflammation, but the SPARC 
KO mice had less severe inflammation at each subsequent time point. This suggests that 
the SPARC KO animals were able to recover more rapidly with a potentially  faster 
healing  rate  although  the  regeneration  sub-score  did  not  detect  a  difference  again 
suggesting that the histology scoring of colonic regeneration is difficult, complex and 96 
 
not  particularly  sensitive.  Regeneration  could  not  be  assessed  during  the  peak  of 
inflammation (day 7) but only from day 14 so it is possible that the peak time point of 
regeneration (perhaps day 9-11) may have been missed in the SPARC KO animals. The 
published effects of SPARC on wound healing appear to be contradictory, but this study 
is  similar  that  of  Bradshaw  and  colleagues  where  SPARC  null  mice  demonstrated 
accelerated healing of 5 mm induced cutaneous wounds (Bradshaw et al. 2002). The 
anti-proliferative properties of SPARC (Brekken and Sage 2000) may cause a slower 
healing in the WT animals as re-epithelialisation usually started from the neighbouring 
epithelium  as  revealed  by  focal  mitoses  in  neighboring  epithelial  cells  bridging  the 
lesions (Dieleman et al. 1998). SPARC KO animals healed faster than the WT and this 
could also be related to SPARC  inhibiting the  function of PDGF, VEGF, and basic 
fibroblast growth factor which are important mediators in healing. It has been showed 
that the dermal structure in SPARC KO mice is difference to WT animals with smaller 
collagen  fibrils  suggesting  a  defect  in  collagen  bundling  in  the  absence  of  SPARC. 
Similar findings were also observed in the colon (Chapter 5) again suggesting that the 
less  structured  ECM  allows  for  a  faster  cellular  infiltrate  and  improved  healing 
(Bradshaw, Puolakkainen, et al. 2003; Bradshaw and Sage 2001).  
 
Cytokines are important immunoregulatory modulators of IBD pathology. The colonic 
explants used in this study allowed evaluation of a wide array of cytokines that were 
produced by the whole intestine under inflammatory conditions (Siegmund et al. 2002; 
Suzuki et al. 2001). The WT mice had greater tissue damage than SPARC KO and this 
might due to the relatively greater local production of the pro-inflammatory cytokines. 
One of roles of SPARC is to promote cell migration (Basu et al. 2001; Yan and Sage 
1999).  SPARC  allows  for  enhanced  migration  of  macrophages,  neutrophils  and 97 
 
epithelial cells and it is primarily from these cells that pro-inflammatory cytokines  IL-6,  
IL-1β and TNF-α derived (Melgar et al. 2005). The DSS-treated SPARC KO animals 
had  significant  lower  levels  of  IL-1β  (p=0.025),  which  has  been  suggested  to  be 
involved  in  the  initiation  and  perpetuation  of  colitis  (Youngman  et  al.  1993).  The 
inflammation in IBD patients and the experimental models of colitis are associated with 
increased levels of IL-1β which is thought to be secreted by the macrophages activated 
within the mucosa and sub-mucosa (Kwon et al. 2005; Guimbaud et al. 1998).  
 
IL-6 works synergistically with IFN-γ to induce B cell differentiation (Jego et al. 2003), 
and IL-6 has been showed to mediate the resistance of T cells to apoptosis in CrD and is 
thus able to contribute to the perpetuation of chronic intestinal inflammation (Atreya et 
al. 2000). In contrast, IL-6 deficient mice developed less severe colitis when submitted 
to the DSS model of colitis (Suzuki et al. 2001). The level of IL-6 in SPARC KO was 
lower  than  the  WT  animals  and  although  the  differences  were  not  statistically 
significant.  This  may  be  a  reason  behind  the  differences  observed  in  the  levels  of 
inflammation between the animal groups and remains to be confirmed statically in more 
detailed experiments. It might also indicate that specific targeting of the SPARC-IL-
6/IL-1β pathway may be a promising new approach for the treatment of CrD.  
 
As mentioned earlier, DSS disrupts the epithelial cell barrier and increases exposure to 
luminal antigens which results in inflammation that involves PMN, macrophages, B and 
T cells as major sources of the pro-inflammatory cytokines. These cytokines then cause 
more tissue damage later, hence, recruitment of leucocytes to the intestine seems to be 
the key event in the DSS induced colitis (Abdelbaqi et al. 2006; Chidlow et al. 2009; 
Stevens et al. 1992) and this will be investigated in Chapter 4.  98 
 
 
The SPARC KO animals were found to have higher TGF-β1 levels which contrasted 
with the report by Socha and colleagues in which, had less expression of TGF-β in the 
kidney in the absence of SPARC (Socha et al. 2007). It is unclear why more TGF-β is 
observed in the SPARC KO colon than the WT, but it may be due to the unique immune 
adaptations of the colon which is colonised with great number of Treg cells that able to 
modulate activity of the immunosuppressive TGF-β. In addition, it has been shown that 
the intestinal mucosa promotes epithelial restitution after injury through the increased 
production of bioactive TGF-β1 by the epithelial cells (Dignass and Podolsky 1993) and 
subepithelial myofibroblasts (McKaig et al. 1999). Hence, the increase in TGF-β1 may 
have contributed to the maintenance of intestinal barrier integrity and intestinal healing 
in the SPARC KO mice that experienced less tissue destruction.     
 
3.4 CONCLUSION 
The  investigations  here  have  shows  that  SPARC  appears  to  have  pro-inflammatory 
properties in the DSS-induced model of colonic inflammation thereby delaying healing. 
This is most likely due to roles in cell migration and regulation of the ECM, which 
subsequently modulate cellular infiltration and the secretion of the pro-inflammatory 
cytokines.  Therefore, the  cellular  components  which  include  cells  of  the  innate  and 
adaptive immune responses will be investigated in the next chapter.  
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Chapter 4 
 
The roles of SPARC in the 
innate and adaptive immune 
system in DSS colitis 
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4.1 INTRODUCTION 
Both  the  innate  and  adaptive  immune  systems  in  the  gut  have  developed  unique 
characteristics  in  order  to  maintain  homeostasis  in  this  antigen-rich  environment 
(Murphy  2008;  Schenk  and  Mueller  2007).  The  intestinal  wall  is  populated  with 
immune cells (e.g. intestinal macrophages) that eliminate invading pathogens without 
inducing  an  over  response  to  the  commensal  microorganisms  located  in  the  lumen 
(Qualls et al. 2006). There is also an enhanced frequency of the presence of regulatory 
T  cell  (Treg)  subsets  that  are  characterised  by  the  production  of  the  potent  anti-
inflammatory cytokines, TGF-β and IL-10 (Izcue et al. 2009; Groux et al. 1997). IEL 
that  may  potentially  exert  immunoregulatory  functions  are  found  abundantly,  and 
strategically  positioned,  in  the  LP  (Newberry  and  Lorenz  2005).  There  is  ample 
evidence  to  suggest  that  disruption  of  the  immune  regulatory  networks  within  the 
intestine may result in IBD. These include abnormalities in the function of the intestinal 
epithelial  cell  barrier,  excessive  production  of  Th1,  Th2  or  Th17  cytokines,  and 
dysregulated activation of the intestinal mucosal inflammatory cells by normal luminal 
bacteria (Fiocchi 1998; Strober et al. 2002; Fujino et al. 2003; Su et al. 2009; Izcue et al. 
2009; Uguccioni et al. 1999; Sanchez-Munoz et al. 2008). 
 
So far, no studies have been done to investigate the role of SPARC on immunity in the 
GIT  despite  its  properties  as  a  matricellular  protein,  which  have  been  shown  to 
modulate numerous cell functions such as cell proliferation and migration as well as 
ECM regulation (Yan and Sage 1999; Tremble et al. 1993;  Tai and Tang 2008). As 
SPARC may play an important role in regulating the immune balance within the GIT it 
could also play a role in the pathogenesis of IBD.  
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The effects of SPARC could result in differences in the recruitment and activation of 
inflammatory cells across different systems. Savani and colleagues showed that SPARC 
KO  mice  had  increased  neutrophil  and  leucocyte  infiltration  in  an  intratracheal 
bleomycin-induced lung injury model (Savani et al. 2000). In a mouse footpad swelling 
model,  SPARC  null  mice  also  exhibited  an  altered  immune  system  with  decreased 
numbers of neutrophils and B cells but increased numbers of T cells, and these animals 
were unable to mount an innate immune response to the bacterial product LPS (Rempel 
et al. 2007). In the absence of SPARC, however, T cell priming was enhanced in a 
murine model of contact hypersensitivity due to the accelerated migration of DCs to the 
draining lymph nodes (Sangaletti et al. 2005).  
 
As discussed in the previous chapter, the increase in production of pro-inflammatory 
cytokines by infiltrating inflammatory cells in WT mice may be the main driver of the 
tissue damage observed in DSS-induced colitis. Cytokines are important mediators of 
both the innate and adaptive arms of the immune responses in mucosal inflammation 
(Dignass and Podolsky 1993). Cytokines also play a key role in IBD as they determine 
T cell differentiation of Th1, Th2, T regulatory and Th17 cells (Sanchez-Munoz et al. 
2008).  In  addition  to  cytokines,  chemokines  and  their  receptors  contribute  to  the 
regulation of intestinal immune responses and mucosal inflammation (Tokuyama et al. 
2005) and monokines induced by IFN-γ (MIG) and RANTES (regulated on activation 
normal  T  cell  expressed  and  excreted)  are  elevated  in  the  intestine  of  IBD  patients 
(Danese and Gasbarrini 2005). 
 
Identification  of  the  different  subsets  of  immune  cells  such  as  the  Th  lymphocytes, 
neutrophils  and  macrophages  within  the  intestinal  mucosa  is  vital  and  will  be 
investigated in this chapter as will the expression of key cytokines and chemokines. 102 
 
These findings will allow us to further determine the role that SPARC may play in cell 
recruitment in the DSS-induced model of colitis. 
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4.2 RESULTS   
4.2.1 Spleen to body weight ratios in WT and SPARC KO mice  
Splenic enlargement was used as one marker for the severity of DSS-induced colitis. 
The spleen wet weight was recorded and normalised to the body weight to determine 
the systemic effect of DSS treatment.   
 
In control animals given plain tap water to drink, there was no statistical difference in 
the ratio of the spleen wet weight to the body weight between WT and SPARC KO 
mice  at  all  time  points  except  at  day  35  (0.49  vs  0.37,  p=0.017;  data  not  shown). 
Following  treatment  with  DSS,  both  WT  and  SPARC  KO  mice  had  an  increased 
spleen/body weight ratio (Figure 4.1; Figure 4.2 A and B). The WT mice, however, 
had an approximately 2 to 4 fold greater increase in this ratio than KO mice. This was 
particularly noted at the time of maximal inflammation on days 7 (1.01 vs 0.61; p<0.01) 
and 21 (0.92 vs 0.60; p=0.037), where DSS-treated WT mice had a statistically larger 
spleen to body weight ratio (Figure 4.2 C). A similar trend was observed throughout the 
experiment, from the acute through to the recovery, or chronic, phase of disease.  
 
 
 
 
 
 
 
 
 
Figure 4.1: Spleen size in WT and SPARC KO mice after 7 days of DSS treatment 
 
WT  SPARC KO 
DSS-treated 
Untreated 
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Figure 4.2: Wet spleen weight was measured at sacrifice and expressed as ratio to 
body weight after DSS treatment. (A) WT VS WT-DSS (B) SPARC KO VS SPARC 
KO-DSS (C) WT-DSS VS SPARC KO-DSS. Ratio was expressed as a mean ±  SEM 
based on 10-15  mice per time point  from 3 different experiments. Statistical  values 
using Student’s unpaired t-test (*p<0.05; **p<0.01).   WT untreated;   SPARC KO 
untreated;   WT DSS-treated;   SPARC KO DSS-treated  
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4.2.2 CD4+ T cell changes in WT and SPARC KO mice 
It has been suggested that an alteration in the CD4+ T cell response is central to the 
immunological pathogenesis of IBD. In order to determine if the CD4+ T cell subset 
differs between WT and SPARC KO following DSS administration, T cells in the MLN 
and the spleen were analysed by flow cytometry. Attempts were made to analyse the T 
cell subtypes  in the colon,  however, the yield of cells  varied  between the treatment 
groups  and  despite  pooling  cells  from  several  animals,  insufficient  numbers  were 
obtained for reliable analysis.   
 
4.2.2.1 Total Lymphocytes 
When compared to the control animals, the percentage of lymphocytes in the spleen was 
reduced at day 14 and 21 in DSS-treated WT mice (Figure 4.3 A). This was in contrast 
to SPARC KO animals, where the percentage lymphocytes did not change with DSS 
treatment  (Figure  4.3  B).  It  was  observed  that  the  SPARC  KO  animals  had  a 
significantly higher percentage of lymphocytes than WT mice in the spleen at days 7 
(p=0.022) and 14 (p<0.01) following DSS treatment (Figure 4.3 C).  
 
In the local draining lymph nodes, there were no differences observed at any time point 
between  the  WT  controls  and  the  DSS-treated  WT  animals.  There  were  also  no 
differences in the percentage of lymphocytes following DSS treatment in the SPARC 
KO mice compared to their untreated controls except on day 14 where a significant 
increase was noted (p=0.028) (Figure 4.4 B).   
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Figure 4.3: Percentage of total lymphocytes in spleen following DSS treatment. (A) 
WT VS WT-DSS (B) SPARC KO VS SPARC KO-DSS (C) WT-DSS VS SPARC KO-
DSS.  Cells  were  isolated  from  spleen  and  MLN  on  day  7,  14,  21,  and  35  and 
determined by flow cytometry. Data represent the mean percentage of lymphocytes. ± 
SEM  from  3  independent  experiments  each  consisting  of  4-5  animals;  *  p<0.05; 
**p<0.01; *** p<0.001).   WT untreated;   SPARC KO untreated;   WT DSS-
treated;   SPARC KO DSS-treated  
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Figure 4.4: Percentage of total lymphocytes in MLN following DSS treatment.  (A) 
WT VS WT-DSS (B) SPARC KO VS SPARC KO-DSS (C) WT-DSS VS SPARC KO-
DSS.  Cells  were  isolated  from  spleen  and  MLN  on  day  7,  14,  21,  and  35  and 
determined by flow cytometry. Data represent the mean percentage of lymphocytes. ± 
SEM from 3 independent experiments each consisting of 4-5 animals;   WT untreated; 
 SPARC KO untreated;   WT DSS-treated;   SPARC KO DSS-treated  
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4.2.2.2 CD4+ T lymphocytes 
The lymphocytes were stained for surface markers, CD3 and CD4, to define the CD4+ 
T lymphocytes or Th cells. The cells were analysed in order to determine if SPARC 
impacts on this cell population. There was a lower percentage of CD4+ lymphocytes in 
the DSS-treated groups compared to the untreated groups in both tissues (Figure 4.5 
and  4.6  A  and  B).  The  SPARC  KO  DSS-treated  mice,  however,  had  a  higher 
percentage of CD4+ T lymphocytes in the spleen relative to the WT DSS-treated mice, 
which was significantly different at day 7 (p=0.017) (Figure 4.5 C). There were no 
statistical differences in the percentage of Th lymphocytes in the MLN (Figure 4.6  B).  
 
4.2.2.3 CD4+ T lymphocyte subsets 
As  differences  were  found  in  the  percentage  of  CD4+  T  lymphocytes  further 
investigations were performed to determine which subset of CD4+ T lymphocytes were 
associated  with  the  DSS-induced  colitis.  The  isolated  leucocytes  were  stimulated  in 
vitro and stained to identify intracellular IFN-γ, IL-4 and IL-17A by flow cytometry.  
 
DSS treatment reduced the number of IFN-γ+ expressing CD4+ T lymphocytes in both 
WT  and  SPARC  KO  mice  when  compared  to  the  untreated  animals  in  the  spleen 
(Figure 4.7 A and B). The SPARC KO DSS-treated animals had a higher percentage of  
IFN-γ+ producing CD4+ T lymphocytes in the spleen than the WT-DSS treated mice at 
most time points and this difference was statistically significant (p=0.035) at day 14 
(Figure 4.7 C). The percentage of IFN-γ producing cells located in the MLNs did not 
statistically differ between the DSS-treated and untreated groups or between WT and 
SPARC KO mice (Figure 4.8).  
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The IL-4+ and IL-17A+ expressing cells were present in low levels in all animals but 
with  no  differences  detected  between  the  groups  (data  not  shown).  These  findings, 
however, suggest that both WT and SPARC KO mice mounted a Th1 inflammatory 
response when treated with DSS as none of the other Th subset specific cytokines were 
able to be detected.  
 
Treg cells are important in maintaining gut immunity (Izcue et al. 2009) and high levels 
of TGF-β1 were found following DSS treatment of the SPARC KO animals.  TGF-β 
plays a role in the Treg-mediated inhibition of systemic and mucosal immune responses. 
The presence of these cells was measured by flow cytometry for intracellular FoxP3 
following DSS-induced colitis. 
 
The percentage of Treg cells (CD4+CD25+FoxP3) was higher in the healthy SPARC 
KO mice compared to the WT animals in both the spleen (13.2 vs 16.8; p<0.01) and 
MLNs (8.55 vs 11.14; p=0.013) (data not shown). Following the induction of colitis, 
this increase was still present and continued to be observed at day 14 in both the spleen 
(p<0.01) (Figure 4.9 C) and MLN (p<0.01) (Figure 4.10 C); and day 21 in the spleen 
(p<0.01) (Figure 4.9 C). 
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Figure 4.5: Percentage of CD4+ T lymphocytes in the spleen. (A) WT VS WT-DSS 
(B) SPARC KO VS SPARC KO-DSS (C) WT-DSS VS SPARC KO-DSS. Cells were 
isolated from spleen and MLN on day 7, 14, 21, and 35 following DSS treatment and 
determined by flow cytometry. Data represent the mean percentage of CD3+CD4+ (Th 
lymphocytes) ±  SEM from 3 independent experiments each consisting of 4-5 animals; 
*p<0.05;  ***p<0.001).   WT  untreated;   SPARC  KO  untreated;   WT  DSS-
treated;   SPARC KO DSS-treated  
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Figure 4.6: Percentage of CD4+ T lymphocytes in the MLN. (A) WT VS WT-DSS 
(B) SPARC KO VS SPARC KO-DSS (C) WT-DSS VS SPARC KO-DSS. Cells were 
isolated from spleen and MLN on day 7, 14, 21, and 35 following DSS treatment and 
determined by flow cytometry. Data represent the mean percentage of CD3+CD4+ (Th 
lymphocytes) ±  SEM from 3 independent experiments each consisting of 4-5 animals; 
*p<0.05;  **p<0.01;  ***p<0.001).   WT  untreated;   SPARC  KO  untreated;   
WT DSS-treated;   SPARC KO DSS-treated  
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Figure 4.7: Percentage of CD3+CD4+ cells expressing IFN-γ in the spleens. (A) WT 
VS WT-DSS (B) SPARC KO VS SPARC KO-DSS (C) WT-DSS VS SPARC KO-DSS.  
Cells were isolated from spleen and MLN on day 7, 14, 21, and 35 following DSS 
treatment and determined by flow cytometry. Data represent the mean percentage of 
CD3+CD4+ (Th lymphocytes) ±  SEM from 3 independent experiments each consisting 
of 4-5 animals; *p<0.05; **p<0.01).   WT untreated;   SPARC KO untreated;   
WT DSS-treated;   SPARC KO DSS-treated  
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Figure 4.8: Percentage of CD3+CD4+ cells expressing IFN-γ in the MLN. (A) WT 
VS WT-DSS (B) SPARC KO VS SPARC KO-DSS (C) WT-DSS VS SPARC KO-DSS. 
Cells were isolated from spleen and MLN on day 7, 14, 21, and 35 following DSS 
treatment and determined by flow cytometry. Data represent the mean percentage of 
CD3+CD4+ (Th lymphocytes) ±  SEM from 3 independent experiments each consisting 
of 4-5 animals;   WT untreated;   SPARC KO untreated;   WT DSS-treated;   
SPARC KO DSS-treated  
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Figure 4.9: Percentage of Treg cells (CD4+CD25+FoxP3+) in the spleen. (A) WT 
VS WT-DSS (B) SPARC KO VS SPARC KO-DSS (C) WT-DSS VS SPARC KO-DSS.  
Cells were isolated from spleen and MLN on day 7, 14, 21, and 35 following DSS 
treatment and determined by flow cytometry. Data represent the mean percentage of 
CD4+CD25+FoxP3+ ±  SEM from 3 independent experiments each consisting of 4-5 
animals;  *p<0.05;  **p<0.01).   WT  untreated;   SPARC  KO  untreated;   WT 
DSS-treated;   SPARC KO DSS-treated  
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Figure 4.10: Percentage of Treg cells (CD4+CD25+FoxP3+) in the MLN. (A) WT 
VS WT-DSS (B) SPARC KO VS SPARC KO-DSS (C) WT-DSS VS SPARC KO-DSS.  
Cells were isolated from spleen and MLN on day 7, 14, 21, and 35 following DSS 
treatment and determined by flow cytometry. Data represent the mean percentage of 
CD4+CD25+FoxP3+ ±  SEM from 3 independent experiments each consisting of 4-5 
animals; *p<0.05).   WT untreated;   SPARC KO untreated;   WT DSS-treated; 
 SPARC KO DSS-treated  
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4.2.3 The cytokine profile in the colon of WT and SPARC KO mice 
As each subset of CD4+ T cells produce a specific set of cytokines. CD4+ T cells have 
been  classified  into  distinct  subsets  namely  Th1,  Th2,  and  Th17  and  depending  on 
which cytokines are produced, different immune responses can be generated (Agnello et 
al. 2003; Brand 2009; Rotteveel et al. 1988). The panels of cytokines to be measured 
were chosen as they have been implicated in the pathogenesis of IBD, and these were 
also  used  to  subcharacterise  the  CD4+  T  cells  located  within  the  colon  after 
unsuccessful  attempts  to  isolate  enough  cells  from  the  colons  for  flow  cytometric 
analysis.  The  cytokines  secreted  from  the  colon  were  measured  without  ex  vivo 
stimulation with a CBA kit.  
 
DSS treatment increased the production of IFN-γ in the colon in both WT and SPARC 
KO mice when compared to untreated animals (Figure 4.11 A). DSS-treated SPARC 
KO animals had a higher mean level of IFN-γ secretion compared to WT DSS-treated 
mice. This was noted during both the acute phase of inflammation and following the 
withdrawal of DSS (day 7-14) with a gradually decrease over time (Figure 4.11 A), but 
it was not statistically higher due to the high variability between the samples.  
 
Consistent  with  the  flow  cytometric  analyses,  no  IL-4  producing  lymphocytes  were 
detected either in the spleen or MLNs. This was also the case in the colon where no IL-4 
production was detected (Figure 4.11 B). There were, however, detectable levels of the 
other Th-2 related cytokines, IL-5 (Figure 4.11 C) and IL-13 (Figure 4.11 D). Due to 
the high inter-individual variation, however, these did not reach statistical significance 
between  the  untreated  and  DSS-treated  groups.  IL-17A  production  was  elevated 
following  the  administration  of  DSS  in  the  WT  animals  (day  21  p=0.035;  day  35 117 
 
p=0.049; Figure 4.12 A). No significant differences were observed in between the DSS-
treated WT and SPARC KO animals (Figure 4.12 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Th1 (IFN-γ) and Th2 related cytokines secretion of the colon during 
the acute and chronic/recovery phases in WT and SPARC KO mice measured with 
CBA. A) IFN-γ B) IL-4, C) IL-5, D) IL-13 production in the acute, chronic/recovery 
phases in SPARC WT and KO mice. Mean ±  SEM (n =12 to mice per group from 3 
different experiments per time point).   WT untreated;   SPARC KO untreated;    
WT DSS-treated;    SPARC KO DSS-treated. 
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Figure 4.12: Th 17 related cytokine, IL-17A, secretion by the colon in WT and 
SPARC KO mice measured with CBA. (A) WT VS WT-DSS (B) SPARC KO VS 
SPARC KO-DSS (C) WT-DSS VS SPARC KO-DSS. Mean ±  SEM (n =12 to mice per 
group from 3 different experiments per time point) (*p<0.05).   WT untreated;   
SPARC KO untreated;   WT DSS-treated;   SPARC KO DSS-treated  
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4.2.4 The chemokines expression in WT and SPARC KO mice  
 
Chemokines contribute to the regulation of the intestinal immune response and mucosal 
inflammation,  as  they  are  critical  elements  in  regulating  the  trafficking  of  cells  to 
inflammatory sites (Tokuyama et al. 2005). Chemokine production was thus measured. 
Both  WT  and  SPARC  KO  untreated  animals  had  similar  levels  of  MCP-1.  MCP-1 
production rose when the animals received DSS (Figure 4.13 A, B). WT mice generally 
had higher levels than SPARC KO animals after DSS treatment. Coinciding with the 
maximal  colonic  inflammation  at  day  7  WT  animals  demonstrated  the  highest 
expression of MCP-1. This fell by day 14, but rose at day 21 before decreasing again by 
day 35. Due to high sample variability no significant differences were detected between 
the disease groups (Figure 4.13 C).  
 
MIG and RANTES were detected in the untreated animals and both were significantly 
induced following DSS treatment for 7 days in both the WT and SPARC KO animals 
although to a lesser extend in the SPARC KO animals (Figure 4.14 and 4.15 A and B). 
The  level  of  MIG  was  significantly  higher  in  the  WT  DSS-treated  group  when 
compared to the SPARC KO at day 7 (p=0.031) and 14 (p=0.014) (Figure 4.14 C).  
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Figure 4.13: Colonic chemokines, MCP-1 production of the colon by SPARC WT 
and KO mice measured with CBA. MCP-1 production in the acute, chronic/recovery 
phases. Mean ±  SEM (n =10 mice per group from 3 different experiments per time point) 
(**p<0.01).   WT  untreated;   SPARC  KO  untreated;   WT  DSS-treated;   
SPARC KO DSS-treated  
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Figure 4.14: Colonic chemokines, MIG production of the colon by SPARC WT and 
KO mice measured with CBA. (A) WT VS WT-DSS (B) SPARC KO VS SPARC 
KO-DSS (C) WT-DSS VS SPARC KO-DSS. Mean ±  SEM (n =10 mice per group from 
3 different experiments per time point) (*p<0.05).   WT untreated;   SPARC KO 
untreated;   WT DSS-treated;   SPARC KO DSS-treated  
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Figure 4.15: Colonic chemokine, RANTES production of the colon by SPARC WT 
and KO mice measured with CBA. (A) WT VS WT-DSS (B) SPARC KO VS SPARC 
KO-DSS (C) WT-DSS VS SPARC KO-DSS. Mean ±  SEM (n =10 mice per group from 
3 different experiments per time point) (*p<0.05).   WT untreated;   SPARC KO 
untreated;   WT DSS-treated;   SPARC KO DSS-treated  
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4.2.5 Innate cell pattern in WT and SPARC KO Mice 
The colon is populated with large numbers of resident intestinal macrophages that are 
able to phagocytoses harmful pathogen but lack certain receptors that allow them to 
generate an inflammatory stimuli. Inflammatory macrophages, however, are recruited 
from  the  systemic  circulation  and  can  secrete  pro-inflammatory  cytokines  thus 
promoting  inflammation  (Smith  et  al.  2010;  Heinsbroek  and  Gordon  2009).  Lower 
levels of chemokines and IL-1β were detected in SPARC KO animals in this study and 
these changes possibly contributed to the less colonic inflammation that was seen as 
those  mediators  are  associated  with  innate  cell  recruitment.  To  determine  any 
differences  in  the  inflammatory  cell  infiltration,  serial  cryosections  of  untreated  and 
DSS-treated  mice  were  stained  for  the  distribution  and  number  of  the  macrophage 
subsets and neutrophils, to determine if this could account for the differences observed 
in  the  level  of  cytokines,  chemokines  and  inflammation.  Immunofluorescence  was 
chosen instead of flow cytometry analysis due to difficulties in cell isolation from the 
colon and as it allows localisation of the cells of interest. Unfortunately, there is a lack 
of markers that accurately differentiate the intestinal macrophage from the inflammatory 
macrophage, however, CD68 and CD11b can be used to characterise some features of 
these cells and were used in this study.  
 
CD68+  cells  were  primarily  located  in  the  LP  within  the  colonic  mucosa,  and  low 
numbers were also detected in the submucosa of control mice. Following DSS treatment, 
the CD68+ cells, in both locations, increased in number and more cells infiltrated the 
submucosa (Figure 4.16 D). WT animals had statistically greater levels of CD68+ cells 
than SPARC KO mice following DSS removal at day 21 (p=0.021) and 35 (p<0.01) 
(Figure 4.16  C).  124 
 
The number of CD11b+ cells was heterogeneous throughout the experiments, which 
might be explained by the fact that CD11b+ stains both monocytes and neutrophils. 
Double staining with another macrophage marker and/or a neutrophil specific marker 
will  be  required  to  further  distinguish  CD11b+  macrophages  from  other  leucocytes. 
Different numbers of CD11b+ cells, however, were still observed between the WT and 
KO mice. DSS treatment significantly increased (WT: p=0.016; SPARC KO: p<0.01) 
the number of CD11b+ cells in both sets of mice. CD11b+ cells were also found around 
the  muscle  and  serosa  layers  instead of  just  in  the  LP  and  submucosa  of the  colon 
(Figure 4.17 D). SPARC KO had greater numbers of CD11b+ cells than the WT at day 
7 but this decreased rapidly with a significantly lower number of CD11b+ cells in the 
SPARC KO animals by day 35 (p=0.025) (Figure 4.17 C).  
 
Staining was also undertaken for Ly6G, a maker for neutrophils, as these are the first 
innate immune cells to infiltrate sites of inflammation. In water control animals, almost 
no neutrophils were present and those that were observed were located within the LP. 
Following DSS treatment, more neutrophils were observed in the LP, particularly at 
sites  of  ulceration,  as  well  as  in  the  submucosa  (Figure  4.18  D).  WT  animals  had 
significantly higher Ly6G+ neutrophils numbers than the SPARC KO mice throughout 
the 4 assessment time points consistent with the greater levels of inflammation (Figure 
4.18 C).    
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Figure 4.16: CD68+ cells in WT and SPARC KO colon. (A) WT VS WT-DSS (B) 
SPARC KO VS SPARC KO-DSS (C) WT-DSS VS SPARC KO-DSS. Total numbers of 
CD68+  cells  per  field  of  view.  Mean  ±   SEM  (n=4  mice  per  time  point;  *p<0.05; 
**p<0.01). (D) In situ visualisation of colonic macrophages at day 21. CD68 staining 
(red) and co-stained nuclei (blue). E - epithelium layer, L - lumen and SM – submucosa. 
Lower panels are the merged phase contrast-florescence images.   WT untreated;   
SPARC KO untreated;   WT DSS-treated;   SPARC KO DSS-treated. Bar: 100µm 
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Figure 4.17: CD11b+ cells in WT and SPARC KO colon. (A) WT VS WT-DSS (B) 
SPARC KO VS SPARC KO-DSS (C) WT-DSS VS SPARC KO-DSS. Total numbers of 
CD11b+ cells per field of view. Mean ±  SEM (n=4  mice per time point;  * p<0.05; 
**p<0.01). (D) In situ visualisation of colonic CD11b+ cells. CD11b staining (red) and 
co-stained nuclei (blue). E - epithelium layer, L - lumen and SM – submucosa. Lower 
panels  are  the  merged  phase  contrast-florescence  images.   WT  untreated;   
SPARC KO untreated;   WT DSS-treated;   SPARC KO DSS-treated. Bar: 100µm  
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Figure 4.18: Ly6G+ cells in SPARC WT and KO colon. (A) WT VS WT-DSS (B) 
SPARC KO VS SPARC KO-DSS (C) WT-DSS VS SPARC KO-DSS.  Total numbers 
of Ly6G+ cells per field of view. Mean ±  SEM (n=4 mice per time point; *p<0.05). (D) 
In situ visualisation of colonic Ly6G staining (red) and co-stained nuclei (blue). E - 
epithelium layer, L - lumen and SM – submucosa. Lower panels are the merged phase 
contrast-florescence  images.   WT  untreated;   SPARC  KO  untreated;   WT 
DSS-treated;   SPARC KO DSS-treated. Bar: 100µ m 
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4.3 DISCUSSION  
The activation of the adaptive immune system is important in protecting the intestinal 
mucosa  that  is  continuously  in  contact  with  numerous  harmless  antigens  as  well  as 
micropathogens and other potentially harmful agents. Numerous studies, however, also 
point  out  that  an  uncontrolled  adaptive  immune  response  could  play  a  role  in  the 
pathogenesis of IBD (Fujino et al. 2003; Izcue et al. 2009; Monteleone et al. 1997). For 
many  years,  the  Th1  and  Th2  paradigm  has  been  used  to  define  the  inflammation 
observed  in  CrD  and  UC  respectively.  Recently,  however,  emerging  evidence  has 
demonstrated that Th17 cells are also involved in IBD pathogenesis and the mucosal 
Th1 and Th2 responses of CrD and UC also suggest that these may be a secondary 
effect to defects in the innate immune response. Thus characterisation of the levels of 
local and systemic inflammation, the pattern of the innate and adaptive CD4+ T cellular 
responses in the DSS model of colitis were conducted. These allowed us to investigate 
whether  SPARC  affects  the  immune  response  as  SPARC  appears  able  to  modify 
cytokine  production  thus  influencing  cell  recruitment  and  polarisation  of  the  T  cell 
response.  
 
The level of colonic inflammation was different between SPARC KO and WT animals 
with SPARC KO colons being less inflamed than WT (Chapter 3). The splenic weights 
and the spleen/body weight ratio, which act as markers of systemic inflammation, also 
demonstrated significant differences between the SPARC KO and the WT animals in 
both the water controls (p<0.05) and following DSS-induced colitis (p<0.01). Rempel 
and colleagues reported that SPARC KO animals had a greater splenic wet weight when 
in  the  healthy  state  (Rempel  et  al.  2007).  The  present  study,  however,  found  that 
SPARC KO mice had smaller spleens and a lower spleen/body ratio than WT. This 
might  be  due  to  the  different  mouse  strain  or  the  age  of  mice  used  experiments. 129 
 
Younger (8 to 12 weeks old) mice were used in the Remple study whereas the animals 
in this study were slightly older with the first assessment occurring after 13 weeks of 
age. Embryonic and developmental mouse studies have previously demonstrated subtle 
phenotypic  differences  between  SPARC  KO  and  WT  mice  but  these  phenotypic 
characteristics become more apparent with age (Norose et al. 2000; Bradshaw et al. 
2002). This effect of aging might thus explain the observed differences between these 
studies.  
 
With larger and heavier spleens, the DSS-treated WT animals had higher numbers of 
cells isolated from these organs. The total number of leucocytes isolated from the WT 
spleens was higher, but these had a lower percentage of lymphocytes than the SPARC 
KO  mice.  This  suggests  that  other  cell  populations  may  be  contributing  more  than 
lymphocytes to the splenic enlargement observed in the DSS-treated WT animals and 
also agrees with a role for SPARC through affecting lymphocyte trafficking (Rempel et 
al. 2007) as SPARC  is a ligand of VCAM-1 that mediates  leucocyte transmigration 
(Kelly et al. 2007). IFN-γ producing Th lymphocytes (Th1) were present in a higher 
percentage in the SPARC KO DSS-treated mice than WT (Figure 4.7 and 4.8). This 
might be due to accelerated DC migration and subsequent increased T cell priming, i.e 
DC  can  move  faster  to  the  draining  lymph  nodes  and  activate  a  stronger  adaptive 
immune response because of a less dense collagen network present in the SPARC KO 
mice (Sangaletti et al. 2005). A similar event may also possibly account for the higher 
percentage of Treg cells that seen in the SPARC KO mice.  
 
Significantly higher TGF-β levels were detected in the colonic tissue of the KO DSS-
treated animals at day 7 compared to the WT mice (Section 3.2.2). This might allow for 
greater differentiation of CD4+ T lymphocytes into Treg cells and possibly explain why 130 
 
the KO DSS-treated animals had significantly higher levels of Treg cells in the isolated 
tissues compared to the WT DSS-group at the time points after day 7. With more Treg 
cells present in the KO-DSS treated animals, more TGF-β may be released, reducing the 
level of inflammation by inhibiting the effector cells, and also aiding in the restoration 
of the integrity of the intestinal mucosal barrier (Izcue et al. 2009).  
 
SPARC has been shown to have a negative regulatory role on levels of IL-6sR, which is 
an IL-6 agonist implicated in IL-6 trans-signalling (Kallen 2002) , and SPARC is also 
able to modulate the expression of TGF-β (Lane and Sage 1994; Francki et al. 2004). 
Both IL-6 and TGF-β are essential in Th17 differentiation. Unfortunately, neither flow 
cytometric  or  cytokines  analyses  were  able  to  clearly  distinguish  any  differences  in 
CD4+ T cells subsets between WT and SPARC KO. It may be that the antibodies used 
to characterise the cells were not sensitive enough to detect subtle differences if they 
were present or due to the use of the C57/BL6 strain which is known to be prone to 
mount a Th1 response (Sacks and Noben-Trauth 2002). Besides TGF-β, IFN-γ has been 
shown to be capable of inducing the Treg cell phenotype as IFN-γ KO mice have a more 
severe form of experimental autoimmune encephalomyelitis and impaired Treg function 
(Wang  et  al.  2006).  Although  not  statically  significant,  SPARC  KO  animals  in  this 
study  had  numerically  higher  levels  of  IFN-γ  and  IFN-γ-expressing  CD4+  T 
lymphocytes  (at  least  during  the  early  phase)  that  could  possibly  contribute  to  the 
greater number of Treg cells that were found.  
   
The greater levels of inflammation observed in the WT mice could be secondary to the 
role that SPARC plays in promoting cell migration, with less neutrophils, monocytes 
and possibly inflammatory macrophages seen in the SPARC KO colons following DSS 
administration. Cell migration is a complex process, which requires many different, and 131 
 
precise,  signals  to  be  present  and  chemokines  are  part  of  this  signalling  process. 
Production of the chemokines, MCP-1, MIG, macrophage inflammatory protein (MIP)-
1α and -1β (data not shown) were lower in the colons of the DSS-treated SPARC KO 
mice  when  compared  to  the  WT  animals.  This  may  explain  the  reduced  levels  of 
infiltrating leucocytes observed in the colonic cyrosections of the SPARC KO mice. 
With  less  production  of  chemokines,  leucocytes,  especially  neutrophils,  may  have 
reduced migrating into the colon. A similar effect can also be observed in chemokine 
receptor-deficient mice, which are protected from the DSS-induced inflammation due to 
lesser immune cellular infiltration (Siegmund et al. 2002; Andres et al. 2000).  
 
4.4 CONCLUSION 
Differences  were  observed  in  the  level  of  inflammation  in  the  SPARC  KO  animals 
compared to WT. Although the only genetic difference between the animals was the 
absence  of  SPARC,  the  exact  mechanism  that  caused  all  the  observed  differences 
remains  unknown  since  SPARC  plays  important  roles  in  numerous  cell  functions. 
Differences in the neutrophil, macrophage and lymphocyte populations; in chemokine 
expression,  as  well  as  cytokine  levels,  suggest  that  numerous  cellular  activities  are 
closely associated with regulation of the ECM and that SPARC is responsible for some 
of these functions. The ECM of SPARC KO mice has been shown to be different to WT 
animals and this may be important to the observed differences (Bradshaw 2009). The 
higher TGF-β levels seen in the KO animals at day 7 also support the observation that 
the colonic ECM of SPARC KO animals differs from WT since ECM is one of the 
major reservoirs of TGF-β. The aim of the next chapter is, therefore, to examine the 
ECM of the colon in both WT and SPARC KO mice to determine what the differences 
that impact on the observed cellular events described above.  132 
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5.1 INTRODUCTION 
From the data presented in chapter 4, it appears that SPARC affects the recruitment of 
immune cells through the modulation of chemokine expression, and also through  an 
effect  on  the  ECM  composition  and  architecture  as  proposed  form  the  literature. 
SPARC is involved in many processes that regulate proliferation, migration, and growth 
factor activities, but some of its major functions involve binding to, and interacting with, 
collagen (Brekken and Sage 2000). SPARC can alter the interaction between collagen 
and  the  cell  surface  possibly  through  the  modulation  of  receptor  binding  and  the 
regulation  of  collagen  incorporation  into  fibrils  that  subsequently  affecting  collagen 
fibril  maturation  (Bradshaw  2009).  SPARC  also  regulates  the  expression  of  several 
MMPs in certain cell types (Shankavaram et al. 1997). Thus, SPARC seems to possess 
the necessary  biological properties that are required to regulate the balance  between 
ECM deposition and degradation.  Fibrosis  is over deposition of ECM and also  is  a 
nonspecific feature of chronic inflammation and is observed in CrD and UC (Harper et 
al. 1987; Pucilowska, Williams, et al. 2000). Many mouse models investigating fibrosis 
in numerous organs such as the skin, lung, heart and kidney have demonstrated that 
SPARC  KO  mice  have  reduced  collagen  deposition  when  compared  to  their  WT 
counterparts (Bradshaw et al. 2009; Bradshaw et al. 2002; Socha et al. 2007; Strandjord 
et al. 1999).  
 
Mesenchymal cells such as fibroblasts and myofibroblasts are the major effector cells of 
wound  repair  and  regenerative  healing.  They  coordinate  the  deposition  and  further 
organisation of the collagenous ECM in the wound bed, and they determine the final 
outcome of the scarring process (Powell et al. 1999a; Tomasek et al. 2002). Colonic 
subepithelial myofibroblasts are located at the interface between the epithelium and LP, 134 
 
immediately adjacent to the basement membrane in the normal intestinal mucosa. These 
cells are specialised mesenchymal cells and have ultrastructural features that resemble 
both fibroblasts and smooth muscle cells. It is these cells that play a vital role in the 
regulation of epithelial cell function and ECM metabolism as well as the development 
of fibrosis in the gut (Brenmoehl et al. 2009; Powell et al. 1999a, 1999b; Andoh et al. 
2005). Recently, the pro-fibrogenic response of hepatic stellate cells, myofibroblast-like 
cells that reside in the liver and are involved in hepatic fibrogenesis, has been attenuated 
by  knock  down  of  SPARC  expression  with  siRNA  (Atorrasagasti  et  al.  2011). 
Therefore, an  investigation of the precise  mechanisms  by which these  mesenchymal 
cells are involved in the ECM modulation and development of fibrosis in colitis is vital 
and will be examined in this chapter. 
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5.2 RESULTS 
5.2.1 Collagen content of colonic section in WT and SPARC KO mice 
Colons commonly become rigid in the presence of acute and/or chronic inflammation 
(Melgar et al. 2005). In order to investigate whether this was due to the presence of 
inflammatory  cells  or  the  resulting  fibrosis,  distal  colonic  tissues  were  stained  with 
Sirius  red  to  analyse  the  production  of  collagen  as  a  marker  of  fibrosis  and  ECM 
changes. 
The collagen content was colour-coded by the Aperio's ImageScope Viewer-Spectrum 
positive pixel count algorithm software. The results are presented as the amalgamation 
of all 3 groups of positive staining pixels (weak, medium and strong) and normalised to 
the  area  selected.  SPARC  KO  animals  had  less  colonic  collagen  on  average  when 
compared to the WT mice in both untreated (0.428 vs 0.238; p=0.015; data not shown) 
and following DSS-treatment (Figure 5.1). At day 7 following the commencement of 
DSS treatment, both WT and SPARC KO DSS-treated animals had more collagen than 
their water treated group. The difference in collagen content diminished over the course 
of the experiment and the collagen content in the treated animals dropped in comparison 
to the water control mice following removal of the DSS at day7.   
Collagen deposition in the mucosa and submucosa of both the SPARC KO and WT 
mice increased with the DSS treatment and was most marked at day 7 (Figure 5.2 A). 
Following removal of the DSS, the level of colonic collagen in SPARC KO animals 
rapidly returned to the pretreatment levels while the collagen levels in the WT remained 
elevated  until  days  21  and  35  (Figure  5.2  B). These  findings  suggest that the  WT 
animals are be more prone to the development of intestinal fibrosis than SPARC KO 
mice.  136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Positive Sirius red stain pixel to area ratio. (A) WT VS WT-DSS (B) 
SPARC KO VS SPARC KO-DSS (C) WT-DSS VS SPARC KO-DSS.Values are mean 
±  SEM based on records of 5 mice at each time point. (**p<0.01).   WT untreated; 
SPARC KO untreated;   WT DSS-treated;   SPARC KO DSS-treated 
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Figure 5.2 A: Increased levels of collagen in the DSS-induced inflamed colons at 
day 7: Representative tissue sections of SPARC WT and KO stained with Sirius red. 
Following  7  days  exposure  to  DSS,  both  SPARC  KO  and  WT  mice  demonstrated 
extensive deposition of collagen within the LP, submucosa and the serosa layer. WT-
DSS - WT DSS-treated; SPARC KO-DSS –SPARC  KO-DSS treated. Bar:200µm 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 B: Colonic collagen at day 21 in SPARC KO and WT mice following 
DSS treatment: Representative tissue sections of SPARC WT and KO stained with 
Sirius red. At day 21, WT-T animals still had great amounts of collagen compared to 
KO mice which appeared to have returned to pre-DSS treatment levels. WT-DSS - WT 
DSS-treated; SPARC  KO-DSS –SPARC KO DSS-treated.  Bar: 200µm 
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5.2.2. Colonic ECM gene expression in DSS-treated WT and SPARC KO 
mice 
5.2.2.1 Collagen expression  
ECM-related gene expression levels were measured in the colonic tissue to determine if 
there  were  any  differences  between  SPARC  KO  and  WT  animals.  Collagen  type  1 
(collagen 1α1)  mRNA expression  in  WT DSS-treated group was significantly  lower 
(p<0.001) than in the WT untreated group (Figure 5.3 A). No statistical differences 
observed between the water and DSS-treated SPARC KO animals (Figure 5.3 B). The 
SPARC KO animals had significantly higher collagen type 1 expression (p<0.01) than 
the WT animals at day 7 after DSS treatment (Figure 5.3 C). There were, however, no 
statistically  significant  differences  detected  between  the  WT  and  SPARC  KO  DSS-
treated mice at the other time points (Figure 5.3 C).  
 
The  collagen  type  3  (collagen  3α1)  gene  expression  in  WT  DSS-treated  group  was 
significantly  lower  (p<0.001)  than  in  the  WT  untreated  group  at  day  7  and  no 
differences observed in other time points (Figure 5.4 A). SPARC KO mice receiving 
DSS  treatment  had  significantly  greater  collagen  3α1  expression  (p<0.01)  than  the 
SPARC KO untreated group only at day 21 (Figure 5.4 B). Similar to collagen 1α1 
expression, the collagen 3α1 expression in the SPARC KO animal was significantly 
higher than WT in the DSS treated group(p<0.001)  (Figure 5.4 C).  
 
5.2.2.2 MMP expression  
MMPs play a crucial role in ECM degradation. MMP-13 (homologous to human MMP-
1) cleaves the triple helixes of native fibrillar collagen that includes collagens I, II, III 
and VII. Stromelysins (MMP-3) degrade the noncollagen components of ECM, such as 
fibronectin, laminin and proteoglycans. These two MMPs are postulated as being the 139 
 
most important of the proteolytic enzymes responsible for the breakdown of ECM in 
IBD (von Lampe et al. 2000; McKaig et al. 2003).  
 
The transcription levels of MMP-13 in the WT DSS-treated animals were significantly 
lower (p<0.01) than in water control WT animals at day 7 (Figure 5.5 A). By contrast, 
the  water  control  SPARC  KO  animals  had  significantly  higher  (p=0.015)  MMP-13 
mRNA expression at day 14 compared to the DSS-treated KO group (Figure 5.5 B). 
The WT-DSS treated animals at day 7 also demonstrated significantly less (p=0.013) 
MMP-13 expression compared to the SPARC KO DSS-treated animals (Figure 5.5 C), 
which also reflected the change in the collagen expression levels.  
 
MMP-3 was also significantly increased (p=0.031) in the DSS-treated SPARC KO mice 
compared to the DSS-treated WT group at day 7, although there was some variability in 
the sample levels (Figure 5.6 C). No statistical differences in the MMP3 expression 
levels were demonstrated at any of the other time points. 
 
5.2.2.3 TIMP expression 
The TIMPs also are regulators involved in the ECM balance as they regulate the actions 
of the MMPs. The SPARC KO animals demonstrated less TIMP-1 expression when 
compared  to the  WT  mice  and  this  difference  was  significantly  different  at  day  35 
between the DSS-treated groups (Figure 5.7 C). No other differences between the WT 
and SPARC KO animals were observed, but DSS was noted to reduce colonic TIMPs 
expression, especially TIMP-2 expression, which was significantly reduced in both WT 140 
 
and  SPARC  KO  groups  when  compared  to  the  untreated  control  animals  at  day  7 
(p<0.001) and 35 (WT: p= 0.026; SPARC KO: p<0.01) (Figure 5.8 A and B).  
 
5.2.2.4 TGF-β expression 
Colonic  TGF-β1  and  β3  expression  levels  were  low  with  a  great  deal  of  variation 
between the different groups when compared to each other across the time points and no 
trend in expression was observed (Figure 5.9 and 5.10). Untreated SPARC KO animals, 
however, had significantly higher TGF-β1 expression than the WT untreated controls at 
day 21 (data not shown).  
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Figure 5.3: Collagen 1α1 mRNA expression in colonic tissue. (A) WT VS WT-DSS 
(B)  SPARC  KO  VS  SPARC  KO-DSS  (C)  WT-DSS  VS  SPARC  KO-DSS.  After 
normalising  with  the  house  keeping  gene  and  expressed  relative  to  untreated  WT 
controls. Values are mean ±  SEM based on records of 5 mice per time point. (**p<0.01; 
***p<0.001).   WT untreated;   SPARC KO untreated;   WT DSS-treated;   
SPARC KO DSS-treated 
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Figure 5.4: Collagen 3α1 mRNA expression in colonic tissue. (A) WT VS WT-DSS 
(B)  SPARC  KO  VS  SPARC  KO-DSS  (C)  WT-DSS  VS  SPARC  KO-DSS.  After 
normalising  with  the  house  keeping  gene  and  expressed  relative  to  untreated  WT 
controls. Values are mean ±  SEM based on records of 5 mice per time point. (**p<0.01; 
***p<0.001).   WT untreated;   SPARC KO untreated;   WT DSS-treated;   
SPARC KO DSS-treated 
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Figure 5.5: MMP-13 mRNA expression in colonic tissue. (A) WT VS WT-DSS (B) 
SPARC  KO  VS  SPARC  KO-DSS  (C)  WT-DSS  VS  SPARC  KO-DSS.  After 
normalising  with  the  house  keeping  gene  and  expressed  relative  to  untreated  WT 
controls. Values are mean ±  SEM based on records of 5 mice per time point. (*p<0.05; 
**p<0.01).   WT  untreated;   SPARC  KO  untreated;   WT  DSS-treated;   
SPARC KO DSS-treated 
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Figure 5.6: MMP-3 mRNA expression in colonic tissue. (A) WT VS WT-DSS (B) 
SPARC  KO  VS  SPARC  KO-DSS  (C)  WT-DSS  VS  SPARC  KO-DSS.  After 
normalising  with  the  house  keeping  gene  and  expressed  relative  to  untreated  WT 
controls. Values are mean ±  SEM based on records of 5 mice per time point. (*p<0.05). 
 WT  untreated;   SPARC  KO  untreated;   WT  DSS-treated;   SPARC  KO 
DSS-treated 
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Figure 5.7: TIMP-1 mRNA expressions in colonic tissue. (A) WT VS WT-DSS (B) 
SPARC  KO  VS  SPARC  KO-DSS  (C)  WT-DSS  VS  SPARC  KO-DSS.  After 
normalising  with  the  house  keeping  gene  and  expressed  relative  to  untreated  WT 
controls. Values are mean ±  SEM based on records of 5 mice per time point. (*p<0.05). 
 WT  untreated;   SPARC  KO  untreated;   WT  DSS-treated;   SPARC  KO 
DSS-treated 
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Figure 5.8: TIMP-2 mRNA expressions in colonic tissue. (A) WT VS WT-DSS (B) 
SPARC  KO  VS  SPARC  KO-DSS  (C)  WT-DSS  VS  SPARC  KO-DSS.  After 
normalising  with  the  house  keeping  gene  and  expressed  relative  to  untreated  WT 
controls. Values are mean ±  SEM based on records of 5 mice per time point. (*p<0.05; 
**p<0.01;  ***p<0.001).   WT untreated;   SPARC KO untreated;   WT DSS-
treated;   SPARC KO DSS-treated 
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Figure 5.9: TGF-β1 mRNA expression in colonic tissue. (A) WT VS WT-DSS (B) 
SPARC  KO  VS  SPARC  KO-DSS  (C)  WT-DSS  VS  SPARC  KO-DSS.  After 
normalising  with  the  house  keeping  gene  and  expressed  relative  to  untreated  WT 
controls. Values are mean ±  SEM based on records of 5 mice per time point.   WT 
untreated;   SPARC  KO  untreated;   WT  DSS-treated;   SPARC  KO  DSS-
treated 
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Figure 5.10: TGF-β3 mRNA expression in colonic tissue. (A) WT VS WT-DSS (B) 
SPARC  KO  VS  SPARC  KO-DSS  (C)  WT-DSS  VS  SPARC  KO-DSS.  After 
normalising  with  the  house  keeping  gene  and  expressed  relative  to  untreated  WT 
controls.. Values are mean ±  SEM based on records of 5 mice per time point.   WT 
untreated;   SPARC  KO  untreated;   WT  DSS-treated;   SPARC  KO  DSS-
treated 
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5.2.3 The ECM gene expression of primary subepithelial myofibroblasts 
cell cultures  
 
The colonic ECM gene expression levels in KO mice demonstrated that at some time 
points the collagens were expressed differently compared to WT animals. At day 7, the 
collagen 1α1 and 3α1 expressions were downregulated in WT but not SPARC KO. WT 
animals, however, have more inflammation than SPARC KO animals at this time point. 
Since gene expression  measurements  were normalised against a house keeping gene 
(HPRT) which is presumably expressed by inflammatory cells as well, hence, it is not 
clear whether collagen expression by fibroblasts is actually decreased on a cellular level 
or whether the observed differences are an indirect effect due to the abundant presence 
of inflammatory cells in the WT animals.   
The cells of mesenchymal orgin, fibroblast/myofibroblast cells, appear to be implicated 
in  ECM  modulation  and  intestinal  fibrosis.  The  colonic  fibroblasts  were,  therefore, 
isolated  from  both  WT  and  SPARC  KO  mice,  in  order  to  determine  the  effect  of 
SPARC on fibroblasts gene expression on a cellular level. 
 
5.2.3.1 Characterisation of primary myofibroblasts cells 
The  isolated  colonic  fibroblast-like  cell  cultures  demonstrated the  normal  anchorage 
dependent fibroblast characteristics. The fibroblasts grew as flat, elongated cells with 
spindle shaped cytoplasm and cytoplasmic extensions of variable length when examined 
under light microscope at confluency. The vast majority of isolated cells were shown to 
be of  mesenchymal origin  and were myofibroblasts, and not epithelial cells, as they 
stained positive for vimentin (Figure 5.11 B), α-smooth muscles actin (Figure 5.11 A) 
and  negative  for  keratin  (Figure  5.11  E).  A  small  percentage  of  the  isolated  cells, 
however, did stain positive for desmin (Figure 5.11 C) suggesting that they had the 
contractile nature that is part of the smooth muscle/myofibroblast cell. There were no 150 
 
detectable  differences  in  light  microscopy  morphology  or  immunohistochemistry 
between the cell cultures from WT and SPARC KO mice.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: Characterisation of the isolated colonic myofibroblasts. Once confluent, 
cellular morphology was examined and immunohistochemical staining undertaken A) α-
smooth muscle actin, B) Vimentin C) Desmin D) No primary antibody control. E) The 
isolated cells stained negative for the epithelial cell marker: keratin F) A549 epithelial 
cell  line  stained positive  for the keratin as a positive control to E. A representative 
photomicrograph was shown for each antibody. Bar:100µm 
 
B 
E 
D  C 
A 
F 151 
 
5.2.3.2 ECM genes expression in the colonic myofibroblast culture 
The in vitro colonic myofibroblast cultures were stimulated with PMA, a mammalian 
tumour  promoter,  to  mimic  the  in  vivo  inflammatory  conditions  in  the  in  vitro 
experiments.   
 
5.2.3.2.1 Collagen expression  
Collagen 1α1 and 3α1 mRNA expressions were significantly lower in the unstimulated 
SPARC KO compared to the control WT myofibroblasts (p<0.001). PMA treatment was 
also  noted to  reduce  collagen  expression  in  both  sets  of  myofibroblast  cultures.  No 
statistical difference, however, was found between the PMA-treated WT and SPARC 
KO myofibroblast cultures (Figure 5.12 A and B).  
 
 
 
 
 
 
 
 
 
 
Figure 5.12: A) Collagen 1α1 B) Collagen 3α1 mRNA expression in myofibroblast 
cultures  with  and  without  PMA  stimulation.  After  normalising  with  the  house 
keeping gene and expressed relative to untreated WT controls. Values are mean ±  SEM 
based  on  records  of  5  independent  experiments,  performed  in  triplicate.  (*p<0.05; 
**p<0.01; *** p<0.001).   WT untreated;   SPARC KO untreated;   WT DSS-
treated;   SPARC KO DSS-treated 
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5.2.3.2.2 MMP expression 
PMA treatment significantly increased MMP-13 expression in both the WT (p<0.001) 
and SPARC KO (p<0.01) myofibroblasts, and the SPARC KO cells were noted to have 
a  trend  of  greater  expression  of  MMP-13  than  the  WT  cells  (Figure  5.13  A).  The 
expression of MMP-3 did not differ between the stimulated and unstimulated isolated 
cells or between the SPARC KO and WT groups (Figure 5.13 B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5.13:  A)  MMP-13  B)  MMP-3  mRNA  expression  in  the  myofibroblast 
cultures with and without PMA. After normalised with the house keeping gene and 
expressed  relative  to  wild  type  controls.  Values  are  mean  ±   SEM  based  on  5 
independent  experiments,  performed  in  triplicate.  (**p<0.01;  ***p<0.001).   WT 
untreated;   SPARC  KO  untreated;   WT  DSS-treated;   SPARC  KO  DSS-
treated 
 
 
 
     
WT KO WT-PMA KO-PMA
0
5
10
15
20
25
***
**
M
M
P
-
1
3
/
b
-
a
c
t
i
n
(
r
e
l
a
t
i
v
e
 
t
o
 
W
T
-
u
n
t
r
e
a
t
e
d
)
A 
WT KO WT-PMA KO-PMA
0.0
0.5
1.0
M
M
P
-
3
/

-
a
c
t
i
n
(
r
e
l
a
t
i
v
e
 
t
o
 
W
T
-
u
n
t
r
e
a
t
e
d
)
B 153 
 
5.2.3.2.3 TIMP expression 
In the non PMA treated cells, the SPARC KO expressed more TIMP-2 and significantly 
higher (p=0.045) TIMP-1 expression compared to the WT controls (Figure 5.14). PMA 
stimulation significantly increased the expression of TIMP-1 by myofibroblasts in both 
the  WT  (p=0.044)  and  SPARC  KO  (p=0.041)  cells  (Figure  5.14  A).  This  was  in 
contrast to TIMP-2 mRNA expression, which, although there was a trend to a reduction 
in expression following PMA stimulation, was not statistically significant (Figure 5.14 
B). 
  
 
 
 
 
 
 
 
 
 
 
 
Figure  5.14:  A)  TIMP-1  B)  TIMP-2  mRNA  expression  in  the  myofibroblast 
cultures with and without PMA. After normalised with the house keeping gene and 
expressed  relative  to  wild  type  controls.  Values  are  mean  ±   SEM  based  on  5 
independent  experiments,  performed  in  triplicate.  (*p<0.05).   WT  untreated;   
SPARC KO untreated;   WT DSS-treated;   SPARC KO DSS-treated 
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5.2.3.2.4 TGF-β expression  
No differences were observed between the expression of TGF-β1 in the unstimulated 
myofibroblast cultures (Figure 5.15 A). PMA, however, significantly reduced TGF-β3 
RNA expression in the WT myofibroblasts, but this was not significantly different to 
the SPARC KO cells (Figure 5.15 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5.15:  A)  TGF-β1  B)  TGF-β3  mRNA  expression  in  the  myofibroblast 
cultures with and without PMA. After normalised with the house keeping gene and 
expressed  relative  to  wild  type  controls.  Values  are  mean  ±   SEM  based  on  5 
independent experiments, performed in triplicate. (***p<0.001).   WT untreated;   
SPARC  KO untreated;   WT DSS-treated;   SPARC KO DSS-treated 
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5.3 DISCUSSION   
Intestinal wound healing is a tightly regulated process of tissue repair and regeneration 
following tissue injury. Inappropriate tissue repair, resulting in  intestinal fibrosis and 
stricture, as seen in CrD patients, can greatly impair function of the GIT and may also 
result  in  the  persistence  of  mucosal  ulceration  and  the  formation  of  fistulous  tracts 
(Suzuki et al. 2011; Abreu et al. 2002). SPARC has been shown to play an important 
role  in  both  wound  healing  and  the  regulation  of  the  ECM  and  potentially  the 
development of fibrosis and may thus represent a potential target in the management of 
intestinal wound  healing. Therefore, the gene expression of key regulatory genes of 
ECM formation was analysed and compared between WT and SPARC KO mice in this 
chapter.  
 
Collagen content was evaluated in colonic tissue taken from WT and SPARC KO mice 
in order to determine if there were any differences between the ECM,  including the 
presence of excessive collagen deposition. Sirius red staining clearly reveals the thin 
collagen  fibres  and  enables  quantitative  morphometric  assessment  of  the  collagen 
amounts (van den Borne et al. 2008). Comparisons between Sirius red and Masson’s 
trichrome  staining,  another  collagen  stain,  did  not  demonstrate  any  significant 
differences (data not shown), but due to ease of use and the potential of the examination 
of  the  collagen  morphology  under  polarised  light  (Trombetta  and  Bradshaw  2010; 
Junqueira et al. 1979), Sirius red staining was chosen for use in this study. The lower 
amount of collagen in the SPARC KO colons demonstrated by this method not only 
indicated that the ECM in the KO animals is different to that of WT mice, but also 
supports the observation of more rapid colonic healing in the KO DSS-treated animals. 
SPARC  KO  animals  treated  with  DSS  also  demonstrated  lower  levels  of  collagen 156 
 
deposition with histological signs of healing from day 21 onwards. These findings are 
consistent with the published literature which states that in the kidney, heart, lung and 
skin fibrosis models SPARC KO mice also have lower collagen deposition (Strandjord 
et al. 1999; Socha et al. 2007; Bradshaw et al. 2009).  
 
It has been reported that collagen type III is increased in CrD strictures (Graham et al. 
1988; Stallmach et al. 1992), such that the ratio of type III:I is >1, while in normal 
tissue the ratio is <0.3 (Lawrance, Maxwell, et al. 2001). Gut fibrosis has also been 
observed  in  adenovirus  expressing  murine  MCP-1  treated  mice,  where  the  ratio  of 
collagen type III and I demonstrated a significant increase from <0.3 at day 3 to >0.8 at 
day 21(Motomura et al. 2006). This suggests that there is a need for future work to be 
done to further investigate the collagen type III and I ratio.  
 
Intracellular  accumulation  of  procollagen  has  been  noted  to  be  less  in  SPARC  KO 
dermal fibroblasts compared to WT cells (Rentz et al. 2007), and the proposed rationale 
for  this  observation  is  that  without  SPARC  the  precise  regulation  of  procollagen 
maturation  into collagen  fibres  is altered and the efficiency of collagen to form the 
cross-linked helical structure that forms the insoluble ECM is compromised (Bradshaw 
2009).  The  data  presented  in  this  chapter  comparing  unstimulated  colonic 
myofibroblasts  demonstrated  a  similar  effect  in  the  colon  with  significantly  less 
collagen  expression  (Figure  5.12;  p<0.001)  and  higher  levels  of  MMP-13  gene 
expression  (Figure  5.13  A)  in  the  SPARC  KO  animals.  This  suggests  that  in 
combination  with  the  lower  collagen  production  there  is  also  enhanced  collagen 
degradation  further  reducing  the  net  deposition  of  collagen.  In  addition,  when  the 
tissues were examined under the transmission electron microscope , it was noted that 157 
 
the collagen bundles in the SPARC KO colon had significantly smaller diameters (WT: 
40nm vs SPARC KO: 30nm; p<0.001) than the WT controls (Lawrance and colleagues 
unpublished observation) similar to what has been observed by others in the skin (Rentz 
et al. 2007). Again this supports the concept that SPARC is implicated in collagen fibril 
deposition and organisation.  
 
ECM  deposition  and  the  degradation  need  to  be  in  balance  in  order  to  maintain 
intestinal homeostasis. Fibrosis is a major, and often a frequent, complication in CrD 
and may lead to intestinal obstruction and the need for surgical intervention. Fibrosis 
also may complicate UC but due to the superficial nature of the colonic inflammation in 
UC, it is less likely to result in clinically significant changes. It has been shown that 
increased  procollagen  RNA  transcription  levels  but  differs  in  collagen  deposition  in 
CrD  and  UC  patients  and  is  has  thus  been  proposed  that  there  are  different 
posttranscriptional,  or  posttranslational,  regulatory  mechanisms  that  affect  collagen 
deposition, such as collagen degradation, that may account for any observed differences 
(Matthes et al. 1992). In the work presented here, there was enhanced expression of the 
colonic procollagens but there was less collagen protein deposition in SPARC KO DSS-
treated animals. This could be related to the level of MMP activity as increased MMP-
13  and  -3  mRNA  expression  levels  were  observed  in  the  DSS-treated  SPARC  KO 
animals and degrade collagen thereby reducing the net deposition. MMP-2 and -9 are 
the two MMPs referred to as gelatinases that  are also highly expressed  in  inflamed 
colonic  mucosa  of  IBD  patient  and  are  associated  with  the  level  of  disease  activity 
(Stallmach et al. 2000; von Lampe et al. 2000). These MMPs have also been suggested 
to contribute to reduced levels of intestinal fibrosis in the DSS-induced colitis model 
(Suzuki et al. 2011). While this thesis focused in MMP-3 and -13, it appears more work, 
however, will  need to be done in order to investigate the impact of these MMPs  in 158 
 
SPARC  KO  animals.  TIMPs  differ  in  their  expression  patterns  and  affinity  for  the 
various MMPs but overall all MMPs are inhibited by one of the TIMPs once they are 
activated (Goldberg et al. 1992). SPARC KO had less TIMP-1 expression than WT may 
contribute to the high MMP expression that present. Hence, MMPs/TIMP-1that act as 
another point of regulates ECM balance shall further be investigated.  
 
The  TGF-β  family  of  growth  factors  is  important  for  many  different  cell  functions, 
including cellular differentiation, epithelial-mesenchymal cell transformation, and these 
growth factors are also regarded as central in the process of tissue fibrosis (Schiller et al. 
2004;  Martens  et  al.  1992).  TGF-β1  in  involved  in  foetal  development  from  early 
gestation through to the postnatal period with high expression in fetal dermis and is 
known to promote fibrosis, while TGF-β3 has, lower expression levels and is postulated 
to be antifibrogenic (Chen et al. 2005). The ‘scar-reducing’ effect of TGF-β3 has been 
observed in the incised and sutured mouse lip model, where elevated levels of TGF-β3 
reduce  type  I  collagen  deposition  by  restricting  myofibroblasts  differentiation  and 
thereby  collagen  synthesis.  It  can  also  promote  collagen  degradation  by  enhancing 
MMP  expression  (Hosokawa  et  al.  2003).  Although  no  statistical  differences  were 
observed in the work presented in this chapter, the DSS-induce colitis model and the 
stimulated  myofibroblasts  demonstrated numerically  higher expression of  TGF-β3  in 
the SPARC KO animals with less collagen deposition and higher in MMP expression. It 
has also been suggested that TGF-β3 does not work alone in reducing scar formation 
but  it  requires  TGF-β1  in  the  appropriate  ratio to  promote  scar-free  regeneration  as 
observed in the healing of fetal wounds (Shah et al. 1995; Hsu et al. 2001; Herdrich et 
al. 2010). Further investigation into to better defining the actions of TGF-β1 and TGF-
β3 and the way that these ratio  link to wound healing phenotype are, however, still 
required since SPARC showed to closely interact with TGF-β1.  159 
 
5.4 CONCLUSION 
When the results are taken together, SPARC would appear to be involved in the matrix 
remodeling  of  the  colon  by  several  interacting  mechanisms  at  the  same  time,  by 
affecting  the  expression  and  processing  of  procollagen,  as  well  as  collagen 
fibrillogenesis, and by modulating MMP/TIMP-1 expression levels that further altering 
the  net  deposition  of  ECM.  Together  with  the  synergistic  interaction  with  TGF-βs 
suggested by others makes SPARC a promising target for development of therapeutic 
approaches to improve healing and avoid intestinal fibrosis.  
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Chapter 6 
 
General discussion and 
Future directions 
 
 
 
 
 
 
 
 
 161 
 
6.1 SUMMARY OF THE FINDINGS FROM THIS THESIS 
The  addition  of  DSS  to  the  drinking  water  of  mice  promotes  the  disruption  of  the 
intestinal  mucosal  epithelial  integrity,  which  then  allows  for  the  influx  of  luminal 
bacterial components into the gut mucosa that were able to promote the recruitment and 
activation of cells of the innate immune system, such as neutrophils, monocytes and 
macrophages.  These  cells  then  further  contributed  to  colonic  mucosal  damage.  This 
appears to constitute a self-amplifying process where colonic bacteria activate immune 
cells and these activated innate cells secrete pro-inflammatory cytokines (TNF-α, IL-1β 
and IL-6) that recruit additional inflammatory cells into the intestinal mucosa, which, in 
turn, stimulate metalloproteinases and other factors that result in further tissue damage.  
 
In the studies presented in this thesis, SPARC KO animals demonstrated less mucosal 
damage,  more rapid resolution of  the mucosal  inflammation and tissue damage, and 
lower levels of inflammatory cell infiltrates when compared to the WT animals. It was 
also demonstrated that SPARC KO animals had higher expression levels of the anti-
inflammatory cytokine, TGF-β1. The lower numbers of innate immune cells seen in the 
SPARC  KO  animals  may  also  be  due  to the  lower  levels  of  chemokine  expression 
(MCP-1, MIG) compared to the WT animals. It appears, therefore, that SPARC is able 
to affect the inflammatory response by modulating inflammatory cell recruitment via 
chemokine and cytokine expression levels,  
 
SPARC has previously been noted to alter tissue ECM and this was also observed for 
the  colon  in  this  study.  The  level  of  collagen  deposition  in  any  tissue  is  a  balance 
between its production and degradation. SPARC KO mice were noted to have lower 162 
 
colonic  collagen  deposition  than  WT  animals.  The  expression  of  the  procollagens, 
however, in the colonic tissue was noted to be higher in KO animals compared to WT 
mice at day 7, but the expression of the MMPs was noted to be higher as well. The 
combination  of  these  findings  suggests  that  the  net  deposition  of  collagens  in  the 
SPARC KO animals would be reduced. Colonic subepithelial myofibroblasts are the 
cells primarily responsible for ECM deposition and were isolated from the SPARC KO 
and WT mice. SPARC KO myofibroblasts had higher MMP-3 expression than the WT 
cells in line with the findings within the colon. SPARC KO myofibroblasts, however, 
had less expression of the procollagens again supporting the concept that the colonic 
ECM is different without SPARC. A higher frequency of Treg cells was also observed 
in the SPARC KO mice and this might be secondary to the less dense ECM that has 
been previously noted SPARC KO animals. This differentially structured ECM could 
potentially allow for more TGF-β to be released and could also be associated with more 
rapid DC migration and subsequent T cells priming.  
 
6.2  HOW  THESE  FINDINGS  ADD  TO  THE  PUBLISHED 
LITERATURE   
SPARC is a matricellular protein expressed in variety of tissues during embryogenesis. 
In adult vertebrates, its expression is restricted to those tissues undergoing remodeling 
such as gut, bone, or following tissue injury. It also has been suggested that SPARC has 
an  important  modulatory  role  in  healing  and  inflammation  as  well  as  fibrosis. 
(Bradshaw  and  Sage  2001;  Brekken  and  Sage  2000).  Increased  SPARC  expression 
levels have already been demonstrated in inflamed, non fibrosed colonic surgical UC 
specimens compared to normal colonic tissue (Lawrance, Fiocchi, et al. 2001) and the 
DSS-induced model of colitis is considered to be a model that mimics UC. The finding 163 
 
that  SPARC  KO  animals  exposed  to  DSS  exhibited  less  inflammation  than  control 
animals  is  consistent  with  a  previous  report  that  SPARC  null  mice  also  exhibit 
attenuated inflammation and fibrosis of the kidneys (Socha et al. 2007). Recent reports 
have also shown that levels of the inflammatory markers also correlate with increased 
SPARC expression (Reding et al. 2009; Kos et al. 2009). In contrast, however, SPARC 
null mice were noted to have increased levels of neutrophil and leucocyte infiltration in 
bleomycin-induced  lung  injury  and  thioglycolate-induced  peritonitis  (Savani  et  al. 
2000). It seems that SPARC inhibition is thus able to alter the composition of the tissue 
microenvironment, which may either promote, or restrain, the inflammatory response 
depending of the tissue specific context. This may be due to the degradation products of 
SPARC as these smaller peptide fragments that represent different domains of SPARC 
also have biological activity. These fragments can oppose the activity of other SPARC 
fragments or the native SPARC protein itself. (Yin et al. 2010). These findings are also 
not surprising since the protease profile of the microenvironment may differ between 
different tissue  types  and  SPARC  is  known  to undergo  rapid  proteolysis  by  MMPs 
(Iruela-Arispe et al. 1995), not to mention the effect that the local composition of matrix 
molecules and cytokines play in contributing to the complex behaviour of SPARC in 
different types of inflammation.  
 
Permeabilisation  of  the  microvascular  endothelial-cell  barrier  permits  leucocytes, 
immunoglobulins, and other immunogenic agents to translocate into the site of tissue 
injury and is a necessary condition for an inflammatory response to occur. While its role 
in inflammation is controversial, and may vary between different systems, SPARC has 
been  proposed  as  a  promoter of  inflammation  by  a  process  of  enhancing  leucocyte 
passage into the extravascular tissues (Workman and Sage 2011). Recently, a binding 164 
 
site  for the  receptor,  stabilin-1,  has  been  identified  on  SPARC  and  the  monoclonal 
antibody that recognises the binding site has also been characterised. SPARC has been 
shown to interact with stabilin-1 (Kzhyshkowska et al. 2006) and stabilin-1 promotes 
inflammation by arresting leucocyte flow in the blood and aiding their positioning for 
extravasation  (Workman  and  Sage  2011).  These  observations  suggest  a  possible 
therapeutic target to modify inflammation through the inhibition of the SPARC/stabilin-
1interaction thereby reducing leucocyte recruitment to inflamed tissue (Workman and 
Sage  2011).  In  addition,  there  are  already  molecules  being  investigated  in  the 
management of both UC and CrD like MLN0002 that reduces recruitment of leucocytes 
through blocking the integrin α4β7 (Feagan et al. 2008).  
 
TGF-β is secreted in a latent, inactive form and is stored at the cell surface or covalently 
linked to the ECM where it is proteolytically cleaved to its active form (Annes et al. 
2003; Border and Noble 1994). SPARC is known to positively regulate TGF-β1 activity 
and  vice versa although the precise  mechanism  is  yet unknown. In the SPARC  KO 
DSS-treated  animals,  low  TGF-β1  expression  levels  were  predicted  but the TGF-β1 
levels were instead noted to be lower in the WT than SPARC KO mice. Chlenski and 
colleagues, however, also demonstrated that SPARC could have a negative effect on 
TGF-β1  activity  both  in  vitro  and  in  vivo  (Chlenski  et  al.  2007)  as  SPARC  null 
pericytes  displayed  increased  basal  TGF-β1  activity  (Rivera  and  Brekken  2011). 
Without SPARC being present, the ECM in the gut was observed to be different to the 
WT mice and this could potentially allowed easier cleavage of TGF-β from its ECM 
storage. As TGF-β1 is very important for multiple different cellular activities (Kisseleva 
and  Brenner  2008),  SPARC  KO  mice  may  generate  an  “adaptive”  mechanism  that 
allows for an increase in the availability of TGF-β1 in order to maintain homeostasis. 165 
 
SPARC deficient HSCs have also been shown to have increased levels of Adamst8, 
thrombospondin-1 and other MMPs, that are known to be involved in the activation of 
TGF-β1, to avoid cell death (Atorrasagasti et al. 2011). In addition, SPARC null mice 
have increased accumulation of white adipose tissue (Bradshaw et al. 2002), which is 
associated with increased TGF-β (Keophiphath et al. 2009). As TGF-β1 is a potent anti-
inflammatory cytokine, the high levels of TGF-β1 may account for the lower intestinal 
inflammation that was observed in the DSS-treated SPARC KO mice. TGF-β1 is also 
vital  in  the  differentiation  of  Treg  cells  that  also  regulate  inflammation,  while,  the 
secretion  of  TGF-β1  by  macrophages  is  known  to  suppress  the  pro-inflammatory 
signalling from Toll-like receptors further enhancing the speed of tissue repair (Barker 
et al. 1999).  
 
SPARC is linked with leptin. Leptin is a key secretory product of adipose tissue (Kos 
and Wilding 2010) and is also a mediator of intestinal inflammation. Leptin deficient 
mice  have  reduced  colitis  severity  and  lower  secretion  levels  of  pro-inflammatory 
cytokines in both the DSS- and TNBS-induced models of colitis (Siegmund et al. 2002). 
This suggests that a lack of SPARC will promote intestinal inflammation as the SPARC 
KO mice have increased fat accumulation and leptin levels (Bradshaw, Graves, et al. 
2003). This trend, however, was not observed in this study and might be due to the 
strain of mice used, despite the fact that the SPARC KO animals used in the experiment 
presented having increased of leptin mRNA levels (data not show). It also suggests that 
leptin  might  require  an  intact  SPARC  pathway  in  order  to  induce  intestinal 
inflammation.  Conversely,  the  increased  level  of  leptin  may  speed  up  the  healing 
process in the SPARC KO animals as leptin has previously been shown to improve 
dermal healing (Frank et al. 2000).  166 
 
Fibrosis occurs when the wound healing response is out of control and causes excessive 
deposition of ECM. Although DSS-induced colitis is not an ideal fibrosis model, the 
findings presented suggest that SPARC  might  impair healing and  be pro-fibrogenic. 
TGF-β1 has anti-inflammatory properties but it is also a key pro-fibrogenic factor. A 
low fibrogenic response was seen in SPARC KO mice following DSS-treatment despite 
high TGF-β1 levels being present in the colon. The lack of fibrosis might be due to the 
fact that the fibrogenic properties of TGF-β are not mediated directly but occur through 
its induction of connective tissue growth factor (CTGF), which acts in an autocrine loop 
to  increase  collagen  synthesis  (Duncan  et  al.  1999)  and  SPARC  is  known  as  an 
upstream regulator of the CTGF (Zhou et al. 2006) and may impact on this interaction. 
Further  research  is,  therefore,  required  in  order to  decipher  any  interaction  between 
TGF-β/CTGF/SPARC and their effects on inflammation.   
 
In  conclusion,  the  work  presented  in  this  thesis  indicates  that  SPARC  is  pro-
inflammatory  in  the  DSS-induced  colitis  model.  SPARC  also  remodeled  ECM  to 
prolong the healing process and potentially has a pro-fibrogenic activity. It also raises 
several  important  avenues  of  future  research  that  should  be  undertaken  in  order  to 
clarify the precise functional involvement of SPARC in intestinal inflammation.  
 
6.3 FUTURE DIRECTIONS  
In addition to those areas of future work mentioned in previous chapters, more analysis 
is required in order to improve the experimental protocol. In chapter 4, the numbers of 
Ly6G+ neutrophils at day 7 and 14 were numerical lower than those at day 21 and 35 
but this was most likely due to the poor tissue structure of the severely inflamed tissue 167 
 
with  less  area  for  viewing  and  subsequent  counting,  and  thus  acted  as  secondary 
evidence  that  neutrophils  were  causing  severe  colonic  tissue  destruction  possibly 
through reactive oxygen species despite lower numbers numerically. That SPARC KO 
mice had fewer neutrophils also supports the proposal that SPARC KO mice heal faster 
than  the  WT  animals  as  effective  elimination  of  neutrophils  is  a  prerequisite  for 
resolution  of  the  inflammatory  response.  Further  biochemical  tests  could  also  be 
performed to measure the enzyme myeloperoxidase within the colonic tissue and this 
may be able to better determine the level of neutrophils present in the colonic tissue 
particularly during the early acute phase of disease. TREM-1 could also be stained in 
colonic  cryosections  in  order  to  distinguish  the  inflammatory  macrophage  from  the 
resident  macrophage  as  TREM-1  enhances  the  secretion  of  the  pro-inflammatory 
cytokines by the inflammatory macrophages.  
 
The adaptive immune system does not appear to be primarily involved in the acute stage 
of the DSS-induced colitis model as severe combined immunodeficient mice that lack 
both T and B cells are still able to develop the DSS-induced acute colitis (Dieleman et 
al.  1994).  The  adaptive  immune  system,  however,  plays  an  important  role  in  the 
development  of  chronic  inflammation  as  observed  in  certain  mice  strains  such  as 
C57BL/6, while chronic inflammation is not seen in BALB/c mice (Melgar et al. 2005). 
The progression of the acute colitis towards that of chronicity observed in C57BL/6 
mice suggests that this is a potential animal model for the pathological inflammatory 
changes seen in patients with UC, while the acute model of colitis in the BALB/c may 
be useful in the study of normal mucosal healing (Melgar et al. 2005). The chronicity 
seen in C57BL/6 mice after a single dose of DSS might also only reflect prolonged 
repair of acute colitis and it is not defined simply as chronic colitis (Suzuki et al. 2011). 168 
 
As mentioned above, DSS-induced colitis  is not a fibrosis  model although  intestinal 
fibrosis was observed in C57BL/6 mice (Melgar et al. 2005). TNBS with concomitant 
administration of ethanol, which disrupts the colonic epithelial barrier, induces colitis 
and is considered as more of a CrD model where chronic, transmural inflammation and 
fibrosis as well as a skewed immune reaction towards the Th1 profile is observed in 
mice (Lawrance et al. 2003). Thus, the use of the DSS experimental model in different 
mice strain could be repeated in the future, as well as using the TNBS-induced colitis 
model to allow for further investigates of the mechanism that SPARC may have on both 
the acute and chronic changes in gut immunity. 
 
The role for SPARC in tumorigenesis is also unclear, as in inflammation, and it appears 
to depend on its functions within a given microenvironment. SPARC has been found to 
be increased in melonama cell lines and other neoplastic cells within tumours (Ledda, 
Bravo, et al. 1997). When the expression of SPARC was suppressed by antisense RNA, 
this resulted in a decrease in both the adhesive and invasive characteristics of the cells 
in vitro and resulted in a complete loss of invasive-metastatic phenotype development in 
human melonoma cells (Alvarez et al. 2005; Ledda, Adris, et al. 1997). In contrasted, to 
the observed effects of SPARC in melanomas, it has been shown to anti-tumorigenic in 
ovarian cancers (Chlenski and Cohn 2010) where overexpression of SPARC is able to 
attenuate mitogenic, chemotactic, and pro-invasive effects that induced by infiltrating 
macrophages in ovarian cancer cells (Said, Socha, et al. 2007; Said and Motamed 2005). 
In colorectal tumours, low or no SPARC is expressed by the neoplastic cells, but it is 
present  within  the  stromal  cells  that  surround the  glandular  tissue  (Tai  et  al.  2005; 
Lussier et al. 2001). Recently, our group identified that SPARC expression levels in the 
primary  tumour  of  patients  with  colorectal  cancer  correlated  with  their  long-term 169 
 
cancer-specific-survival (Chew et al. 2011). Chronic inflammation has been linked with 
the developed of neoplasia and cancer in numerous tissue types and this has particularly 
been  noted  in  patients  with  chronic  inflammatory  bowel  disease  that  may  lead  to 
colorectal cancer (Seril et al. 2003; Katsanos et al. 2011; Neumann et al. 2011). Our 
studies  in  the  animal  colitis  models  demonstrated  that  the  presence  of  SPARC  is 
associated  with  greater  levels  of  inflammation,  but  how  this  may  impact  on 
carcinogenesis in human colorectal cancer require further research. SPARC, however, 
may  represent  a  potentially  clinically  important  therapeutic  target  in  this  matter. 
Currently,  this  is  being  further  investigated  in  our  lab  by  using  the  murine 
tumouroigenesis  models  of  azoxymethane–alone  and  azoxymethane  in  combination 
with DSS.  
 
There is evidence to suggest that ECM fragments or ECM molecules can influence the 
inflammatory  response.  SPARC  has  been  shown  here  to  exacerbate  intestinal 
inflammation.  Inflammation  is  also  closely  associated  with  cancer  where  tumour 
development might arise from sites of unresolved chronic inflammation as seen in IBD 
patients. It is, therefore, possible that SPARC might be a potential therapeutic protein 
for the modification of inflammation levels and reduction of tumour development in the 
colon. 
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